Page last updated: 2024-10-29

ifosfamide and Neoplasms

ifosfamide has been researched along with Neoplasms in 276 studies

Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.

Research Excerpts

ExcerptRelevanceReference
"To investigate the electronic anti-nausea instrument (EANI) combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy."9.19Phase II study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. ( Guo, JX; Huang, XE; Liu, J; Liu, YC; Wei, W; Xiao, Y, 2014)
" Measurements included carnitine plasma levels and self-reported fatigue using established child or adolescent fatigue scales and were collected during the 2nd cycle of chemotherapy, and repeated on alternating cycles up to cycle 8."7.81Fatigue and carnitine levels over multiple cycles of chemotherapy in children and adolescents. ( Hockenberry, MJ; Hooke, MC; McCarthy, K; Taylor, O, 2015)
"To report 2 cases of nonconvulsive status epilepticus (NCSE) following infusion of ifosfamide."7.73Nonconvulsive status epilepticus due to ifosfamide. ( Akoglu, H; Aksoy, S; Cakar, M; Erman, M; Kilickap, S; Onal, IK; Tekuzman, G; Tufan, A, 2006)
"Hallucinations as a symptom of central neurotoxicity are a known but poorly described side effect of ifosfamide."7.69Hallucinations and ifosfamide-induced neurotoxicity. ( Baile, WF; Brown, R; DiMaggio, JR; Schapira, D, 1994)
"We examined the possibility of continuing oxazaphosphorine therapy in patients with previously documented cyclophosphamide- or ifosfamide-induced hematuria by concomitant use of the uroprotective agent, mesna."7.67The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy. ( Andriole, GL; Arasi, V; Linehan, M; Magrath, IT; Miser, JS; Sandlund, JT, 1987)
"Ifosfamide and cisplatin cause urinary loss of carnitine, which is a fundamental molecule for energy production in mammalian cells."6.70Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients. ( Baldelli, AM; Bisonni, R; Canestrari, F; Catalano, V; De Gaetano, A; Ferraro, B; Giordani, P; Graziano, F; Lai, V; Mencarini, E; Rovidati, S; Silva, R; Testa, E, 2002)
"Mucositis is a common toxicity of cancer chemotherapy."6.68Oral glutamine to prevent chemotherapy induced stomatitis: a pilot study. ( Anderson, PM; Skubitz, KM, 1996)
"Ondansetron is a 5-HT3 antagonist and its antiemetic properties have been established in adults receiving chemotherapy."6.67The efficacy and safety of ondansetron in the prophylaxis of cancer-chemotherapy induced nausea and vomiting in children. ( Hewitt, M; McQuade, B; Stevens, R, 1993)
" Increased hydration and dosage of mesna are administered to patients who develop IFO-induced HC; they also receive 24-h continuous infusion of mesna in subsequent treatment cycles."5.43A retrospective study of treatment and prophylaxis of ifosfamide-induced hemorrhagic cystitis in pediatric and adolescent and young adult (AYA) patients with solid tumors. ( Kumamoto, T; Makino, Y; Ogawa, C; Saito, Y; Tamai, I; Terakado, H, 2016)
"Fatigue is the most frequent symptom experienced by children/adolescents with cancer."5.35Carnitine plasma levels and fatigue in children/adolescents receiving cisplatin, ifosfamide, or doxorubicin. ( Gregurich, M; Hockenberry, MJ; Hooke, MC; McCarthy, K, 2009)
"To investigate the electronic anti-nausea instrument (EANI) combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy."5.19Phase II study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. ( Guo, JX; Huang, XE; Liu, J; Liu, YC; Wei, W; Xiao, Y, 2014)
"The MSC cold cap system is effective in preventing alopecia from anthracycline, etoposide or taxane but not from anthracycline-taxane combinations or ifosfamide-containing regimens."5.10Effectiveness of the MSC cold cap system in the prevention of chemotherapy-induced alopecia. ( Christodoulou, C; Efstathiou, E; Klouvas, G; Papazachariou, E; Plyta, M; Skarlos, DV; Zervakis, D, 2002)
"From April 1993 to September 1993, 15 patients with lymphoid or solid neoplasms underwent 16 non-cryopreserved peripheral stem cell transplantation courses using the ICE (ifosfamide, carboplatin, etoposide) program."5.08Misoprostol prophylaxis for high-dose chemotherapy-induced mucositis: a randomized double-blind study. ( Aguilar-Ponce, L; Dueñas-Gonzalez, A; Frias-Mendivil, M; Gallardo-Rincon, D; Lara-Medina, F; Miranda-Lopez, E; Reynoso-Gomez, E; Sobrevilla-Calvo, P; Zinser-Sierra, J, 1996)
"Phase II studies conducted in Europe and the USA on pediatric solid tumors have shown that ifosfamide, as a single agent, is an active drug against a variety of neoplasms - rhabdomyosarcoma (RMS), some non-RMS soft tissue sarcomas, Wilms' tumor, bone sarcomas and neuroblastoma."4.82Ifosfamide in pediatric solid tumors. ( Bisogno, G; Carli, M; Passone, E; Perilongo, G, 2003)
"This article gives highlights of ongoing pediatric solid tumor and leukemia trials in the United States that use ifosfamide in combination with mesna."4.79Ongoing clinical studies of ifosfamide for pediatric cancer in the United States. ( Pratt, CB, 1996)
"Patients who developed gastrointestinal bleeding/ulcer were treated concurrently with vincristine-cyclophosphamide-ifosfamide-etoposide or vincristine-cyclophosphamide, and their ages were older than those of patients without gastrointestinal bleeding/ulcer."4.31Gastrointestinal bleeding/ulcer among paediatric cancer patients after proton beam therapy. ( Fukushima, H; Hosaka, S; Inaba, M; Masumoto, K; Mizumoto, M; Muroi, A; Okunushi, T; Sakurai, H; Suzuki, R; Tagawa, M; Takada, H; Watanabe, A; Yamaki, Y, 2023)
" Measurements included carnitine plasma levels and self-reported fatigue using established child or adolescent fatigue scales and were collected during the 2nd cycle of chemotherapy, and repeated on alternating cycles up to cycle 8."3.81Fatigue and carnitine levels over multiple cycles of chemotherapy in children and adolescents. ( Hockenberry, MJ; Hooke, MC; McCarthy, K; Taylor, O, 2015)
"Ifosfamide is an alkylating agent used in the treatment of germ-cell tumors, sarcomas and lymphomas."3.73[Ifosfamide induced encephalopathy: 15 observations]. ( Behar, C; Dufour, C; Grill, J; Hartmann, O; Motte, J; Munzer, M; Oberlin, O; Paci, A; Sabouraud, P, 2006)
"To report 2 cases of nonconvulsive status epilepticus (NCSE) following infusion of ifosfamide."3.73Nonconvulsive status epilepticus due to ifosfamide. ( Akoglu, H; Aksoy, S; Cakar, M; Erman, M; Kilickap, S; Onal, IK; Tekuzman, G; Tufan, A, 2006)
"To evaluate proteinuria occurring early after ifosfamide therapy and to assess the use of changes in proteinuria in the prediction of severe chronic nephrotoxicity."3.70Acute changes in urine protein excretion may predict chronic ifosfamide nephrotoxicity: a preliminary observation. ( English, M; Hall, AG; MacLean, FR; Pearson, AD; Skinner, R, 1998)
"Hallucinations as a symptom of central neurotoxicity are a known but poorly described side effect of ifosfamide."3.69Hallucinations and ifosfamide-induced neurotoxicity. ( Baile, WF; Brown, R; DiMaggio, JR; Schapira, D, 1994)
"We examined the possibility of continuing oxazaphosphorine therapy in patients with previously documented cyclophosphamide- or ifosfamide-induced hematuria by concomitant use of the uroprotective agent, mesna."3.67The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy. ( Andriole, GL; Arasi, V; Linehan, M; Magrath, IT; Miser, JS; Sandlund, JT, 1987)
" We conducted a phase 1 trial to evaluate the safety of olaratumab and determine a recommended dose in combination with three different chemotherapy regimens in children."3.01Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors. ( Bishop, MW; Borinstein, SC; DuBois, SG; Hingorani, P; Krystal, J; Laetsch, TW; Levy, DE; Mascarenhas, L; Mo, G; Muscal, JA; Ogawa, C; Shahir, A; Slotkin, EK; Weigel, BJ; Wright, J, 2021)
"IFO-induced encephalopathy (IIE) is one of the serious side effects, but there is not enough evidence regarding the clinical features of IIE in children."2.90Analysis of the clinical characteristics of pediatric patients who experience ifosfamide-induced encephalopathy. ( Honda, T; Ide, Y; Kubota, N; Nakamura, T; Sakashita, K; Tozuka, M; Yanagisawa, R, 2019)
" We conducted a dose-finding and pharmacokinetic (PK)/pharmacodynamics study of pazopanib combined with two different schedules of ifosfamide."2.79Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I study. ( Boers-Sonderen, MJ; de Bruijn, P; Eskens, FA; Hamberg, P; Sleijfer, S; Suttle, AB; van der Graaf, WT; van Herpen, CM; Verweij, J, 2014)
"Topotecan AUC was significantly correlated with time to platelet recovery."2.76Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with autologous stem cell transplant in refractory cancer: pharmacokinetic and pharmacodynamic correlates. ( Dawson, JL; Field, TL; Fields, KK; Goldstein, SC; Kim, J; Lush, RM; Maddox, BL; Neuger, AM; Partyka, JS; Perkins, JB; Simonelli, CE; Sullivan, DM, 2011)
" Pharmacokinetic analysis revealed a linear relation between the area under the concentration-versus-time curve (AUC) and dose."2.75Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent D-19575 (glufosfamide) in patients with solid tumors. ( Akashi, Y; Fukuoka, M; Miyazaki, M; Nakagawa, K; Okamoto, I; Ozaki, T; Satoh, T; Shimizu, T; Tamura, K, 2010)
" Pharmacokinetic (PK) and pharmacodynamic (PD) assessments were performed."2.75Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies. ( den Hollander, M; Gelderblom, H; Hamberg, P; Loos, WJ; Sleijfer, S; Steeghs, N; Tascilar, M; van de Biessen, D; Verweij, J, 2010)
"Cancer patients with solid tumors that experienced post chemotherapy thrombocytopenia with a nadir of < = 80,000 platelets/ml were eligible for this clinical trial."2.75Dose escalation study of an anti-thrombocytopenic agent in patients with chemotherapy induced thrombocytopenia. ( Daehler, M; Grutsch, JF; Gupta, D; Hall, JL; Levin, RD; Lis, CG, 2010)
"Paclitaxel was administered as a 6-hr continuous infusion (hr 0-6), followed by intravenous ifosfamide (2 g/m(2)/day x 3 days) over 1 hr at hours 6-7, 24-25, and 48-49."2.74Phase I study of paclitaxel with standard dose ifosfamide in children with refractory solid tumors: a Pediatric Oncology Group study (POG 9376). ( Bernstein, M; Blaney, SM; Geller, JI; Perentesis, J; Wall, D, 2009)
"Ifosfamide (IFOS) is a bifunctional alkylator with a wide spectrum of activity in solid tumors and has an autoinductive liver metabolism through P450 cytochromes."2.73An original administration of ifosfamide given once every other week: a clinical and pharmacological study. ( Alexandre, J; Cacheux, W; Duffau, B; Germann, N; Goldwasser, F; Gourmel, B; Rabillon, F, 2008)
"The grade of oral mucositis was assessed by the WHO per NCI-CTC common toxicity criteria and the assessments were made on days 1, 8 and 15 by a trained examiner blind to the intervention."2.73Influence of low-energy laser in the prevention of oral mucositis in children with cancer receiving chemotherapy. ( Brunetto, AL; Castro, CG; Cruz, LB; Rech, A; Ribeiro, AS; Rosa, LG, 2007)
" The peak concentration and area under the curve (AUC) were determined for the parent compound and the metabolites 4-hydroxyifosfamide and chloracetaldehyde in eight patients who received two cycles of ICE chemotherapy (ifosfamide 5 g/m(2) day 1, carboplatin 300 mg/m(2) day 1, etoposide 100 mg/m(2) days 1-3)."2.73Influence of short-term use of dexamethasone on the pharmacokinetics of ifosfamide in patients. ( Brüggemann, SK; Peters, SO; Pfäffle, S; Wagner, T, 2007)
" The pharmacodynamic effects of mesna on depleting plasma cysteine, a GSH precursor, were evaluated in 22 patients as part of a Phase I study."2.71Pharmacokinetics and pharmacodynamics of mesna-mediated plasma cysteine depletion. ( Booker, BM; Creaven, P; Pendyala, L; Perez, R; Smith, PF, 2003)
"Ifosfamide was administered at a fixed dose of 1."2.71Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks. ( Ambaum, B; Beijnen, JH; Groenewegen, G; Herben, VM; Jansen, S; Kerbusch, T; Mathôt, RA; Rosing, H; Schellens, JH; Swart, M; ten Bokkel Huinink, WW; Voest, EE, 2004)
" Increases in mesna excretion after oral dosing lagged by 2-4 h."2.71Urine mesna excretion after intravenous and oral dosing in ifosfamide-treated children. ( Bush, DA; Epelman, S; Goren, MP, 2004)
" After adjusting for body size, AUC0-6 and Cmax were positively related to dose (P = 0."2.71Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study Group Study. ( Beane, C; Boddy, AV; Brennan, B; Chisholm, JC; Cole, M; Elsworth, AM; Errington, J; Glaser, A; Hale, J; Hemsworth, S; Howe, K; Jenner, G; McDowell, H; Nicholson, J; Parry, A; Pearson, AD; Pinkerton, R; Pritchard-Jones, K; Veal, GJ; Waters, F; Wright, Y, 2005)
"Etoposide was administered on Days 1 and 2 (150 mg/m(2))."2.70Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma. ( Baruchel, S; Fouladi, M; Gammon, J; Grant, R; Greenberg, ML; Klein, J; Koren, G; Stempak, D, 2001)
"Ifosfamide was administered by intravenous infusion over 3 h immediately followed by a 30-min infusion of topotecan."2.70Phase I clinical and pharmacokinetic study of combination chemotherapy with topotecan and ifosfamide in patients with progressive or relapsed solid tumors. ( Grübner, U; Höffken, K; Hoffmann, A; Kath, R; Merkel, U; Schneider, CP, 2002)
"Ifosfamide and cisplatin cause urinary loss of carnitine, which is a fundamental molecule for energy production in mammalian cells."2.70Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients. ( Baldelli, AM; Bisonni, R; Canestrari, F; Catalano, V; De Gaetano, A; Ferraro, B; Giordani, P; Graziano, F; Lai, V; Mencarini, E; Rovidati, S; Silva, R; Testa, E, 2002)
" Pharmacokinetic studies were performed on day 1 of the first course in 33 patients and repeated on day 14 in 13 patients (once-daily schedule only)."2.69Clinical effects and pharmacokinetics of the fusion protein PIXY321 in children receiving myelosuppressive chemotherapy. ( Arnold, B; Furman, WL; Garrison, L; Hanna, R; Luo, X; Marina, N; Meyer, WH; Pratt, CB; Rodman, JH; Tonda, ME, 1998)
"Paclitaxel was given after the first dose of ifosfamide on Day 1."2.69A Phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors. ( Berkowitz, R; Bunnell, CA; Buswell, L; Muto, M; Sheets, E; Shulman, LN; Thompson, L, 1998)
"Ifosfamide is an alkylating drug that has demonstrated activity against non-small cell lung cancer, testicular cancer, breast cancer, and soft tissue sarcoma."2.69Docetaxel and ifosfamide in patients with advanced solid tumors: results of a phase I study. ( de Bruijn, EA; Groult, V; Locci-Tonelli, D; Planting, AS; Pronk, LC; Schellens, JH; Schrijvers, D; van Oosterom, AT; Verweij, J, 1998)
" Effective modulatory doses of etanidazole could not be given with acceptable toxicity using this schedule."2.69Dose escalation of the hypoxic cell sensitizer etanidazole combined with ifosfamide, carboplatin, etoposide, and autologous hematopoietic stem cell support. ( Antman, KH; Ayash, LJ; Coleman, N; Elias, AD; Frei, E; Ibrahim, J; McCauley, M; Mills, L; Schnipper, L; Schwartz, G; Teicher, BA; Warren, D; Wheeler, C, 1998)
"Breast cancer patients treated with the VIPE regimen (including pretreated women) had a significantly higher CFU-GM rate than patients treated with EC (P=0."2.69Correlation between granulocyte/macrophage-colony-forming units and CD34+ cells in apheresis products from patients treated with different chemotherapy regimens and granulocyte-colony-stimulating factor to mobilize peripheral blood progenitor cells. ( Blumenstengel, K; Fricke, HJ; Höffken, K; Kath, R; Kunert, C; Sayer, HG; Vogel, W, 1998)
"Poor-risk solid tumors were treated with four courses of cyclophosphamide (4,200 mg/m2)/ doxorubicin (75 mg/m2), and three courses of ifosfamide (9,000 mg/m2)/etoposide (500 mg/m2)."2.69High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors. ( Bajorin, D; Cheung, NK; Heller, G; Kramer, K; Kushner, BH; Meyers, PA; Polyak, T; Wollner, N, 1998)
"Thirty-one patients with solid tumors stratified according to pretreatment were randomized to receive cisplatin/ifosfamide-based chemotherapy with or without amifostine (1000 mg absolute) given as a short infusion prior to cisplatin."2.69The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide-based chemotherapy in patients with solid tumors. ( Bokemeyer, C; Fels, LM; Hartmann, JT; Kanz, L; Knop, S; Stolte, H; van Vangerow, A, 2000)
"Ifosfamide and mesna were infused over 24 and 36 h, respectively, at equal daily doses; carboplatin was given after ifosfamide to a target plasma area under the curve of 4 mg x min x ml(-1)."2.69Intravenous ifosfamide/mesna is associated with depletion of plasma thiols without depletion of leukocyte glutathione. ( Bolanowska-Higdon, W; Creaven, PJ; Meropol, NJ; Murphy, M; Pendyala, L; Perez, R; Schwartz, G; Zdanowicz, J, 2000)
"Thirty-one patients with solid tumors stratified according to pretreatment were randomized to receive VIP- or TIP-chemotherapy with or without amifostine (910 mg/m2) given as a short infusion prior to cisplatin."2.69A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors. ( Bokemeyer, C; Fels, LM; Hartmann, JT; Kanz, L; Knop, S; Stolt, H, 2000)
"Mucositis is a common toxicity of cancer chemotherapy."2.68Oral glutamine to prevent chemotherapy induced stomatitis: a pilot study. ( Anderson, PM; Skubitz, KM, 1996)
"The purpose of this phase I study is to determine the maximally tolerated doses of paclitaxel and carboplatin (dosed by area under the concentration-time curve) when given at specified times in combination with 6 g/m2 ifosfamide (3 g/m2 at 8 AM on days 1 and 2) with mesna and 5 microg/kg/d filgrastim (from day 4 until the absolute neutrophil count is > 10,000/microL) every 21 days for six cycles."2.68Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results. ( Palackdharry, CS, 1996)
"Patients with metastatic cancers were treated with GM-CSF at 5 micrograms/kg sc, days 1 to 7; leukaphereses were performed on days 6 and 7."2.68Antitumor and accessory immune activities of peripheral blood stem cells mobilized with granulocyte-macrophage colony-stimulating factor. ( Balcerzak, SP; Benzies, T; Triozzi, PL; Tucker, F, 1996)
" Plasma ifosfamide concentrations were assayed by gas liquid chromatography and pharmacokinetic parameters were imputed using non-compartmental analysis."2.68A study of 5 day fractionated ifosfamide pharmacokinetics in consecutive treatment cycles. ( Lewis, LD, 1996)
"Etoposide has reported synergism with these alkylators and produces mucositis as its dose-limiting toxicity."2.67High-dose ifosfamide/carboplatin/etoposide with autologous hematopoietic stem cell support: safety and future directions. ( Antman, KH; Ayash, LJ; Elias, AD; Frei, E; Mazanet, R; McCauley, M; Schnipper, L; Schwartz, G; Tepler, I; Wheeler, C, 1994)
"The tolerance for and activity of escalating targeted doses of carboplatin combined with ifosfamide and etoposide (ICE) were assessed in children with advanced germ cell tumors or other rare solid tumors for which no standard therapy exists."2.67Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in treatment of newly diagnosed pediatric solid tumors. ( Bowman, LC; Furman, W; Jones, DP; Marina, NM; Meyer, WH; Murry, DJ; Pratt, CB; Rodman, JH; Shema, SJ, 1994)
"Ondansetron is a 5-HT3 antagonist and its antiemetic properties have been established in adults receiving chemotherapy."2.67The efficacy and safety of ondansetron in the prophylaxis of cancer-chemotherapy induced nausea and vomiting in children. ( Hewitt, M; McQuade, B; Stevens, R, 1993)
"A continuous 14-day infusion of ifosfamide admixed with carboplatin is feasible in an ambulatory setting with no need for adding mesna for urologic protection and full dosage administration for each agent."2.67Pilot study of ambulatory infusional ifosfamide admixed with carboplatin. ( Anderson, NR; Bern, MM; Coco, F; Gonzalves, L; Lokich, JJ; Moore, C; Zipoli, TE, 1993)
"The tolerance of escalating targeted doses of carboplatin combined with ifosfamide (IFOS)/etoposide (VP-16) (ICE) was assessed in children with recurrent solid tumors."2.67Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors. ( Bowman, LC; Douglass, E; Furman, W; Hudson, M; Marina, NM; Meyer, W; Rodman, J; Santana, VM; Shema, SJ; Wilimas, J, 1993)
"Patients were assigned to dosage cohorts separately on the basis of prior exposure to the platinum alkylating agents cisplatin or carboplatin (n = 20) or the absence of such exposure (n = 9)."2.67A phase I study of ifosfamide with Mesna given daily for 3 consecutive days to children with malignant solid tumors. ( Avery, L; Bowman, L; Douglass, EC; Marina, N; Meyer, WH; Ochs, J; Pratt, CB; Thompson, EI; Wilimas, J, 1993)
"Nephrotoxicity is an important adverse effect of chemotherapy in children."2.67The influence of age on nephrotoxicity following chemotherapy in children. ( Coulthard, MG; Craft, AW; Pearson, AD; Price, L; Skinner, R, 1992)
" Independent of the route of ifosfamide application on day 1, the terminal half-life on day 3 (when the drug was given by the alternative route) was decreased in 6 out of the 12 patients, thus indicating self-induction of hepatic metabolism."2.67Metabolism and pharmacokinetics of oral and intravenous ifosfamide. ( Cerny, T; Küpfer, A; Kurowski, V; Wagner, T, 1991)
"In this phase I study, 16 adult cancer patients were treated with concurrent 4-day continuous infusions of ifosfamide at 12 g/m2 and escalating doses of carboplatin (400-1600 mg/m2) to determine the major non-haematological dose-limiting toxicity of the combination."2.67Escalating doses of carboplatin with high-dose ifosfamide using autologous bone marrow as support: a phase I study. ( Ayash, LJ; Critchlow, J; Deary, J; Eder, JP; Elias, AD; Frei, E; Hunt, M; Schnipper, L; Weissman, L; Wheeler, C, 1991)
"Thirty six patients with advanced solid tumors (24 lung: 3 oat-cell, 14 squamous, 7 adenocarcinomas, 3 soft tissue sarcomas, 6 breast carcinomas; 1 seminoma; 2 ovarian adenocarcinomas) entered a phase II study of high-dose ifosfamide (IF) administered in combination with the uroprotective agent sodium 2-mercapto-ethane-sulfonate (Mesna)."2.65Phase II study of ifosfamide combined with Mesna uroprotection in advanced non-small-cell lung carcinoma and other solid tumors. ( Brema, F; Cinquegrana, A; Nobile, MT; Rosso, R; Santi, L, 1984)
" A daily dosage of 50 to 60 mg/kg ifosfamide on 5 consecutive days produced the best results."2.64Evaluation of a cooperative clinical study of the cytostatic agent ifosfamide. ( Brock, N; Burkert, H; Fichtner, E; Schnitker, J, 1976)
"Overall, childhood cancer survivors have a ninefold higher risk of developing renal failure compared with their siblings."2.58Late renal toxicity of treatment for childhood malignancy: risk factors, long-term outcomes, and surveillance. ( Skinner, R, 2018)
"Since CPA and IFO are widely used anticancer drugs, their efficacy is limited not only by their toxicity but also due to occurring resistance."2.49[Classical oxazaphosphorines--metabolism and therapeutic properties--new implications]. ( Górska, A; Hładoń, B; Misiura, K; Sikorska, M; Sloderbach, A, 2013)
"An assessment of the anticancer potential of glufosfamide is of key importance in therapy."2.47Glufosfamide as a new oxazaphosphorine anticancer agent. ( Mazur, L; Opydo-Chanek, M; Stojak, M, 2011)
"Ifosfamide is an important part of chemotherapeutic regimens used to treat a variety of malignancies."2.43Evaluating risk factors for the development of ifosfamide encephalopathy. ( David, KA; Picus, J, 2005)
"Several anticancer drugs have been added to the therapeutic armamentarium in recent years."2.42New chemotherapy agents in veterinary medicine. ( Kitchell, BE; Moore, AS, 2003)
"Ifosfamide is an alkylating agent used in the treatment of a variety of solid tumours."2.41Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. ( De Vos, F; Pelgrims, J; Prové, A; Schrijvers, D; Van den Brande, J; Vermorken, JB, 2000)
"Ifosfamide is an active drug for various tumors with elevated incidence in the elderly."2.41Ifosfamide in the elderly: clinical considerations for a better drug management. ( Catania, C; Comandone, A; Curigliano, G; de Braud, F; De Pas, T, 2000)
"Several commonly used cancer chemotherapeutic prodrugs, including cyclophosphamide and ifosfamide, are metabolized in the liver by a cytochrome P450 (CYP)-catalyzed prodrug activation reaction that is required for therapeutic activity."2.41Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer. ( Chen, L; Waxman, DJ, 2002)
"Ifosfamide is an active drug in the therapy of paediatric tumours such as rhabdomyosarcoma, Ewings' sarcoma, Wilms' tumour, neuroblastoma, germ cell tumours and lymphomas."2.40The role of ifosfamide in paediatric cancer. ( Advani, SH, 1998)
"Nephrotoxicity is a relatively common and potentially serious adverse effect of treatment with certain cytotoxic drugs (especially ifosfamide)."2.39Strategies to prevent nephrotoxicity of anticancer drugs. ( Skinner, R, 1995)
"Chiral anticancer agents which exist as a pair of enantiomers are commonly administered as racemic (50:50) mixtures of the two isomers."2.38Stereoisomers in clinical oncology: why it is important to know what the right and left hands are doing. ( Wainer, IW, 1993)
"Ifosfamide is an effective drug for the treatment of solid tumors in children and most blastomas and sarcomas react favorably."2.38Ifosfamide in pediatric oncology. ( de Kraker, J; Voûte, PA, 1992)
"Ifosfamide is an oxazaphosphorine alkylating agent with a broad spectrum of antineoplastic activity."2.38Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. ( Brogden, RN; Dechant, KL; Faulds, D; Pilkington, T, 1991)
" Recent clinical trials suggest that oral mesna has adequate bioavailability (roughly 50% by urinary thiol measurements) to prevent urotoxicity in high-dose ifosfamide regimens."2.38Chemoprotectants for cancer chemotherapy. ( Dorr, RT, 1991)
"Mesna may produce gastrointestinal and allergic reactions."2.38Ifosfamide and mesna. ( Dana, WJ; Schoenike, SE, 1990)
"In germ cell tumors, the combination of ifosfamide and etoposide has proved to be an effective salvage regimen in patients resistant to vinblastine, bleomycin, and cisplatin."2.38Ifosfamide in pediatric malignancies. ( Göbel, U; Jürgens, H; Treuner, J; Winkler, K, 1989)
" Concerns about excessive toxicity-as many are infants and/or undergo nephrectomy-have resulted in decreased chemotherapy dosing and omission of the nephrotoxic drug ifosfamide in collaborative group studies."1.91Tolerability of ifosfamide-containing regimen in patients with high-risk renal and INI-1-deficient tumors. ( Benedetti, DJ; Kao, PC; Ma, C; Marcus, KJ; Mullen, EA; Wong, CI, 2023)
"In addition, polyploidy of TEC was observed to correlate with loss of lysozyme staining."1.91Cellular senescence in kidney biopsies is associated with tubular dysfunction and predicts CKD progression in childhood cancer patients with karyomegalic interstitial nephropathy. ( Broekhuizen, R; Goldschmeding, R; Haveman, LM; Janssens, GO; Keijzer-Veen, MG; Knoppert, SN; Lilien, MR; Nguyen, TQ; Stokman, MF; Valentijn, FA; van den Berg, G; van den Heuvel-Eibrink, MM; van Kempen, S, 2023)
"Ifosfamide is an antitumor agent with activity against various malignancies in pediatric patients."1.72Excellent Tolerability of Ifosfamide and Mesna Via Continuous Infusion in a Pediatric Patient Population. ( Anderson, PM; Pierson, CE; Plutt, AA; Stanton, MP; Zahler, S; Zembillas, AS, 2022)
"this study suggests that chemotherapy drug and its cumulative dosage has the most influence on kidney and urinary tract related complications."1.72Chemotherapy induced kidney and urinary tract related complications: A study in the Department of Pediatric Oncology and Hematology. ( Kiaunytė, S; Kiudelienė, R; Maškė, R; Rutkauskienė, G, 2022)
"Ifosfamide is an alkylating agent, mostly used against variety of solid tumors in pediatric oncology practice."1.62Ifosfamide-related encephalopathy with severe clinical presentations in children with cancer. ( Ataseven, E; Göktepe, ŞÖ; Kantar, M, 2021)
"Ifosfamide-related encephalopathy commonly results in a distinct pattern of generalized periodic discharges admixed with intermittent background attenuation on EEG."1.51Clinical and EEG Characteristics of Ifosfamide-Related Encephalopathy. ( Chen, X; Gusdon, AM; Malani, R, 2019)
"Childhood cancer survivors treated with cisplatin, ifosfamide, or carboplatin are at risk for late kidney and blood pressure (BP) abnormalities."1.48Long-term renal follow-up of children treated with cisplatin, carboplatin, or ifosfamide: a pilot study. ( Harel-Sterling, M; Hessey, E; Huynh, L; McMahon, KR; Pizzi, M; Zappitelli, M, 2018)
" Those results are in agreement with literature data reporting that intracellular CAA toxic concentrations range from 35 to 320 μM, after therapeutic ifosfamide dosing."1.43Investigation of ifosfamide and chloroacetaldehyde renal toxicity through integration of in vitro liver-kidney microfluidic data and pharmacokinetic-system biology models. ( Bois, FY; Hamon, J; Leclerc, E, 2016)
" Patients with encephalopathy and patients without encephalopathy were compared on age, Eastern Cooperative Oncology Group (ECOG) performance status (PS), baseline serum creatinine (SCr) level, albumin level, white blood cell count, liver function, brain metastasis, and dosage of ifosfamide."1.43Risk factors of ifosfamide-related encephalopathy in adult patients with cancer: A retrospective analysis. ( Chen, WH; Dong, YH; Lo, Y; Shen, LJ; Wu, FL, 2016)
" Increased hydration and dosage of mesna are administered to patients who develop IFO-induced HC; they also receive 24-h continuous infusion of mesna in subsequent treatment cycles."1.43A retrospective study of treatment and prophylaxis of ifosfamide-induced hemorrhagic cystitis in pediatric and adolescent and young adult (AYA) patients with solid tumors. ( Kumamoto, T; Makino, Y; Ogawa, C; Saito, Y; Tamai, I; Terakado, H, 2016)
"Pediatr Blood Cancer 2015;62:274-278."1.40 ( Adiguzel, R; Andreana, PR; Arslan, Z; Ates, M; Bemis, T; Bercovitch, LG; Bögli, S; Boucherez, J; Boudouf, S; Briat, JF; Brown, BM; Busemann, A; Buters, J; Byers, JS; Cairo, MS; Carrier, F; Chalmers, JJ; Chang, E; Chen, J; Chen, Y; Christenson, MK; Cielecka-Piontek, J; Cole, PA; Cooper, BS; Davis, PH; De Silva, RA; Decato, S; DeFries, RS; Demir, V; Denic, A; Deserno, M; Dickey, AM; Diss, E; Eberlein, B; Eyerich, S; Faluvegi, G; Farlow, MR; Fletcher, JW; Francetic, T; Furlan, L; Garbacki, P; Gartung, A; Garvin, JH; Gates, L; Gaymard, F; Ghetti, B; Gibson, MP; Griffin, RG; Hamed, M; Hammad, LA; Hammond, GB; Han, J; Hann, R; Hao, N; Harrison, LA; Heidecke, CD; Hutchins, GD; Inlow, M; Irmer, H; Jani, P; Jara-Cavieres, A; Jawadi, H; Jiang, Q; Jiang, Y; Kameda, T; Keeler, EG; Kim, H; Kim, R; Kim, S; Kinney, PL; Krause, A; Kumar, V; Kwok, Y; Lam, T; Lanni, F; Le May, M; Lee, A; Lee, JF; Lee, MJ; Leontyev, IV; Li, Q; Li, X; Liu, J; Liu, NK; Lominadze, D; Lösche, M; Lu, QB; Lu, Y; Lu, Z; Mach, H; Madsen, E; Marletta, M; Marlier, ME; McDonald, BC; McKay, IS; Mckenzie, CL; Mecozzi, S; Menges, P; Meyers, D; Michaelis, VK; Montooth, KL; Moore, LR; Morgan, JK; Morris, E; Movahed, M; Nalabothula, N; Narayanan, S; Nguyen, D; Nho, K; Oken, B; Ong, TC; Osborne, LS; Paczkowska, M; Park, EK; Pennino, D; Peters, S; Potluri, LP; Qin, C; Radhakrishnan, K; Randerson, JT; Rantanen, J; Reyt, G; Ring, J; Risacher, SL; Rodriguez, M; Saykin, AJ; Schmidt-Weber, CB; Sengelaub, DR; Shatters, RG; Shen, L; Shen, V; Shindell, DT; Stuchebrukhov, AA; Swaminathan, S; Takahashi, K; Talaczyńska, A; Tallman, EF; Tan, C; Terry, SF; Trabbic, KR; Trease, AJ; Tretter, C; Uitto, J; Váradi, A; von Bernstorff, W; Voulgarakis, A; Wagenhofer, M; Wahbeh, H; Wang, EN; Wang, X; Wells, RJ; West, JD; Williams, PS; Wolff, JE; Wootla, B; Xu, B; Xu, XM; Yoder, KK; Zalewski, P; Zan, GH; Zborowski, M; Zhang, HH; Zhang, W; Zhao, J; Zoecklein, L, 2014)
"Data from 763 adult childhood cancer survivors (414 men) were obtained during regular visits at the late-effects clinic between 2003 and 2009."1.39Long-term nephrotoxicity in adult survivors of childhood cancer. ( Blijdorp, K; Cransberg, K; Dekkers, IA; Neggers, SJ; Pieters, R; Pluijm, SM; van den Heuvel-Eibrink, MM, 2013)
"Nephrotoxicity is a serious side effect associated with ifosfamide use."1.39N-acetylcysteine rescue protocol for nephrotoxicity in children caused by ifosfamide. ( Hanly, L; Huang, SH; Koren, G; Regueira, O; Rieder, MJ; Shah, RK; Vasylyeva, TL, 2013)
"Patients with hematologic or solid tumors who underwent conditioning regimen were asked to score mucositis severity daily from the first day to the tenth day of reinfusion."1.35Self-reported experience of mucositis in cancer patients who underwent conditioning regimen and stem cell transplantation. ( Arpaci, F; Ataergin, S; Kilic, S; Komurcu, S; Kuzhan, O; Ozet, A; Ozturk, B; Ozturk, M, 2009)
"Fatigue is the most frequent symptom experienced by children/adolescents with cancer."1.35Carnitine plasma levels and fatigue in children/adolescents receiving cisplatin, ifosfamide, or doxorubicin. ( Gregurich, M; Hockenberry, MJ; Hooke, MC; McCarthy, K, 2009)
"Ifosfamide was dosed either as a continuous infusion or as fractionated doses over 2 or 3 days."1.33Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer. ( Boddy, AV; Cholerton, S; Ford, D; Parry, A; Pearson, AD; Price, L; Tilby, MJ; Willits, I, 2005)
"9L/2B6 tumors regressed more slowly and exhibited a tumor-free period of only 21 to 39 days."1.33Enhanced antitumor activity of P450 prodrug-based gene therapy using the low Km cyclophosphamide 4-hydroxylase P450 2B11. ( Chen, CS; Jounaidi, Y; Veal, GJ; Waxman, DJ, 2006)
"Despite the continuous improvement of cancer treatment protocols, altered testicular function and infertility frequently represent major adverse effects of oncologic treatments."1.33Progress in the development of childhood cancer therapy. ( Carli, MO; Ferlin, A; Foresta, C; Garolla, A; Pizzato, C; Selice, R, 2006)
"The aim of the study was an assessment of various risk factors for nephrotoxicity of ifosfamide (IF) in children taking into account the importance of the concentrations of toxic metabolites of the drug excreted with urine and the polymorphism of genes encoding S-glutathione transferases of mi, pi, and theta classes (GSTM1, GSTP1 and GSTT1)."1.32[Polymorphism at the glutathione S-transferase pi locus as a risk factor for ifosfamide nephrotoxicity in children]. ( Bodalski, J; Zielińska, E; Zubowska, M, 2003)
"08) and dosage (median 2."1.32Incidence and severity of ifosfamide-induced encephalopathy. ( Fiegl, M; Ostermann, H; Rieger, C; Schiel, X; Tischer, J, 2004)
"The renal functions in pediatric cancer patients who received ifosfamide (IFO) treatment were evaluated and the risk factors related to IFO nephrotoxicity were determined."1.31Ifosfamide nephrotoxicity in pediatric cancer patients. ( Ahn, HS; Cheong, HI; Choi, Y; Ha, IS; Hahn, H; Kang, HG; Lee, BS; Lee, JH; Shin, HY, 2001)
" In this study, we investigated the toxic effects of ifosfamide and cisplatin by clinical and biochemical parameters in relation to (99m)Tc-dimercaptosuccinic acid ((99m)Tc-DMSA) and Tc(99m)N, N-ethylenedicysteine (EC) renal scintigraphy."1.31The utility of (99m)Tc-DMSA and Tc(99m)-EC scintigraphy for early diagnosis of ifosfamide induced nephrotoxicity. ( Akyuz, C; Caglar, M; Yarís, N, 2001)
"Ifosfamide is an analogue of cyclophosphamide active in the treatment of numerous tumours."1.306-Day continuous infusion of high-dose ifosfamide with bone marrow growth factors in advanced refractory malignancies. ( Alexandre, J; Brain, EC; Chaouche, M; Cvitkovic, E; Delord, JP; Errihani, H; Hardy Bessard, AC; Jasmin, C; Misset, JL; Mita, A; Soulié, P, 1997)
" The kinetics of the excretion were compared following short-term and continuous ifosfamide infusion at a dosage of 3 g/m2."1.30Excretion kinetics of ifosfamide side-chain metabolites in children on continuous and short-term infusion. ( Blaschke, G; Boos, J; Hohenlöchter, B; Jürgens, H; Rossi, R; Silies, H, 1998)
"Ifosfamide is an oxazophosphorine widely used in the treatment of cancer in children and adults."1.30Urinary proton magnetic resonance studies of early ifosfamide-induced nephrotoxicity and encephalopathy. ( Foxall, PJ; Hartley, JM; Lapsley, M; Neild, GH; Nicholson, JK; Singer, JM; Souhami, RL, 1997)
"Five patients developed renal Fanconi syndrome during follow-up, and another seven patients developed a generalized subclinical tubulopathy."1.30Development of ifosfamide-induced nephrotoxicity: prospective follow-up in 75 patients. ( Deufel, T; Jürgens, H; Kleta, R; Kuhn, N; Pleyer, J; Rossi, R; Schäfers, P, 1999)
" A critical question in comparing an experimental treatment to a standard is how much increase in an adverse event rate is an acceptable trade-off for achieving a targeted improvement in efficacy, or vice versa."1.30Treatment comparisons based on two-dimensional safety and efficacy alternatives in oncology trials. ( Cheng, SC; Thall, PF, 1999)
"IFM was a common agent among the anti-cancer agents used in these cases."1.29[Ventricular premature contraction observed after anti-cancer chemotherapy with ifosfamide]. ( Abe, Y; Fukuda, H; Kawashima, R; Kubota, K; Sato, T; Takahashi, J; Yamada, K, 1994)
"Paclitaxel was given at a dose of 120 mg/m2 to five patients, 135 mg/m2 to five patients, 150 mg/m2 to three patients, and 175 mg/m2 to 11 patients."1.29Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study. ( Asbury, RF; Boros, L; Chang, AY; Garrow, GC; Hui, L, 1996)
"The ifosfamide treatment schedules had only minimal effects on bromisoval pharmacokinetics."1.29Effect of ifosfamide treatment on glutathione and glutathione conjugation activity in patients with advanced cancers. ( Breimer, DD; Mulder, GJ; Mulders, TM; Ouwerkerk, J; van der Velde, EA, 1995)
"Thirty-two cancer patients were given a 1-day course of chemotherapy consisting of etoposide (VP16), ifosfamide, and cisplatin (VIP; n = 46 cycles), followed by the combined sequential administration of recombinant human interleukin-3 (rhIL-3) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF)."1.28Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide, and cisplatin. ( Bross, K; Brugger, W; Dern, P; Frisch, J; Kanz, L; Mertelsmann, R; Weber, B, 1992)
"Acute encephalopathy following treatment with ifosfamide and mesna was observed in 5 (4 women and 1 men) of 28 patients (17."1.28Encephalopathy in ifosfamide-treated patients. ( Chaitchik, S; Merimsky, O; Reider-Groswasser, I; Wigler, N, 1992)
"Ifosfamide is a newly available analog of cyclophosphamide in the oxazaphosphorine drug class."1.28Ifosfamide vs cyclophosphamide in cancer therapy. ( Weiss, RB, 1991)
" We have studied the feasibility and bioavailability of a subcutaneously (s."1.28Subcutaneous continuous infusion of ifosfamide and cyclophosphamide in ambulatory cancer patients: bioavailability and feasibility. ( Brunner, KW; Cerny, T; Graf, A; Küpfer, A; Rohner, P; Zeugin, T, 1991)
"When ifosfamide 5 g m-2 was given as a 24 h infusion, the decay of the plasma ifosfamide concentration was monoexponential, the median (range) t1/2,z was 4."1.28The pharmacokinetics of ifosfamide given as short and long intravenous infusions in cancer patients. ( Fitzgerald, DL; Harper, PG; Lewis, LD; Mohan, P; Rogers, HJ; Thatcher, N, 1991)
"Ifosfamide has broad cytotoxicity against solid tumors and may prove to be an important addition to high-dose combination chemotherapy regimens."1.28High-dose ifosfamide with mesna uroprotection: a phase I study. ( Antman, KH; Begg, CB; Eder, JP; Elias, AD; Frei, E; Shea, T, 1990)
"Ifosfamide is an important alkylating agent that should be combined with other agents in phase II and III trials."1.28Ifosfamide in pediatric malignant solid tumors. ( Douglass, EC; Etcubanas, EL; Goren, MP; Green, AA; Hayes, FA; Horowitz, ME; Meyer, WH; Pratt, CB; Thompson, EI; Wilimas, JA, 1989)
"Ifosfamide has been shown to be an active agent in the treatment of several childhood cancers."1.28Toxicity of high-dose ifosfamide in children. ( Craft, AW; Davies, SM; Pearson, AD, 1989)
"One hundred and forty-six patients with advanced malignant disease were treated with 6 different dosage schedules of ifosfamide (IFX)."1.28Ifosfamide and mesna in the treatment of malignant disease mesna as urothelial protector. ( Falkson, CI; Falkson, G; Falkson, HC, 1989)
"Ifosfamide (IFS) is a new alkylating oxazaphosphorine related to cyclophosphamide."1.28Ifosfamide cardiotoxicity in humans. ( Efremidis, AP; Kandylis, K; Tsoussis, S; Vassilomanolakis, M, 1989)
"The antitumor activity of ifosfamide in testicular cancer was not reduced by mesna."1.27Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: results of a clinical phase II-study with 151 patients. ( Bremer, K; Niederle, N; Scheulen, ME; Schütte, J; Seeber, S, 1983)
"Ifosfamide/mesna treatment of 50 patients with pediatric malignant solid tumors was associated with the development of neurotoxic signs and symptoms in 11 of these individuals who received 29 courses of treatment."1.27Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna. ( Douglass, E; Etcubanas, E; Green, AA; Hayes, FA; Horowitz, ME; Igarashi, M; Meyer, WH; Pratt, CB; Thompson, E; Wilimas, J, 1986)
"Ifosfamide was given to 61 patients with malignant solid tumors diagnosed before the age of 21 years."1.27Phase II trial of ifosfamide in children with malignant solid tumors. ( Douglass, EC; Etcubanas, E; Green, AA; Hayes, FA; Horowitz, ME; Meyer, WH; Pratt, CB; Thompson, EI; Wilimas, JA, 1987)
" Analysis of the results according to sex, age, dosage of ifosfamide and degree of histological differentiation of the tumour cells failed to show any influence of these factors on the therapeutic results."1.27Treatment of advanced malignancies with ifosfamide under protection with mesna. ( Brock, N; Guan, ZZ; He, YJ; Li, GC; Li, JQ, 1988)
"Thirty-two patients with advanced cancer were treated in a phase I-II trial with ifosfamide plus mesnum."1.26Mesnum as a protector against kidney and bladder toxicity with high-dose ifosfamide treatment. ( Falkson, G; Falkson, HC; Stapelberg, R; Van Dyk, JJ, 1982)
"153 patients with inoperable malignant tumors were treated by the so-called synchronization therapy with vincristine and ifosfamide."1.26[Clinical experiences with holoxan within the framework of sequential combination therapy (author's transl)]. ( Hartwich, G; Lutz, H; Neidhardt, B, 1978)
" Plasma half-life for ifosfamide given in the divided-dose schedule was 6."1.26Pharmacokinetics of divided-dose ifosfamide. ( Allen, LM; Creaven, PJ; Nelson, RL, 1976)
"Ifosfamide was given in i."1.26Reduction of ifosfamide toxicity using dose fractionation. ( Bodey, GP; Freireich, EJ; McCredie, KB; McKelvey, EM; Rodriguez, V; Tashima, CK, 1976)

Research

Studies (276)

TimeframeStudies, this research(%)All Research%
pre-199061 (22.10)18.7374
1990's110 (39.86)18.2507
2000's66 (23.91)29.6817
2010's31 (11.23)24.3611
2020's8 (2.90)2.80

Authors

AuthorsStudies
Plutt, AA1
Stanton, MP1
Zembillas, AS1
Pierson, CE1
Zahler, S1
Anderson, PM2
Kiaunytė, S1
Maškė, R1
Kiudelienė, R1
Rutkauskienė, G1
Fukushima, H1
Mizumoto, M1
Suzuki, R1
Yamaki, Y1
Hosaka, S1
Inaba, M1
Tagawa, M1
Watanabe, A1
Okunushi, T1
Masumoto, K1
Muroi, A1
Sakurai, H1
Takada, H1
Wong, CI1
Benedetti, DJ1
Kao, PC1
Ma, C1
Marcus, KJ1
Mullen, EA1
Knoppert, SN1
Keijzer-Veen, MG1
Valentijn, FA1
van den Heuvel-Eibrink, MM2
Lilien, MR1
van den Berg, G1
Haveman, LM1
Stokman, MF1
Janssens, GO1
van Kempen, S1
Broekhuizen, R1
Goldschmeding, R1
Nguyen, TQ1
Ide, Y1
Yanagisawa, R1
Kubota, N1
Sakashita, K1
Tozuka, M1
Nakamura, T1
Honda, T1
Torres Espíndola, LM1
Rojo-Serrato, D1
Álvaro-Heredia, A1
Castillejos López, MJ1
de Uña-Flores, A1
Pérez-García, M1
Zapata-Tarres, M1
Cárdenas-Cardos, R1
Granados, J1
Chávez-Pacheco, JL1
Salinas-Lara, C1
de Arellano, IT1
Aquino-Gálvez, A1
Mascarenhas, L1
Ogawa, C2
Laetsch, TW1
Weigel, BJ1
Bishop, MW1
Krystal, J1
Borinstein, SC1
Slotkin, EK1
Muscal, JA1
Hingorani, P1
Levy, DE1
Mo, G1
Shahir, A1
Wright, J1
DuBois, SG1
Ataseven, E1
Göktepe, ŞÖ1
Kantar, M1
Sterling, M1
Al-Ismaili, Z1
McMahon, KR2
Piccioni, M1
Pizzi, M2
Mottes, T1
Lands, LC1
Abish, S1
Fleming, AJ1
Bennett, MR1
Palijan, A1
Devarajan, P1
Goldstein, SL1
O'Brien, MM1
Zappitelli, M2
Skinner, R8
Ruggiero, A1
Ferrara, P1
Attinà, G1
Rizzo, D1
Riccardi, R1
Harel-Sterling, M1
Huynh, L1
Hessey, E1
Gusdon, AM1
Malani, R1
Chen, X1
Dekkers, IA1
Blijdorp, K1
Cransberg, K1
Pluijm, SM1
Pieters, R1
Neggers, SJ1
Hanly, L1
Rieder, MJ1
Huang, SH1
Vasylyeva, TL1
Shah, RK1
Regueira, O1
Koren, G3
Hartmann, JT3
Horger, M1
Kluba, T1
Königsrainer, A1
de Zwart, P1
von Weyhern, CH1
Eckert, F1
Budach, W1
Bokemeyer, C4
Hamberg, P2
Boers-Sonderen, MJ1
van der Graaf, WT1
de Bruijn, P1
Suttle, AB1
Eskens, FA1
Verweij, J5
van Herpen, CM1
Sleijfer, S2
Sloderbach, A1
Górska, A1
Sikorska, M1
Misiura, K1
Hładoń, B1
Lowenberg, D1
Thorn, CF1
Desta, Z1
Flockhart, DA1
Altman, RB1
Klein, TE1
Wang, WQ1
Zhang, ZH1
Zhou, JP1
Pang, H1
Lü, HX1
Xiao, Y1
Liu, J2
Liu, YC1
Huang, XE1
Guo, JX1
Wei, W1
Lam, CG1
Furman, WL4
Wang, C1
Spunt, SL1
Wu, J1
Ivy, P1
Santana, VM2
McGregor, LM1
Hooke, MC2
McCarthy, K2
Taylor, O1
Hockenberry, MJ2
Kameda, T1
Takahashi, K1
Kim, R1
Jiang, Y1
Movahed, M1
Park, EK1
Rantanen, J1
Marlier, ME1
DeFries, RS1
Voulgarakis, A1
Kinney, PL1
Randerson, JT1
Shindell, DT1
Chen, Y1
Faluvegi, G1
Diss, E1
Nalabothula, N1
Nguyen, D1
Chang, E1
Kwok, Y1
Carrier, F1
Radhakrishnan, K1
Lee, A1
Harrison, LA1
Morris, E1
Shen, V4
Gates, L1
Wells, RJ1
Wolff, JE1
Garvin, JH1
Cairo, MS7
Eberlein, B1
Hann, R1
Eyerich, S1
Pennino, D1
Ring, J1
Schmidt-Weber, CB1
Buters, J1
Dickey, AM1
Trease, AJ1
Jara-Cavieres, A1
Kumar, V1
Christenson, MK1
Potluri, LP1
Morgan, JK1
Shatters, RG1
Mckenzie, CL1
Davis, PH1
Osborne, LS1
Francetic, T1
Le May, M1
Hamed, M1
Mach, H1
Meyers, D1
Cole, PA1
Chen, J1
Li, Q1
Zborowski, M1
Moore, LR1
Williams, PS1
Chalmers, JJ1
Cooper, BS1
Hammad, LA1
Montooth, KL1
Bögli, S1
Brown, BM1
Marletta, M1
Tretter, C1
Wagenhofer, M1
Leontyev, IV1
Stuchebrukhov, AA1
Ates, M1
Demir, V1
Adiguzel, R1
Arslan, Z1
Zan, GH1
Tan, C1
Deserno, M1
Lanni, F1
Lösche, M1
Decato, S1
Bemis, T1
Madsen, E1
Mecozzi, S1
Trabbic, KR1
De Silva, RA1
Andreana, PR1
Wahbeh, H1
Oken, B1
Uitto, J1
Jiang, Q1
Váradi, A1
Bercovitch, LG1
Terry, SF1
Zhao, J1
Lee, JF1
Gartung, A1
Jawadi, H1
Zhang, W1
Lominadze, D1
Lee, MJ1
Denic, A1
Wootla, B1
Zoecklein, L1
Rodriguez, M1
Kim, S1
Nho, K1
Risacher, SL1
Inlow, M1
Swaminathan, S1
Yoder, KK1
Shen, L1
West, JD1
McDonald, BC1
Tallman, EF1
Hutchins, GD1
Fletcher, JW1
Farlow, MR1
Ghetti, B1
Saykin, AJ1
Reyt, G1
Boudouf, S1
Boucherez, J1
Gaymard, F1
Briat, JF1
Hao, N1
Zhang, HH1
Gibson, MP1
Jani, P1
Wang, X1
Lu, Y1
Qin, C1
Han, J1
Lu, Z1
Hammond, GB1
Xu, B1
Liu, NK1
Byers, JS1
Lam, T1
Lu, QB1
Sengelaub, DR1
Xu, XM1
von Bernstorff, W1
Irmer, H1
Menges, P1
Peters, S1
Heidecke, CD1
Busemann, A1
Li, X1
Narayanan, S1
Michaelis, VK1
Ong, TC1
Keeler, EG1
Kim, H1
McKay, IS1
Griffin, RG1
Wang, EN1
Furlan, L1
Paczkowska, M1
Zalewski, P1
Garbacki, P1
Talaczyńska, A1
Krause, A1
Cielecka-Piontek, J1
Leclerc, E2
Hamon, J1
Bois, FY1
Lo, Y1
Shen, LJ1
Chen, WH1
Dong, YH1
Wu, FL1
Saito, Y1
Kumamoto, T1
Makino, Y1
Tamai, I1
Terakado, H1
Bali Prasad, B1
Kumar, A1
Singh, R1
Cacheux, W1
Gourmel, B1
Alexandre, J2
Germann, N1
Rabillon, F1
Duffau, B1
Goldwasser, F1
Geller, JI1
Wall, D1
Perentesis, J1
Blaney, SM1
Bernstein, M1
Lu, H1
Chen, CS2
Waxman, DJ5
Di Cataldo, A1
Astuto, M1
Rizzo, G1
Bertuna, G1
Russo, G1
Incorpora, G1
Ozturk, M1
Komurcu, S1
Kilic, S1
Ozet, A1
Arpaci, F1
Ozturk, B1
Kuzhan, O1
Ataergin, S1
Ridola, V1
Fawaz, O1
Aubier, F1
Bergeron, C1
de Vathaire, F1
Pichon, F1
Orbach, D1
Gentet, JC1
Schmitt, C1
Dufour, C2
Oberlin, O2
Shimizu, T1
Okamoto, I1
Tamura, K1
Satoh, T2
Miyazaki, M1
Akashi, Y1
Ozaki, T1
Fukuoka, M1
Nakagawa, K1
Gregurich, M1
Specenier, P1
Rasschaert, M1
Van den Brande, J2
Dyck, J1
Schrijvers, D4
Huizing, MT1
Vermorken, JB2
Parry, A3
Price, L6
Cole, M2
Craft, AW5
Pearson, AD9
Giraud, B1
Hebert, G1
Deroussent, A1
Veal, GJ3
Vassal, G1
Paci, A2
Steeghs, N1
Loos, WJ1
van de Biessen, D1
den Hollander, M1
Tascilar, M1
Gelderblom, H1
Levin, RD1
Daehler, M1
Grutsch, JF1
Hall, JL1
Gupta, D1
Lis, CG1
Mazur, L1
Opydo-Chanek, M1
Stojak, M1
Perkins, JB3
Goldstein, SC2
Dawson, JL1
Kim, J1
Field, TL1
Partyka, JS1
Fields, KK4
Maddox, BL1
Simonelli, CE1
Neuger, AM1
Lush, RM1
Sullivan, DM1
Lacombe, D1
Choucha Snouber, L1
Jacques, S1
Monge, M1
Legallais, C1
Marx, G1
Lewis, C1
Hall, K1
Levi, J1
Ackland, S1
Kozuka, T1
Ikeda, K1
Teshima, T1
Kojima, K1
Matsuo, K1
Bessho, A1
Sunami, K1
Hiramatsu, Y1
Maeda, Y1
Noguchi, T1
Yamamoto, K1
Fujii, N1
Imai, T1
Takenaka, K1
Shinagawa, K1
Ishimaru, F1
Niiya, K1
Koide, N1
Tanimoto, M1
Harada, M1
Niculescu-Duvaz, I1
Baldwin, A1
Huang, Z1
Jounaidi, Y2
Moore, AS1
Kitchell, BE1
Zielińska, E1
Zubowska, M1
Bodalski, J1
Buesa, JM2
García-Teijido, P1
Losa, R2
Fra, J1
Carli, M1
Passone, E1
Perilongo, G1
Bisogno, G1
Smith, PF1
Booker, BM1
Creaven, P1
Perez, R2
Pendyala, L2
Kempgens, B1
Kisro, J1
Gruber, Y1
Bahrs, H1
Wagner, T5
Loss, JF1
Santos, PP1
Leone, LD1
Brunetto, AL2
Rieger, C1
Fiegl, M1
Tischer, J1
Ostermann, H1
Schiel, X1
Kerbusch, T2
Groenewegen, G1
Mathôt, RA1
Herben, VM1
ten Bokkel Huinink, WW1
Swart, M1
Ambaum, B1
Rosing, H1
Jansen, S1
Voest, EE1
Beijnen, JH2
Schellens, JH3
Goren, MP7
Epelman, S2
Bush, DA1
Davenport, V3
Bessmertny, O1
Goldman, SC1
Berg, SL1
Kreissman, SG1
Laver, J1
Secola, R3
van de Ven, C4
Reaman, GH4
Angiolillo, AL1
Bonilla, MA1
Ayello, J1
Militano, O1
Miller, LL1
Krailo, M1
Reaman, G1
Willits, I1
Tilby, MJ1
Ford, D1
Cholerton, S1
Boddy, AV3
Sierra, MI1
Fernández, A1
Blanco, D1
Olver, I1
Keefe, D1
Myers, M1
Caruso, D1
David, KA1
Picus, J1
Errington, J1
Hale, J1
Howe, K1
Chisholm, JC1
Beane, C1
Brennan, B1
Waters, F1
Glaser, A1
Hemsworth, S1
McDowell, H1
Wright, Y1
Pritchard-Jones, K1
Pinkerton, R1
Jenner, G1
Nicholson, J1
Elsworth, AM1
Sakai, S1
Kawabata, K1
Tanaka, S1
Harimoto, N1
Hashimoto, I1
Mu, C1
Salmons, B1
Ijima, H1
Kawakami, K1
Roy, P1
Grill, J1
Sabouraud, P1
Behar, C1
Munzer, M1
Motte, J1
Hartmann, O1
Kilickap, S1
Cakar, M1
Onal, IK1
Tufan, A1
Akoglu, H1
Aksoy, S1
Erman, M1
Tekuzman, G1
Holzgrabe, U1
Garolla, A1
Pizzato, C1
Ferlin, A1
Carli, MO1
Selice, R1
Foresta, C1
Cruz, LB1
Ribeiro, AS1
Rech, A1
Rosa, LG1
Castro, CG1
Kopf, B1
De Giorgi, U1
Vertogen, B1
Monti, G1
Molinari, A1
Turci, D1
Dazzi, C1
Leoni, M1
Tienghi, A1
Cariello, A1
Argnani, M1
Frassineti, L1
Scarpi, E1
Rosti, G1
Marangolo, M1
Brain, EG1
Rezai, K1
Weill, S1
Gauzan, MF1
Santoni, J1
Besse, B1
Goupil, A1
Turpin, F1
Urien, S1
Lokiec, F1
Brüggemann, SK1
Pfäffle, S1
Peters, SO1
Phillips, RS1
Tyerman, K1
Al-Kassim, MI1
Picton, S1
Pawlicki, M1
Zuchowska-Vogelgesang, B1
Holoye, PY2
Anderson, T2
Duelge, J2
Hansen, RM2
Ritch, PS2
Scheef, W4
de Kraker, J7
Voûte, PA3
Klein, HO2
Wickramanayake, PD2
Coerper, C2
Christian, E2
Pohl, J2
Brock, N5
Burkert, H3
Scheulen, ME1
Niederle, N2
Bremer, K2
Schütte, J1
Seeber, S2
Nobile, MT1
Rosso, R2
Brema, F1
Cinquegrana, A1
Santi, L1
Retsas, S1
Colvin, M1
Hunter, HL1
Harrison, EF1
Czownicki, Z1
Utracka-Hutka, B1
Falkson, G2
Van Dyk, JJ1
Stapelberg, R1
Falkson, HC2
Spitzer, G1
Dicke, KA1
Litam, J1
Verma, DS1
Zander, A1
Lanzotti, V1
Valdivieso, M1
McCredie, KB2
Samuels, ML1
Higi, M1
Bierbaum, W1
Schmidt, CG1
Takahashi, J1
Kawashima, R1
Abe, Y1
Fukuda, H1
Kubota, K1
Yamada, K1
Sato, T1
Brugger, W6
Henschler, R1
Heimfeld, S2
Berenson, RJ2
Mertelsmann, R6
Kanz, L8
Elfenbein, GJ3
Janssen, WE1
Ballester, OF2
Hiemenz, JW3
Zorsky, PE3
Kronish, LE2
Foody, MC1
Dercksen, MW1
Gerritsen, WR1
Rodenhuis, S1
Dirkson, MK1
Slaper-Cortenbach, IC1
Schaasberg, WP1
Pinedo, HM1
von dem Borne, AE1
van der Schoot, CE1
Toma, S1
Palumbo, R1
Comandone, A2
Oliva, C1
Vincenti, M1
Bumma, C1
González-Manzano, R1
Cid, J1
Brugarolas, A1
Piasecki, CC1
Kung, FH1
Desai, SJ1
Dickerman, JD1
Goorin, AM1
Harris, MB1
Inoue, S1
Krischer, JP1
Murphy, SB1
Pratt, CB16
Toledano, S1
Chang, AY2
Möcklin, W1
Birken, R1
Bertz, H1
Hecht, T1
Pressler, K2
Frisch, J3
Schulz, G2
Keizer, HJ1
Ouwerkerk, J2
Welvaart, K1
van der Velde, CJ1
Cleton, FJ1
van Hoff, J1
Grier, HE1
Douglass, EC5
Green, DM1
Jones, DP2
Chesney, RW1
Katz, A1
Anelli, A1
Gorender, EF1
Cruz, SM1
Oliveira, RM1
Marques, LA1
Anninga, JK1
Valdés Olmos, RA1
van Tinteren, H1
Hoefnagel, CA1
van Royen, EA1
Elias, AD5
Ayash, LJ4
Wheeler, C4
Schwartz, G3
Tepler, I1
McCauley, M2
Mazanet, R1
Schnipper, L4
Frei, E4
Antman, KH3
Rossi, RM1
Kist, C1
Wurster, U1
Külpmann, WR1
Ehrich, JH3
Prasad, VK1
Corlett, SA1
Abaasi, K1
Heney, D1
Lewis, I1
Chrystyn, H1
DiMaggio, JR1
Brown, R1
Baile, WF1
Schapira, D1
Marina, NM2
Rodman, JH2
Murry, DJ1
Shema, SJ2
Bowman, LC2
Furman, W2
Meyer, WH10
Lind, MJ1
Ardiet, C1
Sakuma, H1
Matsumoto, E1
Kanno, H1
Watanabe, M1
Kikuta, A1
Suzuki, H1
Rossi, R5
Gödde, A1
Kleinebrand, A1
Riepenhausen, M1
Boos, J2
Ritter, J1
Jürgens, H4
De Schepper, J1
Hachimi-Idrissi, S1
Verboven, M1
Piepsz, A1
Otten, J1
Wainer, IW2
Cameron, JC1
Rath, B1
Ullrich, K1
Hewitt, M1
McQuade, B1
Stevens, R1
Lokich, JJ1
Zipoli, TE1
Anderson, NR1
Moore, C1
Gonzalves, L1
Bern, MM1
Coco, F1
Rodman, J1
Douglass, E2
Hudson, M1
Wilimas, J3
Meyer, W1
Bowman, L1
Ochs, J1
Marina, N4
Avery, L2
Thompson, EI4
Lokich, J1
Skubitz, KM1
Boros, L1
Garrow, GC1
Asbury, RF1
Hui, L1
Palackdharry, CS1
Luo, X3
Fang, L1
Wiedemann, GJ1
Robins, HI1
Katschinski, DM1
Mentzel, M1
van Heek, R1
Touhidi, RR1
Bucsky, P1
Gillis, W1
Feyerabend, T1
d'Oleire, F1
Freund, C1
Eleftheriadis, S1
Weiss, C1
Dueñas-Gonzalez, A1
Sobrevilla-Calvo, P1
Frias-Mendivil, M1
Gallardo-Rincon, D1
Lara-Medina, F1
Aguilar-Ponce, L1
Miranda-Lopez, E1
Zinser-Sierra, J1
Reynoso-Gomez, E1
Lotz, JP2
Izrael, V1
Womer, RB1
Roguin, A1
Ben Arush, MW1
Higasi, A1
Kuten, A1
English, MW2
Wyllie, RA1
Coulthard, MG2
Triozzi, PL1
Tucker, F1
Benzies, T1
Balcerzak, SP1
Lewis, LD5
Fairclough, D1
Garrison, L3
Bleyer, A1
Wyllie, R1
Brain, EC1
Mita, A1
Soulié, P1
Errihani, H1
Hardy Bessard, AC1
Chaouche, M1
Delord, JP1
Cvitkovic, E1
Jasmin, C1
Misset, JL1
Agaliotis, DP1
Mattox, T1
Rosen, RM1
Liubimova, NV1
Kumykova, ZhKh1
Kushlinskiĭ, NE1
Kasumov, ChM1
Durnov, LA1
Tonda, ME1
Arnold, B1
Hanna, R1
Bunnell, CA1
Thompson, L1
Buswell, L1
Berkowitz, R1
Muto, M1
Sheets, E1
Shulman, LN1
Pronk, LC2
de Bruijn, EA2
Planting, AS3
Locci-Tonelli, D2
Groult, V2
van Oosterom, AT2
MacLean, FR1
Hall, AG1
English, M1
Ibrahim, J1
Mills, L1
Coleman, N1
Warren, D1
Teicher, BA1
Silies, H1
Blaschke, G1
Hohenlöchter, B1
de Wit, R1
Kruit, WH1
Lamers, CH1
van 't Veer, MB1
Luyten, AA1
van Beurden, V1
Harteveld, M1
Schmitz, PI1
Stoter, G1
Bolhuis, RL1
Advani, SH1
Vogel, W1
Kunert, C1
Blumenstengel, K1
Fricke, HJ1
Kath, R2
Sayer, HG1
Höffken, K2
Kushner, BH1
Heller, G1
Cheung, NK1
Wollner, N1
Kramer, K1
Bajorin, D1
Polyak, T1
Meyers, PA1
Krailo, MD3
Weinthal, JA1
Bergeron, S2
Blazar, BR3
Yule, SM1
Foxall, PJ1
Singer, JM1
Hartley, JM1
Neild, GH1
Lapsley, M1
Nicholson, JK1
Souhami, RL1
Mulders, TM1
van der Velde, EA1
Breimer, DD1
Mulder, GJ1
Pleyer, J1
Schäfers, P1
Kuhn, N1
Kleta, R1
Deufel, T1
Cesana, C1
Regazzi, E1
Garau, D1
Caramatti, C1
Mangoni, L1
Rizzoli, V1
Pelgrims, J1
De Vos, F1
Prové, A1
Kosmas, C1
Tsavaris, NB1
Polyzos, A1
Malamos, NA1
Katsikas, M1
Antonopoulos, MJ1
Ando, Y1
Moyano, AJ1
Seguí, MA1
Abad, T1
Urruticoechea, L1
García López, JL1
Nogué, M1
Dominguez, MS1
Balcells, M1
Dorado, JF1
De Pas, T1
Curigliano, G1
Catania, C1
de Braud, F1
Knop, S2
Fels, LM2
van Vangerow, A1
Stolte, H1
Creaven, PJ3
Meropol, NJ1
Bolanowska-Higdon, W1
Zdanowicz, J1
Murphy, M1
Payne, GS1
Pinkerton, CR3
Bouffet, E1
Leach, MO1
Di Marco, MP1
Granvil, CL1
Batist, G1
Ducharme, MP1
Stolt, H1
Briasoulis, E1
Judson, I1
Pavlidis, N1
Beale, P1
Wanders, J1
Groot, Y1
Veerman, G1
Schuessler, M1
Niebch, G1
Siamopoulos, K1
Tzamakou, E1
Rammou, D1
Wolf, L1
Walker, R1
Hanauske, A1
Bauer, M1
Miser, JS2
Sato, JK1
Blatt, J1
Frierdich, S1
Liu-Mares, W2
Bracho, F1
Panoskaltsis-Mortari, A1
Ames, MM1
Reid, JM1
Miglietta, L1
Marenghi, C1
Nizzo, R1
Foglia, G1
Ragni, N1
Boccardo, F1
Thall, PF1
Cheng, SC1
Mathĵt, RA1
Fouladi, M1
Stempak, D1
Gammon, J1
Klein, J1
Grant, R1
Greenberg, ML1
Baruchel, S1
Lee, BS1
Lee, JH2
Kang, HG1
Hahn, H1
Shin, HY1
Ha, IS1
Cheong, HI1
Ahn, HS1
Choi, Y1
Caglar, M1
Yarís, N1
Akyuz, C1
Christodoulou, C1
Klouvas, G1
Efstathiou, E1
Zervakis, D1
Papazachariou, E1
Plyta, M1
Skarlos, DV1
Nielsen, E1
Brant, J1
Dittrich, C1
Chen, L1
Schneider, CP1
Merkel, U1
Grübner, U1
Hoffmann, A1
Graziano, F1
Bisonni, R1
Catalano, V1
Silva, R1
Rovidati, S1
Mencarini, E1
Ferraro, B1
Canestrari, F1
Baldelli, AM1
De Gaetano, A1
Giordani, P1
Testa, E1
Lai, V1
Brühl, P2
Hoefer-Janker, H3
Vahlensieck, W2
Carter, SK2
Slavik, M2
Ritter, S1
Schröder, HJ1
Costanzi, JJ1
Hartwich, G1
Neidhardt, B1
Lutz, H1
Wicart, L1
Nelson, RL2
Cohen, MH1
Fossieck, BE1
Günther, U2
Hüls, W2
Schnitker, J1
Fichtner, E1
Przybylski, M1
Ringsdorf, H1
Lenssen, U1
Peter, G1
Voelcker, G1
Hohorst, HJ1
Madej, G1
Zelechowska, JA1
Clavel, B1
Mathé, G1
Hayat, M1
Allen, LM1
Rodriguez, V1
Bodey, GP1
Freireich, EJ1
McKelvey, EM1
Tashima, CK1
Bross, K1
Dern, P1
Weber, B1
Weiss, RB2
Wilson, WH1
Jain, V1
Bryant, G1
Cowan, KH1
Carter, C1
Cottler-Fox, M1
Goldspiel, B1
Steinberg, SM1
Longo, DL1
Wittes, RE1
Burton, LC1
Harper, PG3
Rogers, HJ4
Merimsky, O1
Reider-Groswasser, I1
Wigler, N1
Chaitchik, S1
Schmoll, HJ1
Harstrick, A1
Illiger, HJ1
Metzner, B1
Ruther, U1
Osternamm, A1
Preiss, J1
Wilke, H1
Hohnloser, J1
Shore, R1
Greenberg, M1
Geary, D1
Uhlenbusch, R1
Dechant, KL1
Brogden, RN1
Pilkington, T1
Faulds, D1
Loeffler, TM1
Weber, FW1
Hausamen, TU1
Cerny, T2
Graf, A1
Rohner, P1
Zeugin, T1
Brunner, KW1
Küpfer, A2
Kurowski, V1
Eder, JP3
Deary, J2
Weissman, L2
Hunt, M2
Critchlow, J2
Vogelzang, NJ1
Schryber, S1
Dorr, RT1
Machover, D1
Malassagne, B1
Hingh, B1
Donsimoni, R1
Gumus, Y1
Gerota, J1
Lam, Y1
Tulliez, M1
Marsiglia, H1
Shaw, PJ1
Eden, T1
Fitzgerald, DL2
Mohan, P1
Thatcher, N1
Shea, T1
Begg, CB1
Schoenike, SE1
Dana, WJ1
Perevodchikova, NI1
Orel, NF1
Trofimova, NV1
Schneider, B1
Singh, B1
Dodge, RK3
Etcubanas, E3
Green, AA4
Hayes, FA4
Horowitz, ME5
Wilimas, JA3
Ninane, J1
Baurain, R1
Ferster, A1
Trouet, A1
Cornu, G1
Etcubanas, EL1
Davies, SM1
Falkson, CI1
Wright, RK2
Viar, MJ2
Treuner, J1
Winkler, K1
Göbel, U1
Pritchard, J2
Kandylis, K1
Vassilomanolakis, M1
Tsoussis, S1
Efremidis, AP1
Thompson, E1
Igarashi, M1
Andriole, GL1
Sandlund, JT1
Arasi, V1
Linehan, M1
Magrath, IT1
Li, GC2
Li, JQ2
Guan, ZZ2
He, YJ2
Philip, PA1
James, CA1
Lazarus, HM1
Berger, NA1
Cavalli, F1
Muchi, H1
Taniguchi, Y1
Makino, S1
Kovnar, EH1
Brade, WP1
Herdrich, K1
Varini, M1
Rogers, H1
James, C1
Bowman, A1
Barbor, PR1
Eden, OB1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase II Dose of Escalation Design to Investigate the Therapeutic Role of RNA Fragments in the Protection of Platelet Production During Chemotherapy[NCT01163110]Phase 132 participants (Actual)Interventional2004-03-31Completed
A Phase I Study of Thrombopoietin (rhTPO) Plus G-CSF in Children Receiving Ifosfamide, Carboplatin, and Etoposide (I.C.E.) Chemotherapy for Recurrent or Refractory Solid Tumors[NCT00003597]Phase 116 participants (Actual)Interventional1998-11-30Completed
Laser Therapy Associated With Photodynamic Therapy in the Treatment of Oral Mucositis Induced by Chemotherapy in Young Patients: Randomized Blind Clinical Trial[NCT02555501]Phase 318 participants (Actual)Interventional2014-10-31Completed
A Randomised, Double Blinded Cross-over Study Comparing the Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis[NCT01149525]Phase 359 participants (Actual)Interventional2010-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

48 reviews available for ifosfamide and Neoplasms

ArticleYear
Late renal toxicity of treatment for childhood malignancy: risk factors, long-term outcomes, and surveillance.
    Pediatric nephrology (Berlin, Germany), 2018, Volume: 33, Issue:2

    Topics: Antineoplastic Agents; Carboplatin; Child; Cisplatin; Humans; Ifosfamide; Kidney; Kidney Diseases; N

2018
Late renal toxicity of treatment for childhood malignancy: risk factors, long-term outcomes, and surveillance.
    Pediatric nephrology (Berlin, Germany), 2018, Volume: 33, Issue:2

    Topics: Antineoplastic Agents; Carboplatin; Child; Cisplatin; Humans; Ifosfamide; Kidney; Kidney Diseases; N

2018
Renal toxicity and chemotherapy in children with cancer.
    British journal of clinical pharmacology, 2017, Volume: 83, Issue:12

    Topics: Age of Onset; Antineoplastic Agents; Child; Child, Preschool; Cisplatin; Humans; Ifosfamide; Inciden

2017
Renal toxicity and chemotherapy in children with cancer.
    British journal of clinical pharmacology, 2017, Volume: 83, Issue:12

    Topics: Age of Onset; Antineoplastic Agents; Child; Child, Preschool; Cisplatin; Humans; Ifosfamide; Inciden

2017
[Classical oxazaphosphorines--metabolism and therapeutic properties--new implications].
    Postepy higieny i medycyny doswiadczalnej (Online), 2013, Dec-10, Volume: 67

    Topics: Acetaldehyde; Aldehyde Dehydrogenase; Animals; Antineoplastic Agents; Biotransformation; Cyclophosph

2013
[Classical oxazaphosphorines--metabolism and therapeutic properties--new implications].
    Postepy higieny i medycyny doswiadczalnej (Online), 2013, Dec-10, Volume: 67

    Topics: Acetaldehyde; Aldehyde Dehydrogenase; Animals; Antineoplastic Agents; Biotransformation; Cyclophosph

2013
[An overview of glycoconjugates for cancer targeting therapy and diagnosis].
    Yao xue xue bao = Acta pharmaceutica Sinica, 2013, Volume: 48, Issue:12

    Topics: Animals; Antineoplastic Agents; Drug Carriers; Energy Metabolism; Glucose; Glycoconjugates; Glycolys

2013
[An overview of glycoconjugates for cancer targeting therapy and diagnosis].
    Yao xue xue bao = Acta pharmaceutica Sinica, 2013, Volume: 48, Issue:12

    Topics: Animals; Antineoplastic Agents; Drug Carriers; Energy Metabolism; Glucose; Glycoconjugates; Glycolys

2013
Oxazaphosphorines: new therapeutic strategies for an old class of drugs.
    Expert opinion on drug metabolism & toxicology, 2010, Volume: 6, Issue:8

    Topics: Animals; Antineoplastic Agents, Alkylating; Cyclophosphamide; Cytochrome P-450 Enzyme System; Drug D

2010
Oxazaphosphorines: new therapeutic strategies for an old class of drugs.
    Expert opinion on drug metabolism & toxicology, 2010, Volume: 6, Issue:8

    Topics: Animals; Antineoplastic Agents, Alkylating; Cyclophosphamide; Cytochrome P-450 Enzyme System; Drug D

2010
Glufosfamide as a new oxazaphosphorine anticancer agent.
    Anti-cancer drugs, 2011, Volume: 22, Issue:6

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell

2011
Glufosfamide as a new oxazaphosphorine anticancer agent.
    Anti-cancer drugs, 2011, Volume: 22, Issue:6

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell

2011
Glufosfamide: can we improve the process of anticancer agent development?
    Expert opinion on investigational drugs, 2012, Volume: 21, Issue:5

    Topics: Alkylating Agents; Animals; Antineoplastic Agents; Drug Discovery; Glucose; Humans; Ifosfamide; Neop

2012
Glufosfamide: can we improve the process of anticancer agent development?
    Expert opinion on investigational drugs, 2012, Volume: 21, Issue:5

    Topics: Alkylating Agents; Animals; Antineoplastic Agents; Drug Discovery; Glucose; Humans; Ifosfamide; Neop

2012
Glufosfamide (Baxter Oncology).
    Current opinion in investigational drugs (London, England : 2000), 2002, Volume: 3, Issue:10

    Topics: Animals; Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Glucose; Humans; Ifosfamide; N

2002
Glufosfamide (Baxter Oncology).
    Current opinion in investigational drugs (London, England : 2000), 2002, Volume: 3, Issue:10

    Topics: Animals; Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Glucose; Humans; Ifosfamide; N

2002
New chemotherapy agents in veterinary medicine.
    The Veterinary clinics of North America. Small animal practice, 2003, Volume: 33, Issue:3

    Topics: Animals; Antineoplastic Agents; Cat Diseases; Cats; Deoxycytidine; Dog Diseases; Dogs; Gemcitabine;

2003
New chemotherapy agents in veterinary medicine.
    The Veterinary clinics of North America. Small animal practice, 2003, Volume: 33, Issue:3

    Topics: Animals; Antineoplastic Agents; Cat Diseases; Cats; Deoxycytidine; Dog Diseases; Dogs; Gemcitabine;

2003
Chronic ifosfamide nephrotoxicity in children.
    Medical and pediatric oncology, 2003, Volume: 41, Issue:3

    Topics: Antineoplastic Agents, Alkylating; Child; Chronic Disease; Humans; Ifosfamide; Kidney Diseases; Neop

2003
Chronic ifosfamide nephrotoxicity in children.
    Medical and pediatric oncology, 2003, Volume: 41, Issue:3

    Topics: Antineoplastic Agents, Alkylating; Child; Chronic Disease; Humans; Ifosfamide; Kidney Diseases; Neop

2003
Ifosfamide in pediatric solid tumors.
    Oncology, 2003, Volume: 65 Suppl 2

    Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Cyclophosphamide; Germinoma; Humans; Ifosf

2003
Ifosfamide in pediatric solid tumors.
    Oncology, 2003, Volume: 65 Suppl 2

    Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Cyclophosphamide; Germinoma; Humans; Ifosf

2003
Glufosfamide: beta-D-Glc-IPM, D 19575.
    Drugs in R&D, 2005, Volume: 6, Issue:1

    Topics: Antineoplastic Agents, Alkylating; Breast Neoplasms; Clinical Trials as Topic; Female; Glucose; Huma

2005
Glufosfamide: beta-D-Glc-IPM, D 19575.
    Drugs in R&D, 2005, Volume: 6, Issue:1

    Topics: Antineoplastic Agents, Alkylating; Breast Neoplasms; Clinical Trials as Topic; Female; Glucose; Huma

2005
Evaluating risk factors for the development of ifosfamide encephalopathy.
    American journal of clinical oncology, 2005, Volume: 28, Issue:3

    Topics: Adult; Aged; Akathisia, Drug-Induced; Antineoplastic Agents, Alkylating; Brain Diseases; Cohort Stud

2005
Evaluating risk factors for the development of ifosfamide encephalopathy.
    American journal of clinical oncology, 2005, Volume: 28, Issue:3

    Topics: Adult; Aged; Akathisia, Drug-Induced; Antineoplastic Agents, Alkylating; Brain Diseases; Cohort Stud

2005
Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.
    Toxicology in vitro : an international journal published in association with BIBRA, 2006, Volume: 20, Issue:2

    Topics: Animals; Antineoplastic Agents, Alkylating; Cyclophosphamide; Cytochrome P-450 Enzyme System; Geneti

2006
Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer.
    Toxicology in vitro : an international journal published in association with BIBRA, 2006, Volume: 20, Issue:2

    Topics: Animals; Antineoplastic Agents, Alkylating; Cyclophosphamide; Cytochrome P-450 Enzyme System; Geneti

2006
A systematic review of the accuracy and utility of early markers of Ifosfamide-induced proximal tubulopathy in survivors of childhood cancers.
    Pediatric hematology and oncology, 2008, Volume: 25, Issue:2

    Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents, Alkylating; Biomarkers; Child; Child, Presc

2008
A systematic review of the accuracy and utility of early markers of Ifosfamide-induced proximal tubulopathy in survivors of childhood cancers.
    Pediatric hematology and oncology, 2008, Volume: 25, Issue:2

    Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents, Alkylating; Biomarkers; Child; Child, Presc

2008
[New antineoplastic agents, their value and use].
    Przeglad lekarski, 1982, Volume: 39, Issue:8

    Topics: Aminacrine; Antineoplastic Agents; Aspartic Acid; Cisplatin; Etoposide; Humans; Ifosfamide; Interfer

1982
[New antineoplastic agents, their value and use].
    Przeglad lekarski, 1982, Volume: 39, Issue:8

    Topics: Aminacrine; Antineoplastic Agents; Aspartic Acid; Cisplatin; Etoposide; Humans; Ifosfamide; Interfer

1982
The comparative pharmacology of cyclophosphamide and ifosfamide.
    Seminars in oncology, 1982, Volume: 9, Issue:4 Suppl 1

    Topics: Alkylation; Biotransformation; Chemical Phenomena; Chemistry; Cyclophosphamide; Half-Life; Humans; I

1982
The comparative pharmacology of cyclophosphamide and ifosfamide.
    Seminars in oncology, 1982, Volume: 9, Issue:4 Suppl 1

    Topics: Alkylation; Biotransformation; Chemical Phenomena; Chemistry; Cyclophosphamide; Half-Life; Humans; I

1982
Ifosfamide: European perspective.
    Seminars in oncology, 1982, Volume: 9, Issue:4 Suppl 1

    Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Administrat

1982
Ifosfamide: European perspective.
    Seminars in oncology, 1982, Volume: 9, Issue:4 Suppl 1

    Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Administrat

1982
The anticancer spectrum of ifosfamide.
    Seminars in oncology, 1982, Volume: 9, Issue:4 Suppl 1

    Topics: Breast Neoplasms; Cyclophosphamide; Drug Evaluation; Female; Humans; Ifosfamide; Lung Neoplasms; Mal

1982
The anticancer spectrum of ifosfamide.
    Seminars in oncology, 1982, Volume: 9, Issue:4 Suppl 1

    Topics: Breast Neoplasms; Cyclophosphamide; Drug Evaluation; Female; Humans; Ifosfamide; Lung Neoplasms; Mal

1982
Strategies to prevent nephrotoxicity of anticancer drugs.
    Current opinion in oncology, 1995, Volume: 7, Issue:4

    Topics: Adult; Antineoplastic Agents; Cell Line; Chelating Agents; Child; Child, Preschool; Cisplatin; Human

1995
Strategies to prevent nephrotoxicity of anticancer drugs.
    Current opinion in oncology, 1995, Volume: 7, Issue:4

    Topics: Adult; Antineoplastic Agents; Cell Line; Chelating Agents; Child; Child, Preschool; Cisplatin; Human

1995
The use of ifosfamide, carboplatin, and etoposide in children with solid tumors.
    Seminars in oncology, 1995, Volume: 22, Issue:3 Suppl 7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Etoposide; Humans; Ifosfamide; L

1995
The use of ifosfamide, carboplatin, and etoposide in children with solid tumors.
    Seminars in oncology, 1995, Volume: 22, Issue:3 Suppl 7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Etoposide; Humans; Ifosfamide; L

1995
Renal toxicity of cancer chemotherapeutic agents in children: ifosfamide and cisplatin.
    Current opinion in pediatrics, 1995, Volume: 7, Issue:2

    Topics: Child; Cisplatin; Glomerular Filtration Rate; Humans; Ifosfamide; Kidney; Kidney Diseases; Kidney Tu

1995
Renal toxicity of cancer chemotherapeutic agents in children: ifosfamide and cisplatin.
    Current opinion in pediatrics, 1995, Volume: 7, Issue:2

    Topics: Child; Cisplatin; Glomerular Filtration Rate; Humans; Ifosfamide; Kidney; Kidney Diseases; Kidney Tu

1995
Pharmacokinetics of alkylating agents.
    Cancer surveys, 1993, Volume: 17

    Topics: Alkylating Agents; Carmustine; Chlorambucil; Cyclophosphamide; Humans; Ifosfamide; Lomustine; Melpha

1993
Pharmacokinetics of alkylating agents.
    Cancer surveys, 1993, Volume: 17

    Topics: Alkylating Agents; Carmustine; Chlorambucil; Cyclophosphamide; Humans; Ifosfamide; Lomustine; Melpha

1993
Haematopoietic growth factors and peripheral blood stem cells as supportive agents in dose intensification.
    European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A Suppl 5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Transfusion, Autologous; Cis

1993
Haematopoietic growth factors and peripheral blood stem cells as supportive agents in dose intensification.
    European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A Suppl 5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Transfusion, Autologous; Cis

1993
Stereoisomers in clinical oncology: why it is important to know what the right and left hands are doing.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1993, Volume: 4 Suppl 2

    Topics: Antineoplastic Agents; Humans; Ifosfamide; Leucovorin; Neoplasms; Stereoisomerism; Verapamil

1993
Stereoisomers in clinical oncology: why it is important to know what the right and left hands are doing.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1993, Volume: 4 Suppl 2

    Topics: Antineoplastic Agents; Humans; Ifosfamide; Leucovorin; Neoplasms; Stereoisomerism; Verapamil

1993
Ongoing clinical studies of ifosfamide for pediatric cancer in the United States.
    Seminars in oncology, 1996, Volume: 23, Issue:3 Suppl 6

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Proto

1996
Ongoing clinical studies of ifosfamide for pediatric cancer in the United States.
    Seminars in oncology, 1996, Volume: 23, Issue:3 Suppl 6

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Proto

1996
[Clinical studies on combination of ifosfamide, carboplatin and etoposide (ICE) with whole body hyperthermia].
    Medizinische Klinik (Munich, Germany : 1983), 1996, May-15, Volume: 91, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Etoposide; H

1996
[Clinical studies on combination of ifosfamide, carboplatin and etoposide (ICE) with whole body hyperthermia].
    Medizinische Klinik (Munich, Germany : 1983), 1996, May-15, Volume: 91, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Etoposide; H

1996
The role of ifosfamide in paediatric cancer.
    Australian and New Zealand journal of medicine, 1998, Volume: 28, Issue:3

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Child; Humans; If

1998
The role of ifosfamide in paediatric cancer.
    Australian and New Zealand journal of medicine, 1998, Volume: 28, Issue:3

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Child; Humans; If

1998
Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.
    British journal of cancer, 2000, Volume: 82, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Diseases; Dose-Response Relationsh

2000
Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.
    British journal of cancer, 2000, Volume: 82, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Diseases; Dose-Response Relationsh

2000
Ifosfamide in the elderly: clinical considerations for a better drug management.
    Critical reviews in oncology/hematology, 2000, Volume: 33, Issue:2

    Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Humans; Ifosfamide; Neoplas

2000
Ifosfamide in the elderly: clinical considerations for a better drug management.
    Critical reviews in oncology/hematology, 2000, Volume: 33, Issue:2

    Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Humans; Ifosfamide; Neoplas

2000
Chemotherapy-induced neurotoxicity: assessment and interventions for patients at risk.
    The American journal of nursing, 2002, Volume: 102 Suppl 4

    Topics: Antineoplastic Agents; Cisplatin; Cytarabine; Humans; Ifosfamide; Methotrexate; Neoplasms; Neurotoxi

2002
Chemotherapy-induced neurotoxicity: assessment and interventions for patients at risk.
    The American journal of nursing, 2002, Volume: 102 Suppl 4

    Topics: Antineoplastic Agents; Cisplatin; Cytarabine; Humans; Ifosfamide; Methotrexate; Neoplasms; Neurotoxi

2002
Introducing ifosfamide in innovative treatment modalities.
    Cancer chemotherapy and pharmacology, 2002, Volume: 49 Suppl 1

    Topics: Antineoplastic Agents, Alkylating; Area Under Curve; Child; Drug Delivery Systems; Humans; Ifosfamid

2002
Introducing ifosfamide in innovative treatment modalities.
    Cancer chemotherapy and pharmacology, 2002, Volume: 49 Suppl 1

    Topics: Antineoplastic Agents, Alkylating; Area Under Curve; Child; Drug Delivery Systems; Humans; Ifosfamid

2002
Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer.
    Current pharmaceutical design, 2002, Volume: 8, Issue:15

    Topics: Antineoplastic Agents, Alkylating; Bystander Effect; Cyclophosphamide; Cytochrome P-450 Enzyme Syste

2002
Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer.
    Current pharmaceutical design, 2002, Volume: 8, Issue:15

    Topics: Antineoplastic Agents, Alkylating; Bystander Effect; Cyclophosphamide; Cytochrome P-450 Enzyme Syste

2002
Investigational drugs under study by the United States National Cancer Institute.
    Cancer treatment reviews, 1976, Volume: 3, Issue:1

    Topics: Acrylates; Alkylating Agents; Ancitabine; Animals; Antibiotics, Antineoplastic; Antimetabolites, Ant

1976
Investigational drugs under study by the United States National Cancer Institute.
    Cancer treatment reviews, 1976, Volume: 3, Issue:1

    Topics: Acrylates; Alkylating Agents; Ancitabine; Animals; Antibiotics, Antineoplastic; Antimetabolites, Ant

1976
Current investigational drugs of interest in the Chemotherapy Program of the National Cancer Institute.
    National Cancer Institute monograph, 1977, Issue:45

    Topics: Altretamine; Animals; Antineoplastic Agents; Asparaginase; Azacitidine; Bleomycin; Cisplatin; Dacarb

1977
Current investigational drugs of interest in the Chemotherapy Program of the National Cancer Institute.
    National Cancer Institute monograph, 1977, Issue:45

    Topics: Altretamine; Animals; Antineoplastic Agents; Asparaginase; Azacitidine; Bleomycin; Cisplatin; Dacarb

1977
Hypersensitivity reactions.
    Seminars in oncology, 1992, Volume: 19, Issue:5

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Asparaginase; Aziridines; Benzoquinones; Bleomyc

1992
Hypersensitivity reactions.
    Seminars in oncology, 1992, Volume: 19, Issue:5

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Asparaginase; Aziridines; Benzoquinones; Bleomyc

1992
Ifosfamide in pediatric oncology.
    Seminars in oncology, 1992, Volume: 19, Issue:1 Suppl 1

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Clinical Protoc

1992
Ifosfamide in pediatric oncology.
    Seminars in oncology, 1992, Volume: 19, Issue:1 Suppl 1

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Clinical Protoc

1992
Current studies of ifosfamide for pediatric solid tumors and leukemia in the United States.
    Seminars in oncology, 1992, Volume: 19, Issue:6 Suppl 12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Child; Chil

1992
Current studies of ifosfamide for pediatric solid tumors and leukemia in the United States.
    Seminars in oncology, 1992, Volume: 19, Issue:6 Suppl 12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Child; Chil

1992
Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.
    Drugs, 1991, Volume: 42, Issue:3

    Topics: Drug Evaluation; Drug Therapy, Combination; Female; Humans; Ifosfamide; Male; Mesna; Neoplasms

1991
Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.
    Drugs, 1991, Volume: 42, Issue:3

    Topics: Drug Evaluation; Drug Therapy, Combination; Female; Humans; Ifosfamide; Male; Mesna; Neoplasms

1991
Ifosfamide in pediatric oncology.
    Anti-cancer drugs, 1991, Volume: 2, Issue:4

    Topics: Child; Child, Preschool; Humans; Ifosfamide; Infant; Neoplasms

1991
Ifosfamide in pediatric oncology.
    Anti-cancer drugs, 1991, Volume: 2, Issue:4

    Topics: Child; Child, Preschool; Humans; Ifosfamide; Infant; Neoplasms

1991
Nephrotoxicity from chemotherapy: prevention and management.
    Oncology (Williston Park, N.Y.), 1991, Volume: 5, Issue:10

    Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Gallium; Humans; Ifosfamide; Kidney Diseases; Methotr

1991
Nephrotoxicity from chemotherapy: prevention and management.
    Oncology (Williston Park, N.Y.), 1991, Volume: 5, Issue:10

    Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Gallium; Humans; Ifosfamide; Kidney Diseases; Methotr

1991
Chemoprotectants for cancer chemotherapy.
    Seminars in oncology, 1991, Volume: 18, Issue:1 Suppl 2

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Asparaginase; Cisplatin; Cyclophosphamide; Fluor

1991
Chemoprotectants for cancer chemotherapy.
    Seminars in oncology, 1991, Volume: 18, Issue:1 Suppl 2

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Asparaginase; Cisplatin; Cyclophosphamide; Fluor

1991
Ifosfamide in paediatric oncology: tried but not tested?
    Lancet (London, England), 1990, Apr-28, Volume: 335, Issue:8696

    Topics: Child; Cyclophosphamide; Evaluation Studies as Topic; Humans; Ifosfamide; Neoplasms; Prognosis; Sarc

1990
Ifosfamide in paediatric oncology: tried but not tested?
    Lancet (London, England), 1990, Apr-28, Volume: 335, Issue:8696

    Topics: Child; Cyclophosphamide; Evaluation Studies as Topic; Humans; Ifosfamide; Neoplasms; Prognosis; Sarc

1990
Ifosfamide and mesna.
    Clinical pharmacy, 1990, Volume: 9, Issue:3

    Topics: Animals; Humans; Ifosfamide; Mercaptoethanol; Mesna; Neoplasms

1990
Ifosfamide and mesna.
    Clinical pharmacy, 1990, Volume: 9, Issue:3

    Topics: Animals; Humans; Ifosfamide; Mercaptoethanol; Mesna; Neoplasms

1990
Ifosfamide studies for primary or recurrent pediatric malignant solid tumors and leukemia.
    Seminars in oncology, 1990, Volume: 17, Issue:2 Suppl 4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Humans; Ifosfamide; Leukemia; Lymphoma; Neopl

1990
Ifosfamide studies for primary or recurrent pediatric malignant solid tumors and leukemia.
    Seminars in oncology, 1990, Volume: 17, Issue:2 Suppl 4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Humans; Ifosfamide; Leukemia; Lymphoma; Neopl

1990
Ifosfamide in pediatric malignancies.
    Seminars in oncology, 1989, Volume: 16, Issue:1 Suppl 3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Humans; Ifosfamide; Neoplasms

1989
Ifosfamide in pediatric malignancies.
    Seminars in oncology, 1989, Volume: 16, Issue:1 Suppl 3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Humans; Ifosfamide; Neoplasms

1989
Chemotherapy of malignant disease: an update.
    Comprehensive therapy, 1988, Volume: 14, Issue:5

    Topics: Amsacrine; Antineoplastic Agents; Cisplatin; Coformycin; Etoposide; Female; Humans; Ifosfamide; Male

1988
Chemotherapy of malignant disease: an update.
    Comprehensive therapy, 1988, Volume: 14, Issue:5

    Topics: Amsacrine; Antineoplastic Agents; Cisplatin; Coformycin; Etoposide; Female; Humans; Ifosfamide; Male

1988
Ifosfamide--pharmacology, safety and therapeutic potential.
    Cancer treatment reviews, 1985, Volume: 12, Issue:1

    Topics: Animals; Biotransformation; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Evalu

1985
Ifosfamide--pharmacology, safety and therapeutic potential.
    Cancer treatment reviews, 1985, Volume: 12, Issue:1

    Topics: Animals; Biotransformation; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Evalu

1985

Trials

96 trials available for ifosfamide and Neoplasms

ArticleYear
Analysis of the clinical characteristics of pediatric patients who experience ifosfamide-induced encephalopathy.
    Pediatric blood & cancer, 2019, Volume: 66, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Carboplatin; Child; Child, Preschool

2019
Analysis of the clinical characteristics of pediatric patients who experience ifosfamide-induced encephalopathy.
    Pediatric blood & cancer, 2019, Volume: 66, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Carboplatin; Child; Child, Preschool

2019
Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors.
    Cancer medicine, 2021, Volume: 10, Issue:3

    Topics: Adolescent; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Central Nervous

2021
Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors.
    Cancer medicine, 2021, Volume: 10, Issue:3

    Topics: Adolescent; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Central Nervous

2021
Urine biomarkers of acute kidney injury in noncritically ill, hospitalized children treated with chemotherapy.
    Pediatric blood & cancer, 2017, Volume: 64, Issue:10

    Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carboplatin; Child;

2017
Urine biomarkers of acute kidney injury in noncritically ill, hospitalized children treated with chemotherapy.
    Pediatric blood & cancer, 2017, Volume: 64, Issue:10

    Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carboplatin; Child;

2017
A non-comparative phase II study of dose intensive chemotherapy with doxorubicin and ifosfamide followed by high dose ICE consolidation with PBSCT in non-resectable, high grade, adult type soft tissue sarcomas.
    Investigational new drugs, 2013, Volume: 31, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Doxorubicin; Etoposide; Female;

2013
A non-comparative phase II study of dose intensive chemotherapy with doxorubicin and ifosfamide followed by high dose ICE consolidation with PBSCT in non-resectable, high grade, adult type soft tissue sarcomas.
    Investigational new drugs, 2013, Volume: 31, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Doxorubicin; Etoposide; Female;

2013
Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I study.
    British journal of cancer, 2014, Feb-18, Volume: 110, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship,

2014
Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I study.
    British journal of cancer, 2014, Feb-18, Volume: 110, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship,

2014
Phase II study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:9

    Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Carmustine; Cisplatin; Cyclophosphamide; Dacarbazin

2014
Phase II study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:9

    Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Carmustine; Cisplatin; Cyclophosphamide; Dacarbazin

2014
Phase I clinical trial of ifosfamide, oxaliplatin, and etoposide (IOE) in pediatric patients with refractory solid tumors.
    Journal of pediatric hematology/oncology, 2015, Volume: 37, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Etoposid

2015
Phase I clinical trial of ifosfamide, oxaliplatin, and etoposide (IOE) in pediatric patients with refractory solid tumors.
    Journal of pediatric hematology/oncology, 2015, Volume: 37, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Etoposid

2015
An original administration of ifosfamide given once every other week: a clinical and pharmacological study.
    Anti-cancer drugs, 2008, Volume: 19, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Chromatography, Gas; Cytochrome P-

2008
An original administration of ifosfamide given once every other week: a clinical and pharmacological study.
    Anti-cancer drugs, 2008, Volume: 19, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Chromatography, Gas; Cytochrome P-

2008
Phase I study of paclitaxel with standard dose ifosfamide in children with refractory solid tumors: a Pediatric Oncology Group study (POG 9376).
    Pediatric blood & cancer, 2009, Volume: 52, Issue:3

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dose-Response R

2009
Phase I study of paclitaxel with standard dose ifosfamide in children with refractory solid tumors: a Pediatric Oncology Group study (POG 9376).
    Pediatric blood & cancer, 2009, Volume: 52, Issue:3

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dose-Response R

2009
Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent D-19575 (glufosfamide) in patients with solid tumors.
    Cancer chemotherapy and pharmacology, 2010, Volume: 65, Issue:2

    Topics: Aged; Antineoplastic Agents; Female; Glucose; Humans; Ifosfamide; Infusions, Intravenous; Male; Midd

2010
Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent D-19575 (glufosfamide) in patients with solid tumors.
    Cancer chemotherapy and pharmacology, 2010, Volume: 65, Issue:2

    Topics: Aged; Antineoplastic Agents; Female; Glucose; Humans; Ifosfamide; Infusions, Intravenous; Male; Midd

2010
Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I study.
    Anti-cancer drugs, 2010, Volume: 21, Issue:3

    Topics: Adult; Aged; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Brain Injuries;

2010
Docetaxel, ifosfamide and cisplatin in solid tumour treatment: a phase I study.
    Anti-cancer drugs, 2010, Volume: 21, Issue:3

    Topics: Adult; Aged; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Brain Injuries;

2010
Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies.
    British journal of cancer, 2010, Jun-08, Volume: 102, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Inte

2010
Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies.
    British journal of cancer, 2010, Jun-08, Volume: 102, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Inte

2010
Dose escalation study of an anti-thrombocytopenic agent in patients with chemotherapy induced thrombocytopenia.
    BMC cancer, 2010, Oct-19, Volume: 10

    Topics: Adult; Aged; Antineoplastic Agents; Blood Platelets; Dacarbazine; Dose-Response Relationship, Drug;

2010
Dose escalation study of an anti-thrombocytopenic agent in patients with chemotherapy induced thrombocytopenia.
    BMC cancer, 2010, Oct-19, Volume: 10

    Topics: Adult; Aged; Antineoplastic Agents; Blood Platelets; Dacarbazine; Dose-Response Relationship, Drug;

2010
Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with autologous stem cell transplant in refractory cancer: pharmacokinetic and pharmacodynamic correlates.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Dec-15, Volume: 17, Issue:24

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Combined Modality Therapy;

2011
Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with autologous stem cell transplant in refractory cancer: pharmacokinetic and pharmacodynamic correlates.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Dec-15, Volume: 17, Issue:24

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Combined Modality Therapy;

2011
Phase I study of docetaxel plus ifosfamide in patients with advanced cancer.
    British journal of cancer, 2002, Oct-07, Volume: 87, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Respons

2002
Phase I study of docetaxel plus ifosfamide in patients with advanced cancer.
    British journal of cancer, 2002, Oct-07, Volume: 87, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Respons

2002
Pharmacokinetics and pharmacodynamics of mesna-mediated plasma cysteine depletion.
    Journal of clinical pharmacology, 2003, Volume: 43, Issue:12

    Topics: Antineoplastic Agents, Alkylating; Area Under Curve; Carboplatin; Chromatography, High Pressure Liqu

2003
Pharmacokinetics and pharmacodynamics of mesna-mediated plasma cysteine depletion.
    Journal of clinical pharmacology, 2003, Volume: 43, Issue:12

    Topics: Antineoplastic Agents, Alkylating; Area Under Curve; Carboplatin; Chromatography, High Pressure Liqu

2003
Two schedules of application for mesna and their influence on the thiol-metabolism.
    International journal of clinical pharmacology and therapeutics, 2003, Volume: 41, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Epirubicin; Etoposide;

2003
Two schedules of application for mesna and their influence on the thiol-metabolism.
    International journal of clinical pharmacology and therapeutics, 2003, Volume: 41, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Epirubicin; Etoposide;

2003
Outcome of pediatric recurrent and refractory malignant solid tumors following ifosfamide/carboplatin/etoposide (ICE): A phase II study in a pediatric oncology centre in Brazil.
    Pediatric blood & cancer, 2004, Volume: 42, Issue:2

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brazil; Carboplatin; Child; Child, Presc

2004
Outcome of pediatric recurrent and refractory malignant solid tumors following ifosfamide/carboplatin/etoposide (ICE): A phase II study in a pediatric oncology centre in Brazil.
    Pediatric blood & cancer, 2004, Volume: 42, Issue:2

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brazil; Carboplatin; Child; Child, Presc

2004
Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks.
    British journal of cancer, 2004, Jun-14, Volume: 90, Issue:12

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; D

2004
Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks.
    British journal of cancer, 2004, Jun-14, Volume: 90, Issue:12

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; D

2004
Urine mesna excretion after intravenous and oral dosing in ifosfamide-treated children.
    Cancer chemotherapy and pharmacology, 2004, Volume: 54, Issue:3

    Topics: Administration, Oral; Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Female

2004
Urine mesna excretion after intravenous and oral dosing in ifosfamide-treated children.
    Cancer chemotherapy and pharmacology, 2004, Volume: 54, Issue:3

    Topics: Administration, Oral; Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Female

2004
Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study.
    British journal of haematology, 2005, Volume: 128, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Presch

2005
Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study.
    British journal of haematology, 2005, Volume: 128, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Presch

2005
A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children's Oncology Gro
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Apr-01, Volume: 11, Issue:7

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Child; Ch

2005
A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children's Oncology Gro
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Apr-01, Volume: 11, Issue:7

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Child; Ch

2005
A phase I study of prolonged ambulatory infusion of Ifosfamide with oral mesna.
    Chemotherapy, 2005, Volume: 51, Issue:2-3

    Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Antineoplastic Agents, Alkylating; Cohort Studie

2005
A phase I study of prolonged ambulatory infusion of Ifosfamide with oral mesna.
    Chemotherapy, 2005, Volume: 51, Issue:2-3

    Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Antineoplastic Agents, Alkylating; Cohort Studie

2005
Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study Group Study.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Aug-15, Volume: 11, Issue:16

    Topics: Adolescent; Adult; Analysis of Variance; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylat

2005
Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study Group Study.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Aug-15, Volume: 11, Issue:16

    Topics: Adolescent; Adult; Analysis of Variance; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylat

2005
Influence of low-energy laser in the prevention of oral mucositis in children with cancer receiving chemotherapy.
    Pediatric blood & cancer, 2007, Volume: 48, Issue:4

    Topics: Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Campt

2007
Influence of low-energy laser in the prevention of oral mucositis in children with cancer receiving chemotherapy.
    Pediatric blood & cancer, 2007, Volume: 48, Issue:4

    Topics: Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Campt

2007
A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization.
    Bone marrow transplantation, 2006, Volume: 38, Issue:6

    Topics: Adjuvants, Immunologic; Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemothera

2006
A randomized study comparing filgrastim versus lenograstim versus molgramostim plus chemotherapy for peripheral blood progenitor cell mobilization.
    Bone marrow transplantation, 2006, Volume: 38, Issue:6

    Topics: Adjuvants, Immunologic; Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemothera

2006
Variations in schedules of ifosfamide administration: a better understanding of its implications on pharmacokinetics through a randomized cross-over study.
    Cancer chemotherapy and pharmacology, 2007, Volume: 60, Issue:3

    Topics: Adult; Antineoplastic Agents, Alkylating; Area Under Curve; Cross-Over Studies; Drug Administration

2007
Variations in schedules of ifosfamide administration: a better understanding of its implications on pharmacokinetics through a randomized cross-over study.
    Cancer chemotherapy and pharmacology, 2007, Volume: 60, Issue:3

    Topics: Adult; Antineoplastic Agents, Alkylating; Area Under Curve; Cross-Over Studies; Drug Administration

2007
Influence of short-term use of dexamethasone on the pharmacokinetics of ifosfamide in patients.
    Drug metabolism and disposition: the biological fate of chemicals, 2007, Volume: 35, Issue:10

    Topics: Acetaldehyde; Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents, Alkylating; Dexamethasone

2007
Influence of short-term use of dexamethasone on the pharmacokinetics of ifosfamide in patients.
    Drug metabolism and disposition: the biological fate of chemicals, 2007, Volume: 35, Issue:10

    Topics: Acetaldehyde; Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents, Alkylating; Dexamethasone

2007
Use and safety of high-dose ifosfamide.
    Seminars in oncology, 1982, Volume: 9, Issue:4 Suppl 1

    Topics: Adenocarcinoma; Aged; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Clinical Trials as Topic; Cyc

1982
Use and safety of high-dose ifosfamide.
    Seminars in oncology, 1982, Volume: 9, Issue:4 Suppl 1

    Topics: Adenocarcinoma; Aged; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Clinical Trials as Topic; Cyc

1982
Clinical overview of mesna.
    Cancer treatment reviews, 1983, Volume: 10 Suppl A

    Topics: Clinical Trials as Topic; Cyclophosphamide; Drug Interactions; Hematuria; Humans; Ifosfamide; Mercap

1983
Clinical overview of mesna.
    Cancer treatment reviews, 1983, Volume: 10 Suppl A

    Topics: Clinical Trials as Topic; Cyclophosphamide; Drug Interactions; Hematuria; Humans; Ifosfamide; Mercap

1983
Therapeutic effects of single-push or fractionated injections or continuous infusion of oxazaphosphorines (cyclophosphamide, ifosfamide, Asta Z 7557).
    Cancer, 1984, Sep-15, Volume: 54, Issue:6 Suppl

    Topics: Animals; Clinical Trials as Topic; Cyclophosphamide; Humans; Ifosfamide; Infusions, Parenteral; Kidn

1984
Therapeutic effects of single-push or fractionated injections or continuous infusion of oxazaphosphorines (cyclophosphamide, ifosfamide, Asta Z 7557).
    Cancer, 1984, Sep-15, Volume: 54, Issue:6 Suppl

    Topics: Animals; Clinical Trials as Topic; Cyclophosphamide; Humans; Ifosfamide; Infusions, Parenteral; Kidn

1984
Phase II study of ifosfamide combined with Mesna uroprotection in advanced non-small-cell lung carcinoma and other solid tumors.
    Tumori, 1984, Oct-31, Volume: 70, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; Humans; Ifosfa

1984
Phase II study of ifosfamide combined with Mesna uroprotection in advanced non-small-cell lung carcinoma and other solid tumors.
    Tumori, 1984, Oct-31, Volume: 70, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; Humans; Ifosfa

1984
Ifosfamide: European perspective.
    Seminars in oncology, 1982, Volume: 9, Issue:4 Suppl 1

    Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Administrat

1982
Ifosfamide: European perspective.
    Seminars in oncology, 1982, Volume: 9, Issue:4 Suppl 1

    Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Administrat

1982
[Clinical evaluation of Mitexan in the prevention of urinary tract complications during treatment with Holoxan].
    Nowotwory, 1981, Volume: 30, Issue:4

    Topics: Clinical Trials as Topic; Cyclophosphamide; Cystitis; Hematuria; Humans; Ifosfamide; Mercaptoethanol

1981
[Clinical evaluation of Mitexan in the prevention of urinary tract complications during treatment with Holoxan].
    Nowotwory, 1981, Volume: 30, Issue:4

    Topics: Clinical Trials as Topic; Cyclophosphamide; Cystitis; Hematuria; Humans; Ifosfamide; Mercaptoethanol

1981
Positively selected autologous blood CD34+ cells and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP16, ifosfamide, carboplatin, and epirubicin.
    Blood, 1994, Sep-01, Volume: 84, Issue:5

    Topics: Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Ble

1994
Positively selected autologous blood CD34+ cells and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP16, ifosfamide, carboplatin, and epirubicin.
    Blood, 1994, Sep-01, Volume: 84, Issue:5

    Topics: Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Ble

1994
High-dose ifosfamide/carboplatin/etoposide: maximum tolerable doses, toxicities, and hematopoietic recovery after autologous stem cell reinfusion.
    Seminars in oncology, 1994, Volume: 21, Issue:5 Suppl 12

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relati

1994
High-dose ifosfamide/carboplatin/etoposide: maximum tolerable doses, toxicities, and hematopoietic recovery after autologous stem cell reinfusion.
    Seminars in oncology, 1994, Volume: 21, Issue:5 Suppl 12

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relati

1994
Ambulatory 4-day continuous-infusion schedule of high-dose ifosfamide with mesna uroprotection and granulocyte colony-stimulating factor in advanced solid tumours: a phase I study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1995, Volume: 6, Issue:2

    Topics: Adult; Aged; Ambulatory Care; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Imm

1995
Ambulatory 4-day continuous-infusion schedule of high-dose ifosfamide with mesna uroprotection and granulocyte colony-stimulating factor in advanced solid tumours: a phase I study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1995, Volume: 6, Issue:2

    Topics: Adult; Aged; Ambulatory Care; Female; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Imm

1995
Cyclosporin A and doxorubicin-ifosfamide in resistant solid tumours: a phase I and an immunological study.
    British journal of cancer, 1995, Volume: 72, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfa

1995
Cyclosporin A and doxorubicin-ifosfamide in resistant solid tumours: a phase I and an immunological study.
    British journal of cancer, 1995, Volume: 72, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfa

1995
Ifosfamide/carboplatin/etoposide (ICE) for recurrent malignant solid tumors of childhood: a Pediatric Oncology Group Phase I/II study.
    Journal of pediatric hematology/oncology, 1995, Volume: 17, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Presch

1995
Ifosfamide/carboplatin/etoposide (ICE) for recurrent malignant solid tumors of childhood: a Pediatric Oncology Group Phase I/II study.
    Journal of pediatric hematology/oncology, 1995, Volume: 17, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Presch

1995
Etoposide, ifosfamide, and cisplatin therapy for refractory childhood solid tumors. Response and toxicity.
    Cancer, 1995, Jun-15, Volume: 75, Issue:12

    Topics: Adolescent; Adult; Bone Marrow; Child; Child, Preschool; Cisplatin; Drug Administration Schedule; Dr

1995
Etoposide, ifosfamide, and cisplatin therapy for refractory childhood solid tumors. Response and toxicity.
    Cancer, 1995, Jun-15, Volume: 75, Issue:12

    Topics: Adolescent; Adult; Bone Marrow; Child; Child, Preschool; Cisplatin; Drug Administration Schedule; Dr

1995
A prospective randomized evaluation of three schedules of mesna administration in patients receiving an ifosfamide-containing chemotherapy regimen: sustained efficiency and simplified administration.
    Journal of cancer research and clinical oncology, 1995, Volume: 121, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Fe

1995
A prospective randomized evaluation of three schedules of mesna administration in patients receiving an ifosfamide-containing chemotherapy regimen: sustained efficiency and simplified administration.
    Journal of cancer research and clinical oncology, 1995, Volume: 121, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Fe

1995
High-dose ifosfamide/carboplatin/etoposide with autologous hematopoietic stem cell support: safety and future directions.
    Seminars in oncology, 1994, Volume: 21, Issue:5 Suppl 12

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Forecasting; Hematolo

1994
High-dose ifosfamide/carboplatin/etoposide with autologous hematopoietic stem cell support: safety and future directions.
    Seminars in oncology, 1994, Volume: 21, Issue:5 Suppl 12

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Forecasting; Hematolo

1994
Ifosfamide, carboplatin, and etoposide: a new regimen with a broad spectrum of activity.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; H

1994
Ifosfamide, carboplatin, and etoposide: a new regimen with a broad spectrum of activity.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; H

1994
Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in treatment of newly diagnosed pediatric solid tumors.
    Journal of the National Cancer Institute, 1994, Apr-06, Volume: 86, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carboplatin; Child; Child, Pre

1994
Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in treatment of newly diagnosed pediatric solid tumors.
    Journal of the National Cancer Institute, 1994, Apr-06, Volume: 86, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carboplatin; Child; Child, Pre

1994
[Ifosfamide-induced nephrotoxicity].
    Monatsschrift Kinderheilkunde : Organ der Deutschen Gesellschaft fur Kinderheilkunde, 1993, Volume: 141, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Child; Cisplatin; Creatinine

1993
[Ifosfamide-induced nephrotoxicity].
    Monatsschrift Kinderheilkunde : Organ der Deutschen Gesellschaft fur Kinderheilkunde, 1993, Volume: 141, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Child; Cisplatin; Creatinine

1993
The efficacy and safety of ondansetron in the prophylaxis of cancer-chemotherapy induced nausea and vomiting in children.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 1993, Volume: 5, Issue:1

    Topics: Antineoplastic Agents; Child; Cisplatin; Female; Humans; Ifosfamide; Male; Nausea; Neoplasms; Ondans

1993
The efficacy and safety of ondansetron in the prophylaxis of cancer-chemotherapy induced nausea and vomiting in children.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 1993, Volume: 5, Issue:1

    Topics: Antineoplastic Agents; Child; Cisplatin; Female; Humans; Ifosfamide; Male; Nausea; Neoplasms; Ondans

1993
Pilot study of ambulatory infusional ifosfamide admixed with carboplatin.
    Cancer, 1993, Mar-15, Volume: 71, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Humans; Ifosfamide; Infusions, Intraven

1993
Pilot study of ambulatory infusional ifosfamide admixed with carboplatin.
    Cancer, 1993, Mar-15, Volume: 71, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Humans; Ifosfamide; Infusions, Intraven

1993
Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Presch

1993
Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Presch

1993
A phase I study of ifosfamide with Mesna given daily for 3 consecutive days to children with malignant solid tumors.
    Cancer, 1993, Jun-01, Volume: 71, Issue:11

    Topics: Adolescent; Adult; Carboplatin; Child; Child, Preschool; Cisplatin; Drug Administration Schedule; Fe

1993
A phase I study of ifosfamide with Mesna given daily for 3 consecutive days to children with malignant solid tumors.
    Cancer, 1993, Jun-01, Volume: 71, Issue:11

    Topics: Adolescent; Adult; Carboplatin; Child; Child, Preschool; Cisplatin; Drug Administration Schedule; Fe

1993
Oral glutamine to prevent chemotherapy induced stomatitis: a pilot study.
    The Journal of laboratory and clinical medicine, 1996, Volume: 127, Issue:2

    Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Antineoplastic Combined Chemotherapy Proto

1996
Oral glutamine to prevent chemotherapy induced stomatitis: a pilot study.
    The Journal of laboratory and clinical medicine, 1996, Volume: 127, Issue:2

    Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Antineoplastic Combined Chemotherapy Proto

1996
Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results.
    Seminars in oncology, 1996, Volume: 23, Issue:3 Suppl 6

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytog

1996
Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results.
    Seminars in oncology, 1996, Volume: 23, Issue:3 Suppl 6

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytog

1996
Response of pediatric malignant solid tumors following ifosfamide or ifosfamide/carboplatin/etoposide: a single hospital experience.
    Medical and pediatric oncology, 1996, Volume: 27, Issue:3

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chil

1996
Response of pediatric malignant solid tumors following ifosfamide or ifosfamide/carboplatin/etoposide: a single hospital experience.
    Medical and pediatric oncology, 1996, Volume: 27, Issue:3

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chil

1996
Misoprostol prophylaxis for high-dose chemotherapy-induced mucositis: a randomized double-blind study.
    Bone marrow transplantation, 1996, Volume: 17, Issue:5

    Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Antineoplastic Combined Chemotherapy Protocols; Carbopla

1996
Misoprostol prophylaxis for high-dose chemotherapy-induced mucositis: a randomized double-blind study.
    Bone marrow transplantation, 1996, Volume: 17, Issue:5

    Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Antineoplastic Combined Chemotherapy Protocols; Carbopla

1996
Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support.
    Bone marrow transplantation, 1995, Volume: 16, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Etopo

1995
Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support.
    Bone marrow transplantation, 1995, Volume: 16, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Etopo

1995
Antitumor and accessory immune activities of peripheral blood stem cells mobilized with granulocyte-macrophage colony-stimulating factor.
    Bone marrow transplantation, 1996, Volume: 18, Issue:1

    Topics: Adult; Aged; Antigen-Presenting Cells; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols;

1996
Antitumor and accessory immune activities of peripheral blood stem cells mobilized with granulocyte-macrophage colony-stimulating factor.
    Bone marrow transplantation, 1996, Volume: 18, Issue:1

    Topics: Adult; Aged; Antigen-Presenting Cells; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols;

1996
A study of 5 day fractionated ifosfamide pharmacokinetics in consecutive treatment cycles.
    British journal of clinical pharmacology, 1996, Volume: 42, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Female; Half-Life; Humans; Ifosfam

1996
A study of 5 day fractionated ifosfamide pharmacokinetics in consecutive treatment cycles.
    British journal of clinical pharmacology, 1996, Volume: 42, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Female; Half-Life; Humans; Ifosfam

1996
Phase I trial of subcutaneous interleukin-1 alpha in children with malignant solid tumors.
    Medical and pediatric oncology, 1997, Volume: 28, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Bone Marrow; Bon

1997
Phase I trial of subcutaneous interleukin-1 alpha in children with malignant solid tumors.
    Medical and pediatric oncology, 1997, Volume: 28, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Bone Marrow; Bon

1997
Clinical effects and pharmacokinetics of the fusion protein PIXY321 in children receiving myelosuppressive chemotherapy.
    Cancer chemotherapy and pharmacology, 1998, Volume: 41, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplati

1998
Clinical effects and pharmacokinetics of the fusion protein PIXY321 in children receiving myelosuppressive chemotherapy.
    Cancer chemotherapy and pharmacology, 1998, Volume: 41, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cisplati

1998
A Phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors.
    Cancer, 1998, Feb-01, Volume: 82, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Fe

1998
A Phase I trial of ifosfamide and paclitaxel with granulocyte-colony stimulating factor in the treatment of patients with refractory solid tumors.
    Cancer, 1998, Feb-01, Volume: 82, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Fe

1998
Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours.
    British journal of cancer, 1998, Volume: 77, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Feasibility Studies; Female;

1998
Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours.
    British journal of cancer, 1998, Volume: 77, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Feasibility Studies; Female;

1998
Docetaxel and ifosfamide in patients with advanced solid tumors: results of a phase I study.
    Seminars in oncology, 1998, Volume: 25, Issue:1 Suppl 2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Feasibility Studies; Female;

1998
Docetaxel and ifosfamide in patients with advanced solid tumors: results of a phase I study.
    Seminars in oncology, 1998, Volume: 25, Issue:1 Suppl 2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Feasibility Studies; Female;

1998
Dose escalation of the hypoxic cell sensitizer etanidazole combined with ifosfamide, carboplatin, etoposide, and autologous hematopoietic stem cell support.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Hypoxia; Disease-Free Survi

1998
Dose escalation of the hypoxic cell sensitizer etanidazole combined with ifosfamide, carboplatin, etoposide, and autologous hematopoietic stem cell support.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Hypoxia; Disease-Free Survi

1998
A phase I/II study of multicyclic dose-intensive chemotherapy supported with G-CSF, or G-CSF and haematopoietic progenitor cells in whole blood, in two consecutive cohorts of patients.
    British journal of cancer, 1998, Volume: 77, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship,

1998
A phase I/II study of multicyclic dose-intensive chemotherapy supported with G-CSF, or G-CSF and haematopoietic progenitor cells in whole blood, in two consecutive cohorts of patients.
    British journal of cancer, 1998, Volume: 77, Issue:12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship,

1998
Correlation between granulocyte/macrophage-colony-forming units and CD34+ cells in apheresis products from patients treated with different chemotherapy regimens and granulocyte-colony-stimulating factor to mobilize peripheral blood progenitor cells.
    Journal of cancer research and clinical oncology, 1998, Volume: 124, Issue:6

    Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Carmustine;

1998
Correlation between granulocyte/macrophage-colony-forming units and CD34+ cells in apheresis products from patients treated with different chemotherapy regimens and granulocyte-colony-stimulating factor to mobilize peripheral blood progenitor cells.
    Journal of cancer research and clinical oncology, 1998, Volume: 124, Issue:6

    Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Carmustine;

1998
High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:9

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Dose-Res

1998
High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:9

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Dose-Res

1998
A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors: a report of the Children's Cancer G
    Cancer, 1998, Oct-01, Volume: 83, Issue:7

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Transfusion; Car

1998
A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors: a report of the Children's Cancer G
    Cancer, 1998, Oct-01, Volume: 83, Issue:7

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Transfusion; Car

1998
Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours.
    British journal of cancer, 2000, Volume: 82, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship,

2000
Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours.
    British journal of cancer, 2000, Volume: 82, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship,

2000
Ifosfamide and irinotecan in solid tumors: a phase I dose-finding trial.
    Seminars in oncology, 2000, Volume: 27, Issue:1 Suppl 1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Humans; Ifosfamid

2000
Ifosfamide and irinotecan in solid tumors: a phase I dose-finding trial.
    Seminars in oncology, 2000, Volume: 27, Issue:1 Suppl 1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Humans; Ifosfamid

2000
The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide-based chemotherapy in patients with solid tumors.
    Anti-cancer drugs, 2000, Volume: 11, Issue:1

    Topics: Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Ifosfa

2000
The use of reduced doses of amifostine to ameliorate nephrotoxicity of cisplatin/ifosfamide-based chemotherapy in patients with solid tumors.
    Anti-cancer drugs, 2000, Volume: 11, Issue:1

    Topics: Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Ifosfa

2000
Intravenous ifosfamide/mesna is associated with depletion of plasma thiols without depletion of leukocyte glutathione.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:4

    Topics: Acetaldehyde; Antineoplastic Agents, Alkylating; Cysteine; Dose-Response Relationship, Drug; Glutath

2000
Intravenous ifosfamide/mesna is associated with depletion of plasma thiols without depletion of leukocyte glutathione.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:4

    Topics: Acetaldehyde; Antineoplastic Agents, Alkylating; Cysteine; Dose-Response Relationship, Drug; Glutath

2000
A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors.
    Investigational new drugs, 2000, Volume: 18, Issue:3

    Topics: Adolescent; Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Gl

2000
A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors.
    Investigational new drugs, 2000, Volume: 18, Issue:3

    Topics: Adolescent; Adult; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Gl

2000
Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: a study of the European Organization for Research and Treatment of Cancer Early
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Oct-15, Volume: 18, Issue:20

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dose-Response Relationship, Drug; Drug Administratio

2000
Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: a study of the European Organization for Research and Treatment of Cancer Early
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Oct-15, Volume: 18, Issue:20

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dose-Response Relationship, Drug; Drug Administratio

2000
Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report.
    Journal of pediatric hematology/oncology, 2001, Volume: 23, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Presch

2001
Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report.
    Journal of pediatric hematology/oncology, 2001, Volume: 23, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Presch

2001
A phase I clinical, pharmacological, and biological trial of interleukin 6 plus granulocyte-colony stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent/refractory solid tumors: enhanced hematological responses but a h
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Presch

2001
A phase I clinical, pharmacological, and biological trial of interleukin 6 plus granulocyte-colony stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent/refractory solid tumors: enhanced hematological responses but a h
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Presch

2001
Paclitaxel by 72-hour continuous infusion followed by bolus intravenous ifosfamide or epirubicin: results of two phase I studies.
    Oncology, 2001, Volume: 60, Issue:2

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents,

2001
Paclitaxel by 72-hour continuous infusion followed by bolus intravenous ifosfamide or epirubicin: results of two phase I studies.
    Oncology, 2001, Volume: 60, Issue:2

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents,

2001
Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma.
    Cancer, 2001, Aug-15, Volume: 92, Issue:4

    Topics: Adolescent; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, P

2001
Phase I trial of a twice-daily regimen of amifostine with ifosfamide, carboplatin, and etoposide chemotherapy in children with refractory carcinoma.
    Cancer, 2001, Aug-15, Volume: 92, Issue:4

    Topics: Adolescent; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, P

2001
Effectiveness of the MSC cold cap system in the prevention of chemotherapy-induced alopecia.
    Oncology, 2002, Volume: 62, Issue:2

    Topics: Adult; Aged; Alopecia; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined C

2002
Effectiveness of the MSC cold cap system in the prevention of chemotherapy-induced alopecia.
    Oncology, 2002, Volume: 62, Issue:2

    Topics: Adult; Aged; Alopecia; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined C

2002
Phase I clinical and pharmacokinetic study of combination chemotherapy with topotecan and ifosfamide in patients with progressive or relapsed solid tumors.
    Journal of cancer research and clinical oncology, 2002, Volume: 128, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve

2002
Phase I clinical and pharmacokinetic study of combination chemotherapy with topotecan and ifosfamide in patients with progressive or relapsed solid tumors.
    Journal of cancer research and clinical oncology, 2002, Volume: 128, Issue:6

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve

2002
Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients.
    British journal of cancer, 2002, Jun-17, Volume: 86, Issue:12

    Topics: Acetylcarnitine; Aged; Antineoplastic Agents; Carnitine; Cisplatin; Fatigue; Female; Humans; Ifosfam

2002
Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients.
    British journal of cancer, 2002, Jun-17, Volume: 86, Issue:12

    Topics: Acetylcarnitine; Aged; Antineoplastic Agents; Carnitine; Cisplatin; Fatigue; Female; Humans; Ifosfam

2002
[Clinical experience with the cytostatic drug ifosfamide].
    Die Medizinische Welt, 1977, Sep-02, Volume: 28, Issue:35

    Topics: Adolescent; Adult; Aged; Bleomycin; Carcinoma; Clinical Trials as Topic; Cyclophosphamide; Drug Ther

1977
[Clinical experience with the cytostatic drug ifosfamide].
    Die Medizinische Welt, 1977, Sep-02, Volume: 28, Issue:35

    Topics: Adolescent; Adult; Aged; Bleomycin; Carcinoma; Clinical Trials as Topic; Cyclophosphamide; Drug Ther

1977
Advances in cancer management--an essay on the application of basic science principles.
    Texas reports on biology and medicine, 1979, Volume: 38

    Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Division; Clinical Trials as Topic; Cytological Tec

1979
Advances in cancer management--an essay on the application of basic science principles.
    Texas reports on biology and medicine, 1979, Volume: 38

    Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Division; Clinical Trials as Topic; Cytological Tec

1979
[Ifosfamide in the treatment of solid tumors and their metastases].
    La Nouvelle presse medicale, 1976, Apr-10, Volume: 5, Issue:15

    Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Drug Tolerance; Female; Humans;

1976
[Ifosfamide in the treatment of solid tumors and their metastases].
    La Nouvelle presse medicale, 1976, Apr-10, Volume: 5, Issue:15

    Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Drug Tolerance; Female; Humans;

1976
Phase I clinical trial of a 3-day divided dose schedule of ifosfamide (NSC 109724).
    European journal of cancer, 1976, Volume: 12, Issue:3

    Topics: Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Hematuria; Humans; Ifosfamide; Kidney Tubul

1976
Phase I clinical trial of a 3-day divided dose schedule of ifosfamide (NSC 109724).
    European journal of cancer, 1976, Volume: 12, Issue:3

    Topics: Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Hematuria; Humans; Ifosfamide; Kidney Tubul

1976
Results obtained with fractionated ifosfamide massive-dose treatment in generalized malignant tumours.
    International journal of clinical pharmacology and biopharmacy, 1976, Volume: 14, Issue:1

    Topics: Adolescent; Adult; Aged; Child; Clinical Trials as Topic; Cyclophosphamide; Female; Humans; Ifosfami

1976
Results obtained with fractionated ifosfamide massive-dose treatment in generalized malignant tumours.
    International journal of clinical pharmacology and biopharmacy, 1976, Volume: 14, Issue:1

    Topics: Adolescent; Adult; Aged; Child; Clinical Trials as Topic; Cyclophosphamide; Female; Humans; Ifosfami

1976
Evaluation of a cooperative clinical study of the cytostatic agent ifosfamide.
    Arzneimittel-Forschung, 1976, Volume: 26, Issue:10

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Breast Neoplasms; Child; Clinical Trials as Topic; Cyclopho

1976
Evaluation of a cooperative clinical study of the cytostatic agent ifosfamide.
    Arzneimittel-Forschung, 1976, Volume: 26, Issue:10

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Breast Neoplasms; Child; Clinical Trials as Topic; Cyclopho

1976
[Experience with fractionate massive-dose Ifosfamid therapy of generalized malignant tumors].
    Die Medizinische Welt, 1975, May-16, Volume: 26, Issue:20

    Topics: Adolescent; Adult; Aged; Child; Clinical Trials as Topic; Cyclophosphamide; Female; Humans; Ifosfami

1975
[Experience with fractionate massive-dose Ifosfamid therapy of generalized malignant tumors].
    Die Medizinische Welt, 1975, May-16, Volume: 26, Issue:20

    Topics: Adolescent; Adult; Aged; Child; Clinical Trials as Topic; Cyclophosphamide; Female; Humans; Ifosfami

1975
Phase I and II study of high-dose ifosfamide, carboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplati

1992
Phase I and II study of high-dose ifosfamide, carboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplati

1992
The influence of age on nephrotoxicity following chemotherapy in children.
    The British journal of cancer. Supplement, 1992, Volume: 18

    Topics: Age Factors; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; C

1992
The influence of age on nephrotoxicity following chemotherapy in children.
    The British journal of cancer. Supplement, 1992, Volume: 18

    Topics: Age Factors; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; C

1992
Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following standard-dose combination chemotherapy with etoposide, ifosfamide, and cisplatin.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule

1992
Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following standard-dose combination chemotherapy with etoposide, ifosfamide, and cisplatin.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule

1992
[Comparison of the antiemetic effectiveness of granisetron and alizapride plus dexamethasone in cytostatic therapy].
    Deutsche medizinische Wochenschrift (1946), 1991, Nov-29, Volume: 116, Issue:48

    Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Dexamethasone; Drug Therapy, Combination; Et

1991
[Comparison of the antiemetic effectiveness of granisetron and alizapride plus dexamethasone in cytostatic therapy].
    Deutsche medizinische Wochenschrift (1946), 1991, Nov-29, Volume: 116, Issue:48

    Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Cisplatin; Dexamethasone; Drug Therapy, Combination; Et

1991
Metabolism and pharmacokinetics of oral and intravenous ifosfamide.
    Journal of cancer research and clinical oncology, 1991, Volume: 117 Suppl 4

    Topics: Acetaldehyde; Administration, Oral; Adult; Aged; Female; Humans; Ifosfamide; Infusions, Intravenous;

1991
Metabolism and pharmacokinetics of oral and intravenous ifosfamide.
    Journal of cancer research and clinical oncology, 1991, Volume: 117 Suppl 4

    Topics: Acetaldehyde; Administration, Oral; Adult; Aged; Female; Humans; Ifosfamide; Infusions, Intravenous;

1991
Escalating doses of carboplatin with high-dose ifosfamide using autologous bone marrow as support: a phase I study.
    Journal of cancer research and clinical oncology, 1991, Volume: 117 Suppl 4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Com

1991
Escalating doses of carboplatin with high-dose ifosfamide using autologous bone marrow as support: a phase I study.
    Journal of cancer research and clinical oncology, 1991, Volume: 117 Suppl 4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Com

1991
A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991, Volume: 9, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Com

1991
A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991, Volume: 9, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Com

1991
Phase I-II study of two consecutive courses of high-dose epipodophyllotoxin, ifosfamide, and carboplatin with autologous bone marrow transplantation for treatment of adult patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991, Volume: 9, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplati

1991
Phase I-II study of two consecutive courses of high-dose epipodophyllotoxin, ifosfamide, and carboplatin with autologous bone marrow transplantation for treatment of adult patients with solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991, Volume: 9, Issue:10

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplati

1991
[The use of holoxan (iphosphamide) in malignant tumors].
    Voprosy onkologii, 1990, Volume: 36, Issue:9

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Ifosfamide; Infusio

1990
[The use of holoxan (iphosphamide) in malignant tumors].
    Voprosy onkologii, 1990, Volume: 36, Issue:9

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Humans; Ifosfamide; Infusio

1990
Ifosfamide--pharmacology, safety and therapeutic potential.
    Cancer treatment reviews, 1985, Volume: 12, Issue:1

    Topics: Animals; Biotransformation; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Evalu

1985
Ifosfamide--pharmacology, safety and therapeutic potential.
    Cancer treatment reviews, 1985, Volume: 12, Issue:1

    Topics: Animals; Biotransformation; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Evalu

1985

Other Studies

134 other studies available for ifosfamide and Neoplasms

ArticleYear
Excellent Tolerability of Ifosfamide and Mesna Via Continuous Infusion in a Pediatric Patient Population.
    Journal of pediatric hematology/oncology, 2022, 11-01, Volume: 44, Issue:8

    Topics: Child; Drug Administration Schedule; Humans; Ifosfamide; Infusions, Intravenous; Mesna; Neoplasms

2022
Excellent Tolerability of Ifosfamide and Mesna Via Continuous Infusion in a Pediatric Patient Population.
    Journal of pediatric hematology/oncology, 2022, 11-01, Volume: 44, Issue:8

    Topics: Child; Drug Administration Schedule; Humans; Ifosfamide; Infusions, Intravenous; Mesna; Neoplasms

2022
Chemotherapy induced kidney and urinary tract related complications: A study in the Department of Pediatric Oncology and Hematology.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, Volume: 153

    Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Female; Hematology; Humans; Ifosfamide;

2022
Chemotherapy induced kidney and urinary tract related complications: A study in the Department of Pediatric Oncology and Hematology.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, Volume: 153

    Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Female; Hematology; Humans; Ifosfamide;

2022
Gastrointestinal bleeding/ulcer among paediatric cancer patients after proton beam therapy.
    Japanese journal of clinical oncology, 2023, Jun-01, Volume: 53, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Doxorubic

2023
Gastrointestinal bleeding/ulcer among paediatric cancer patients after proton beam therapy.
    Japanese journal of clinical oncology, 2023, Jun-01, Volume: 53, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Doxorubic

2023
Tolerability of ifosfamide-containing regimen in patients with high-risk renal and INI-1-deficient tumors.
    Pediatric blood & cancer, 2023, Volume: 70, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cyclophosphami

2023
Tolerability of ifosfamide-containing regimen in patients with high-risk renal and INI-1-deficient tumors.
    Pediatric blood & cancer, 2023, Volume: 70, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cyclophosphami

2023
Cellular senescence in kidney biopsies is associated with tubular dysfunction and predicts CKD progression in childhood cancer patients with karyomegalic interstitial nephropathy.
    The Journal of pathology, 2023, Volume: 261, Issue:4

    Topics: Biopsy; Cellular Senescence; Child; Humans; Ifosfamide; In Situ Hybridization, Fluorescence; Kidney;

2023
Cellular senescence in kidney biopsies is associated with tubular dysfunction and predicts CKD progression in childhood cancer patients with karyomegalic interstitial nephropathy.
    The Journal of pathology, 2023, Volume: 261, Issue:4

    Topics: Biopsy; Cellular Senescence; Child; Humans; Ifosfamide; In Situ Hybridization, Fluorescence; Kidney;

2023
Analysis of
    Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals, 2020, Volume: 25, Issue:4

    Topics: Adolescent; Alleles; Child; Child, Preschool; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C9; Cyto

2020
Analysis of
    Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals, 2020, Volume: 25, Issue:4

    Topics: Adolescent; Alleles; Child; Child, Preschool; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C9; Cyto

2020
Ifosfamide-related encephalopathy with severe clinical presentations in children with cancer.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2021, Volume: 27, Issue:8

    Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Diseases; Child; Female; Humans; Ifosfamide; Me

2021
Ifosfamide-related encephalopathy with severe clinical presentations in children with cancer.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2021, Volume: 27, Issue:8

    Topics: Adolescent; Antineoplastic Agents, Alkylating; Brain Diseases; Child; Female; Humans; Ifosfamide; Me

2021
Long-term renal follow-up of children treated with cisplatin, carboplatin, or ifosfamide: a pilot study.
    Pediatric nephrology (Berlin, Germany), 2018, Volume: 33, Issue:12

    Topics: Acute Kidney Injury; Antineoplastic Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; C

2018
Long-term renal follow-up of children treated with cisplatin, carboplatin, or ifosfamide: a pilot study.
    Pediatric nephrology (Berlin, Germany), 2018, Volume: 33, Issue:12

    Topics: Acute Kidney Injury; Antineoplastic Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; C

2018
Clinical and EEG Characteristics of Ifosfamide-Related Encephalopathy.
    Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society, 2019, Volume: 36, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Diseases; Electroencephalography;

2019
Clinical and EEG Characteristics of Ifosfamide-Related Encephalopathy.
    Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society, 2019, Volume: 36, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Brain Diseases; Electroencephalography;

2019
Long-term nephrotoxicity in adult survivors of childhood cancer.
    Clinical journal of the American Society of Nephrology : CJASN, 2013, Volume: 8, Issue:6

    Topics: Adolescent; Adult; Albuminuria; Antineoplastic Agents; beta 2-Microglobulin; Biomarkers; Chemotherap

2013
Long-term nephrotoxicity in adult survivors of childhood cancer.
    Clinical journal of the American Society of Nephrology : CJASN, 2013, Volume: 8, Issue:6

    Topics: Adolescent; Adult; Albuminuria; Antineoplastic Agents; beta 2-Microglobulin; Biomarkers; Chemotherap

2013
N-acetylcysteine rescue protocol for nephrotoxicity in children caused by ifosfamide.
    Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharmacologie clinique, 2013, Volume: 20, Issue:2

    Topics: Acetylcysteine; Animals; Antidotes; Antineoplastic Agents, Alkylating; Antioxidants; Child; Drug Adm

2013
N-acetylcysteine rescue protocol for nephrotoxicity in children caused by ifosfamide.
    Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharmacologie clinique, 2013, Volume: 20, Issue:2

    Topics: Acetylcysteine; Animals; Antidotes; Antineoplastic Agents, Alkylating; Antioxidants; Child; Drug Adm

2013
PharmGKB summary: ifosfamide pathways, pharmacokinetics and pharmacodynamics.
    Pharmacogenetics and genomics, 2014, Volume: 24, Issue:2

    Topics: Antineoplastic Agents, Alkylating; Cytochrome P-450 Enzyme System; Humans; Ifosfamide; Neoplasms; Ph

2014
PharmGKB summary: ifosfamide pathways, pharmacokinetics and pharmacodynamics.
    Pharmacogenetics and genomics, 2014, Volume: 24, Issue:2

    Topics: Antineoplastic Agents, Alkylating; Cytochrome P-450 Enzyme System; Humans; Ifosfamide; Neoplasms; Ph

2014
Fatigue and carnitine levels over multiple cycles of chemotherapy in children and adolescents.
    European journal of oncology nursing : the official journal of European Oncology Nursing Society, 2015, Volume: 19, Issue:1

    Topics: Adolescent; Antineoplastic Agents; Carnitine; Child; Child, Preschool; Cisplatin; Dose-Response Rela

2015
Fatigue and carnitine levels over multiple cycles of chemotherapy in children and adolescents.
    European journal of oncology nursing : the official journal of European Oncology Nursing Society, 2015, Volume: 19, Issue:1

    Topics: Adolescent; Antineoplastic Agents; Carnitine; Child; Child, Preschool; Cisplatin; Dose-Response Rela

2015
    Bulletin of the World Health Organization, 2014, Nov-01, Volume: 92, Issue:11

    Topics: Adolescent; Adult; Animals; Antineoplastic Agents; Arachidonic Acids; Asbestos; Asbestosis; Attitude

2014
    Bulletin of the World Health Organization, 2014, Nov-01, Volume: 92, Issue:11

    Topics: Adolescent; Adult; Animals; Antineoplastic Agents; Arachidonic Acids; Asbestos; Asbestosis; Attitude

2014
Investigation of ifosfamide and chloroacetaldehyde renal toxicity through integration of in vitro liver-kidney microfluidic data and pharmacokinetic-system biology models.
    Journal of applied toxicology : JAT, 2016, Volume: 36, Issue:2

    Topics: Acetaldehyde; Antineoplastic Agents, Alkylating; Bayes Theorem; Cells, Cultured; Hepatocytes; Ifosfa

2016
Investigation of ifosfamide and chloroacetaldehyde renal toxicity through integration of in vitro liver-kidney microfluidic data and pharmacokinetic-system biology models.
    Journal of applied toxicology : JAT, 2016, Volume: 36, Issue:2

    Topics: Acetaldehyde; Antineoplastic Agents, Alkylating; Bayes Theorem; Cells, Cultured; Hepatocytes; Ifosfa

2016
Risk factors of ifosfamide-related encephalopathy in adult patients with cancer: A retrospective analysis.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2016, Volume: 115, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Diseases; Creatinine; Female; Humans; Ifosfami

2016
Risk factors of ifosfamide-related encephalopathy in adult patients with cancer: A retrospective analysis.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2016, Volume: 115, Issue:9

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Diseases; Creatinine; Female; Humans; Ifosfami

2016
A retrospective study of treatment and prophylaxis of ifosfamide-induced hemorrhagic cystitis in pediatric and adolescent and young adult (AYA) patients with solid tumors.
    Japanese journal of clinical oncology, 2016, Volume: 46, Issue:9

    Topics: Adolescent; Adult; Child; Child, Preschool; Cystitis; Drug Administration Schedule; Female; Hemorrha

2016
A retrospective study of treatment and prophylaxis of ifosfamide-induced hemorrhagic cystitis in pediatric and adolescent and young adult (AYA) patients with solid tumors.
    Japanese journal of clinical oncology, 2016, Volume: 46, Issue:9

    Topics: Adolescent; Adult; Child; Child, Preschool; Cystitis; Drug Administration Schedule; Female; Hemorrha

2016
Synthesis of novel monomeric graphene quantum dots and corresponding nanocomposite with molecularly imprinted polymer for electrochemical detection of an anticancerous ifosfamide drug.
    Biosensors & bioelectronics, 2017, Aug-15, Volume: 94

    Topics: Biosensing Techniques; Electrochemical Techniques; Graphite; Humans; Ifosfamide; Limit of Detection;

2017
Synthesis of novel monomeric graphene quantum dots and corresponding nanocomposite with molecularly imprinted polymer for electrochemical detection of an anticancerous ifosfamide drug.
    Biosensors & bioelectronics, 2017, Aug-15, Volume: 94

    Topics: Biosensing Techniques; Electrochemical Techniques; Graphite; Humans; Ifosfamide; Limit of Detection;

2017
Potentiation of methoxymorpholinyl doxorubicin antitumor activity by P450 3A4 gene transfer.
    Cancer gene therapy, 2009, Volume: 16, Issue:5

    Topics: Adenoviridae; Animals; Antineoplastic Agents; Cell Line, Tumor; CHO Cells; Cricetinae; Cricetulus; C

2009
Potentiation of methoxymorpholinyl doxorubicin antitumor activity by P450 3A4 gene transfer.
    Cancer gene therapy, 2009, Volume: 16, Issue:5

    Topics: Adenoviridae; Animals; Antineoplastic Agents; Cell Line, Tumor; CHO Cells; Cricetinae; Cricetulus; C

2009
Neurotoxicity during ifosfamide treatment in children.
    Medical science monitor : international medical journal of experimental and clinical research, 2009, Volume: 15, Issue:1

    Topics: Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Cyclophosphamide; Female; Hu

2009
Neurotoxicity during ifosfamide treatment in children.
    Medical science monitor : international medical journal of experimental and clinical research, 2009, Volume: 15, Issue:1

    Topics: Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Cyclophosphamide; Female; Hu

2009
Self-reported experience of mucositis in cancer patients who underwent conditioning regimen and stem cell transplantation.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2009, Volume: 17, Issue:10

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cy

2009
Self-reported experience of mucositis in cancer patients who underwent conditioning regimen and stem cell transplantation.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2009, Volume: 17, Issue:10

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cy

2009
Testicular function of survivors of childhood cancer: a comparative study between ifosfamide- and cyclophosphamide-based regimens.
    European journal of cancer (Oxford, England : 1990), 2009, Volume: 45, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Biomarkers; Child; Cyclophosphamide; Dose-Resp

2009
Testicular function of survivors of childhood cancer: a comparative study between ifosfamide- and cyclophosphamide-based regimens.
    European journal of cancer (Oxford, England : 1990), 2009, Volume: 45, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Biomarkers; Child; Cyclophosphamide; Dose-Resp

2009
Carnitine plasma levels and fatigue in children/adolescents receiving cisplatin, ifosfamide, or doxorubicin.
    Journal of pediatric hematology/oncology, 2009, Volume: 31, Issue:9

    Topics: Adenosine Triphosphate; Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Prot

2009
Carnitine plasma levels and fatigue in children/adolescents receiving cisplatin, ifosfamide, or doxorubicin.
    Journal of pediatric hematology/oncology, 2009, Volume: 31, Issue:9

    Topics: Adenosine Triphosphate; Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Prot

2009
Glomerular toxicity persists 10 years after ifosfamide treatment in childhood and is not predictable by age or dose.
    Pediatric blood & cancer, 2010, Jul-01, Volume: 54, Issue:7

    Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Female

2010
Glomerular toxicity persists 10 years after ifosfamide treatment in childhood and is not predictable by age or dose.
    Pediatric blood & cancer, 2010, Jul-01, Volume: 54, Issue:7

    Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Female

2010
Transcriptomic analysis of the effect of ifosfamide on MDCK cells cultivated in microfluidic biochips.
    Genomics, 2012, Volume: 100, Issue:1

    Topics: Animals; Antineoplastic Agents, Alkylating; Cell Culture Techniques; Dogs; Drug Evaluation, Preclini

2012
Transcriptomic analysis of the effect of ifosfamide on MDCK cells cultivated in microfluidic biochips.
    Genomics, 2012, Volume: 100, Issue:1

    Topics: Animals; Antineoplastic Agents, Alkylating; Cell Culture Techniques; Dogs; Drug Evaluation, Preclini

2012
Predictive value of circulating immature cell counts in peripheral blood for timing of peripheral blood progenitor cell collection after G-CSF plus chemotherapy-induced mobilization.
    Transfusion, 2002, Volume: 42, Issue:11

    Topics: Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cell

2002
Predictive value of circulating immature cell counts in peripheral blood for timing of peripheral blood progenitor cell collection after G-CSF plus chemotherapy-induced mobilization.
    Transfusion, 2002, Volume: 42, Issue:11

    Topics: Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cell

2002
Identification of novel enzyme-prodrug combinations for use in cytochrome P450-based gene therapy for cancer.
    Archives of biochemistry and biophysics, 2003, Jan-01, Volume: 409, Issue:1

    Topics: Animals; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Agents; Antineoplastic Agents, Alk

2003
Identification of novel enzyme-prodrug combinations for use in cytochrome P450-based gene therapy for cancer.
    Archives of biochemistry and biophysics, 2003, Jan-01, Volume: 409, Issue:1

    Topics: Animals; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Agents; Antineoplastic Agents, Alk

2003
[Polymorphism at the glutathione S-transferase pi locus as a risk factor for ifosfamide nephrotoxicity in children].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2003, Volume: 14, Issue:82

    Topics: Adolescent; Child; Child, Preschool; Female; Gene Deletion; Genotype; Glomerular Filtration Rate; Gl

2003
[Polymorphism at the glutathione S-transferase pi locus as a risk factor for ifosfamide nephrotoxicity in children].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2003, Volume: 14, Issue:82

    Topics: Adolescent; Child; Child, Preschool; Female; Gene Deletion; Genotype; Glomerular Filtration Rate; Gl

2003
Treatment of ifosfamide encephalopathy with intravenous thiamin.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Oct-01, Volume: 9, Issue:12

    Topics: Adult; Antineoplastic Agents, Alkylating; Brain Diseases; Humans; Ifosfamide; Infusions, Intravenous

2003
Treatment of ifosfamide encephalopathy with intravenous thiamin.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Oct-01, Volume: 9, Issue:12

    Topics: Adult; Antineoplastic Agents, Alkylating; Brain Diseases; Humans; Ifosfamide; Infusions, Intravenous

2003
Incidence and severity of ifosfamide-induced encephalopathy.
    Anti-cancer drugs, 2004, Volume: 15, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Cohort Studies; Dose-Response Relationship, Drug; Fe

2004
Incidence and severity of ifosfamide-induced encephalopathy.
    Anti-cancer drugs, 2004, Volume: 15, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Cohort Studies; Dose-Response Relationship, Drug; Fe

2004
Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer.
    British journal of cancer, 2005, May-09, Volume: 92, Issue:9

    Topics: Adult; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Comet Assay; DNA Damage; Female;

2005
Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer.
    British journal of cancer, 2005, May-09, Volume: 92, Issue:9

    Topics: Adult; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Comet Assay; DNA Damage; Female;

2005
Determination of thiamine and its phosphorylated forms in human plasma, erythrocytes and urine by HPLC and fluorescence detection: a preliminary study on cancer patients.
    Journal of pharmaceutical and biomedical analysis, 2005, Apr-29, Volume: 37, Issue:5

    Topics: Chromatography, High Pressure Liquid; Erythrocytes; Humans; Ifosfamide; Neoplasms; Phosphorylation;

2005
Determination of thiamine and its phosphorylated forms in human plasma, erythrocytes and urine by HPLC and fluorescence detection: a preliminary study on cancer patients.
    Journal of pharmaceutical and biomedical analysis, 2005, Apr-29, Volume: 37, Issue:5

    Topics: Chromatography, High Pressure Liquid; Erythrocytes; Humans; Ifosfamide; Neoplasms; Phosphorylation;

2005
Subsieve-size agarose capsules enclosing ifosfamide-activating cells: a strategy toward chemotherapeutic targeting to tumors.
    Molecular cancer therapeutics, 2005, Volume: 4, Issue:11

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biophysics; Cats; Cell Line; Cell

2005
Subsieve-size agarose capsules enclosing ifosfamide-activating cells: a strategy toward chemotherapeutic targeting to tumors.
    Molecular cancer therapeutics, 2005, Volume: 4, Issue:11

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biophysics; Cats; Cell Line; Cell

2005
[Ifosfamide induced encephalopathy: 15 observations].
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2006, Volume: 13, Issue:2

    Topics: Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Coma; Enzyme Inhibitors; Fat

2006
[Ifosfamide induced encephalopathy: 15 observations].
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2006, Volume: 13, Issue:2

    Topics: Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Coma; Enzyme Inhibitors; Fat

2006
Nonconvulsive status epilepticus due to ifosfamide.
    The Annals of pharmacotherapy, 2006, Volume: 40, Issue:2

    Topics: Anticonvulsants; Antineoplastic Agents, Alkylating; Diazepam; Female; Humans; Ifosfamide; Levetirace

2006
Nonconvulsive status epilepticus due to ifosfamide.
    The Annals of pharmacotherapy, 2006, Volume: 40, Issue:2

    Topics: Anticonvulsants; Antineoplastic Agents, Alkylating; Diazepam; Female; Humans; Ifosfamide; Levetirace

2006
Enhanced antitumor activity of P450 prodrug-based gene therapy using the low Km cyclophosphamide 4-hydroxylase P450 2B11.
    Molecular cancer therapeutics, 2006, Volume: 5, Issue:3

    Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Aryl Hydrocarbon Hydroxylases; Catalysis;

2006
Enhanced antitumor activity of P450 prodrug-based gene therapy using the low Km cyclophosphamide 4-hydroxylase P450 2B11.
    Molecular cancer therapeutics, 2006, Volume: 5, Issue:3

    Topics: Adenoviridae; Animals; Antineoplastic Agents, Alkylating; Aryl Hydrocarbon Hydroxylases; Catalysis;

2006
[Perfect drug targeting. Glufosfamide a new derivative].
    Pharmazie in unserer Zeit, 2006, Volume: 35, Issue:2

    Topics: Antineoplastic Agents, Alkylating; Cyclophosphamide; DNA, Neoplasm; Drug Delivery Systems; Glucose;

2006
[Perfect drug targeting. Glufosfamide a new derivative].
    Pharmazie in unserer Zeit, 2006, Volume: 35, Issue:2

    Topics: Antineoplastic Agents, Alkylating; Cyclophosphamide; DNA, Neoplasm; Drug Delivery Systems; Glucose;

2006
Progress in the development of childhood cancer therapy.
    Reproductive toxicology (Elmsford, N.Y.), 2006, Volume: 22, Issue:2

    Topics: Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Chromosomes; Cyclophosphamid

2006
Progress in the development of childhood cancer therapy.
    Reproductive toxicology (Elmsford, N.Y.), 2006, Volume: 22, Issue:2

    Topics: Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Chromosomes; Cyclophosphamid

2006
[Psychotic states of mind in the course of ifosfamide therapy and prevention with piracetam (Nootrop). Preliminary report].
    MMW, Munchener medizinische Wochenschrift, 1983, Jan-14, Volume: 125, Issue:2

    Topics: Adult; Aged; Cyclophosphamide; Humans; Ifosfamide; Middle Aged; Neoplasms; Piracetam; Psychoses, Sub

1983
[Psychotic states of mind in the course of ifosfamide therapy and prevention with piracetam (Nootrop). Preliminary report].
    MMW, Munchener medizinische Wochenschrift, 1983, Jan-14, Volume: 125, Issue:2

    Topics: Adult; Aged; Cyclophosphamide; Humans; Ifosfamide; Middle Aged; Neoplasms; Piracetam; Psychoses, Sub

1983
Proceedings of a symposium on ifosfamide (Mitoxana; Holoxan) and Mesna (Uromitexan). Coventry, U.K., 16-18 March 1983.
    Cancer treatment reviews, 1983, Volume: 10 Suppl A

    Topics: Animals; Cyclophosphamide; Humans; Ifosfamide; Mercaptoethanol; Mesna; Neoplasms

1983
Proceedings of a symposium on ifosfamide (Mitoxana; Holoxan) and Mesna (Uromitexan). Coventry, U.K., 16-18 March 1983.
    Cancer treatment reviews, 1983, Volume: 10 Suppl A

    Topics: Animals; Cyclophosphamide; Humans; Ifosfamide; Mercaptoethanol; Mesna; Neoplasms

1983
Ifosfamide, mesna and vincristine in paediatric oncology.
    Cancer treatment reviews, 1983, Volume: 10 Suppl A

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Humans; Ifosfam

1983
Ifosfamide, mesna and vincristine in paediatric oncology.
    Cancer treatment reviews, 1983, Volume: 10 Suppl A

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Humans; Ifosfam

1983
High-dose ifosfamide and mesna as continuous infusion over five days--a phase I/II trial.
    Cancer treatment reviews, 1983, Volume: 10 Suppl A

    Topics: Cyclophosphamide; Drug Evaluation; Humans; Ifosfamide; Mercaptoethanol; Mesna; Neoplasms

1983
High-dose ifosfamide and mesna as continuous infusion over five days--a phase I/II trial.
    Cancer treatment reviews, 1983, Volume: 10 Suppl A

    Topics: Cyclophosphamide; Drug Evaluation; Humans; Ifosfamide; Mercaptoethanol; Mesna; Neoplasms

1983
Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: results of a clinical phase II-study with 151 patients.
    Cancer treatment reviews, 1983, Volume: 10 Suppl A

    Topics: Cyclophosphamide; Drug Evaluation; Drug Interactions; Female; Humans; Ifosfamide; Male; Mercaptoetha

1983
Efficacy of ifosfamide in refractory malignant diseases and uroprotection by mesna: results of a clinical phase II-study with 151 patients.
    Cancer treatment reviews, 1983, Volume: 10 Suppl A

    Topics: Cyclophosphamide; Drug Evaluation; Drug Interactions; Female; Humans; Ifosfamide; Male; Mercaptoetha

1983
Treatment of refractory malignant neoplasms with ifosfamide as single agent and in combination chemotherapy.
    Cancer treatment reviews, 1983, Volume: 10 Suppl A

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Ifosfamide;

1983
Treatment of refractory malignant neoplasms with ifosfamide as single agent and in combination chemotherapy.
    Cancer treatment reviews, 1983, Volume: 10 Suppl A

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Ifosfamide;

1983
Mesnum as a protector against kidney and bladder toxicity with high-dose ifosfamide treatment.
    Cancer chemotherapy and pharmacology, 1982, Volume: 9, Issue:2

    Topics: Adult; Aged; Cyclophosphamide; Female; Humans; Ifosfamide; Kidney Diseases; Leukopenia; Male; Mercap

1982
Mesnum as a protector against kidney and bladder toxicity with high-dose ifosfamide treatment.
    Cancer chemotherapy and pharmacology, 1982, Volume: 9, Issue:2

    Topics: Adult; Aged; Cyclophosphamide; Female; Humans; Ifosfamide; Kidney Diseases; Leukopenia; Male; Mercap

1982
Prophylaxis of ifosfamide toxicity with oral acetylcysteine.
    Seminars in oncology, 1983, Volume: 10, Issue:1 Suppl 1

    Topics: Acetylcysteine; Adenocarcinoma; Aged; Carcinoma, Squamous Cell; Cyclophosphamide; Dose-Response Rela

1983
Prophylaxis of ifosfamide toxicity with oral acetylcysteine.
    Seminars in oncology, 1983, Volume: 10, Issue:1 Suppl 1

    Topics: Acetylcysteine; Adenocarcinoma; Aged; Carcinoma, Squamous Cell; Cyclophosphamide; Dose-Response Rela

1983
High-dose combination chemotherapy with autologous bone marrow transplantation in adult solid tumors.
    Cancer, 1980, Jun-15, Volume: 45, Issue:12

    Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Drug

1980
High-dose combination chemotherapy with autologous bone marrow transplantation in adult solid tumors.
    Cancer, 1980, Jun-15, Volume: 45, Issue:12

    Topics: Adult; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Carmustine; Cyclophosphamide; Drug

1980
Pronounced antiemetic activity of the antipsychotic drug levomepromacine (L) in patients receiving cancer chemotherapy.
    Journal of cancer research and clinical oncology, 1980, Volume: 97, Issue:1

    Topics: Antineoplastic Agents; Cisplatin; Doxorubicin; Humans; Ifosfamide; Male; Methotrimeprazine; Neoplasm

1980
Pronounced antiemetic activity of the antipsychotic drug levomepromacine (L) in patients receiving cancer chemotherapy.
    Journal of cancer research and clinical oncology, 1980, Volume: 97, Issue:1

    Topics: Antineoplastic Agents; Cisplatin; Doxorubicin; Humans; Ifosfamide; Male; Methotrimeprazine; Neoplasm

1980
[Ventricular premature contraction observed after anti-cancer chemotherapy with ifosfamide].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:10

    Topics: Aged; Cardiac Complexes, Premature; Female; Humans; Ifosfamide; Male; Middle Aged; Neoplasms

1994
[Ventricular premature contraction observed after anti-cancer chemotherapy with ifosfamide].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:10

    Topics: Aged; Cardiac Complexes, Premature; Female; Humans; Ifosfamide; Male; Middle Aged; Neoplasms

1994
Expression of adhesion molecules on CD34+ cells: CD34+ L-selectin+ cells predict a rapid platelet recovery after peripheral blood stem cell transplantation.
    Blood, 1995, Jun-01, Volume: 85, Issue:11

    Topics: Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bon

1995
Expression of adhesion molecules on CD34+ cells: CD34+ L-selectin+ cells predict a rapid platelet recovery after peripheral blood stem cell transplantation.
    Blood, 1995, Jun-01, Volume: 85, Issue:11

    Topics: Adult; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bon

1995
Ifosfamide: let's not end the honeymoon too soon.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7

    Topics: Cyclophosphamide; Drug Resistance; Humans; Ifosfamide; Neoplasms

1995
Ifosfamide: let's not end the honeymoon too soon.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7

    Topics: Cyclophosphamide; Drug Resistance; Humans; Ifosfamide; Neoplasms

1995
Ex vivo expansion of enriched peripheral blood CD34+ progenitor cells by stem cell factor, interleukin-1 beta (IL-1 beta), IL-6, IL-3, interferon-gamma, and erythropoietin.
    Blood, 1993, May-15, Volume: 81, Issue:10

    Topics: Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cell Divisi

1993
Ex vivo expansion of enriched peripheral blood CD34+ progenitor cells by stem cell factor, interleukin-1 beta (IL-1 beta), IL-6, IL-3, interferon-gamma, and erythropoietin.
    Blood, 1993, May-15, Volume: 81, Issue:10

    Topics: Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cell Divisi

1993
Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophil and platelet recovery after high-dose VP16, ifosfamide and cisplatin.
    British journal of haematology, 1993, Volume: 84, Issue:3

    Topics: Adult; Aged; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Pla

1993
Peripheral blood progenitor cells mobilized by chemotherapy plus granulocyte-colony stimulating factor accelerate both neutrophil and platelet recovery after high-dose VP16, ifosfamide and cisplatin.
    British journal of haematology, 1993, Volume: 84, Issue:3

    Topics: Adult; Aged; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Pla

1993
Ifosfamide treatment as a 10-day continuous intravenous infusion.
    Journal of cancer research and clinical oncology, 1995, Volume: 121, Issue:5

    Topics: Adult; Aged; Bone Marrow; Humans; Ifosfamide; Infusions, Intravenous; Middle Aged; Neoplasms

1995
Ifosfamide treatment as a 10-day continuous intravenous infusion.
    Journal of cancer research and clinical oncology, 1995, Volume: 121, Issue:5

    Topics: Adult; Aged; Bone Marrow; Humans; Ifosfamide; Infusions, Intravenous; Middle Aged; Neoplasms

1995
Technetium-99m dimercaptosuccinic acid and ifosfamide tubular dysfunction in children with cancer.
    European journal of nuclear medicine, 1994, Volume: 21, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dose-Response Relationship,

1994
Technetium-99m dimercaptosuccinic acid and ifosfamide tubular dysfunction in children with cancer.
    European journal of nuclear medicine, 1994, Volume: 21, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dose-Response Relationship,

1994
Estimation of ifosfamide/cisplatinum-induced renal toxicity by urinary protein analysis.
    Pediatric nephrology (Berlin, Germany), 1994, Volume: 8, Issue:2

    Topics: Adolescent; Adult; Child; Child, Preschool; Cisplatin; Drug Therapy, Combination; Electrophoresis, P

1994
Estimation of ifosfamide/cisplatinum-induced renal toxicity by urinary protein analysis.
    Pediatric nephrology (Berlin, Germany), 1994, Volume: 8, Issue:2

    Topics: Adolescent; Adult; Child; Child, Preschool; Cisplatin; Drug Therapy, Combination; Electrophoresis, P

1994
Ifosfamide enantiomers: pharmacokinetics in children.
    Cancer chemotherapy and pharmacology, 1994, Volume: 34, Issue:5

    Topics: Adolescent; Child; Child, Preschool; Drug Administration Schedule; Female; Half-Life; Humans; Ifosfa

1994
Ifosfamide enantiomers: pharmacokinetics in children.
    Cancer chemotherapy and pharmacology, 1994, Volume: 34, Issue:5

    Topics: Adolescent; Child; Child, Preschool; Drug Administration Schedule; Female; Half-Life; Humans; Ifosfa

1994
Hallucinations and ifosfamide-induced neurotoxicity.
    Cancer, 1994, Mar-01, Volume: 73, Issue:5

    Topics: Adult; Bone Marrow Transplantation; Female; Hallucinations; Humans; Ifosfamide; Male; Middle Aged; N

1994
Hallucinations and ifosfamide-induced neurotoxicity.
    Cancer, 1994, Mar-01, Volume: 73, Issue:5

    Topics: Adult; Bone Marrow Transplantation; Female; Hallucinations; Humans; Ifosfamide; Male; Middle Aged; N

1994
[The clinical effect of factor XIII on drug-induced hemorrhagic cystitis].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 1994, Volume: 35, Issue:3

    Topics: Adolescent; Child; Child, Preschool; Cyclophosphamide; Cystitis; Factor XIII; Female; Hemorrhage; Hu

1994
[The clinical effect of factor XIII on drug-induced hemorrhagic cystitis].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 1994, Volume: 35, Issue:3

    Topics: Adolescent; Child; Child, Preschool; Cyclophosphamide; Cystitis; Factor XIII; Female; Hemorrhage; Hu

1994
Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:1

    Topics: Adolescent; Adult; Child; Child, Preschool; Cisplatin; Fanconi Syndrome; Humans; Ifosfamide; Infant;

1994
Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:1

    Topics: Adolescent; Adult; Child; Child, Preschool; Cisplatin; Fanconi Syndrome; Humans; Ifosfamide; Infant;

1994
Renal function abnormalities after ifosfamide treatment in children.
    Acta paediatrica (Oslo, Norway : 1992), 1993, Volume: 82, Issue:4

    Topics: Adolescent; Child; Child, Preschool; Cross-Sectional Studies; Female; Humans; Ifosfamide; Kidney Dis

1993
Renal function abnormalities after ifosfamide treatment in children.
    Acta paediatrica (Oslo, Norway : 1992), 1993, Volume: 82, Issue:4

    Topics: Adolescent; Child; Child, Preschool; Cross-Sectional Studies; Female; Humans; Ifosfamide; Kidney Dis

1993
Ifosfamide neurotoxicity. A challenge for nurses, a potential nightmare for patients.
    Cancer nursing, 1993, Volume: 16, Issue:1

    Topics: Brain Diseases; Carcinoma, Small Cell; Central Nervous System; Female; Humans; Ifosfamide; Lung Neop

1993
Ifosfamide neurotoxicity. A challenge for nurses, a potential nightmare for patients.
    Cancer nursing, 1993, Volume: 16, Issue:1

    Topics: Brain Diseases; Carcinoma, Small Cell; Central Nervous System; Female; Humans; Ifosfamide; Lung Neop

1993
Partial and complete de Toni-Debré-Fanconi syndrome after ifosfamide chemotherapy of childhood malignancy.
    European journal of clinical pharmacology, 1993, Volume: 44 Suppl 1

    Topics: Child; Cisplatin; Fanconi Syndrome; Humans; Ifosfamide; Kidney Function Tests; Kidney Glomerulus; Ki

1993
Partial and complete de Toni-Debré-Fanconi syndrome after ifosfamide chemotherapy of childhood malignancy.
    European journal of clinical pharmacology, 1993, Volume: 44 Suppl 1

    Topics: Child; Cisplatin; Fanconi Syndrome; Humans; Ifosfamide; Kidney Function Tests; Kidney Glomerulus; Ki

1993
Etoposide, ifosfamide, and cisplatin therapy for refractory childhood solid tumors.
    Cancer, 1995, Nov-01, Volume: 76, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cisplatin; Etoposide; Humans; Ifosfamide; Neo

1995
Etoposide, ifosfamide, and cisplatin therapy for refractory childhood solid tumors.
    Cancer, 1995, Nov-01, Volume: 76, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Cisplatin; Etoposide; Humans; Ifosfamide; Neo

1995
Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
    Seminars in oncology, 1996, Volume: 23, Issue:3 Suppl 6

    Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agen

1996
Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
    Seminars in oncology, 1996, Volume: 23, Issue:3 Suppl 6

    Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agen

1996
Ifosfamide and paediatrics: should this marriage be saved?
    European journal of cancer (Oxford, England : 1990), 1996, Volume: 32A, Issue:7

    Topics: Antineoplastic Agents, Alkylating; Child; Humans; Ifosfamide; Kidney; Neoplasms; Rhabdomyosarcoma

1996
Ifosfamide and paediatrics: should this marriage be saved?
    European journal of cancer (Oxford, England : 1990), 1996, Volume: 32A, Issue:7

    Topics: Antineoplastic Agents, Alkylating; Child; Humans; Ifosfamide; Kidney; Neoplasms; Rhabdomyosarcoma

1996
[Ifosfamide in pediatric malignancy--experiences in the Northern Israel Oncology Center].
    Harefuah, 1996, Apr-15, Volume: 130, Issue:8

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; C

1996
[Ifosfamide in pediatric malignancy--experiences in the Northern Israel Oncology Center].
    Harefuah, 1996, Apr-15, Volume: 130, Issue:8

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; C

1996
Risk factors for ifosfamide nephrotoxicity in children.
    Lancet (London, England), 1996, Aug-31, Volume: 348, Issue:9027

    Topics: Adolescent; Child; Child, Preschool; Cohort Studies; Female; Glomerular Filtration Rate; Humans; Ifo

1996
Risk factors for ifosfamide nephrotoxicity in children.
    Lancet (London, England), 1996, Aug-31, Volume: 348, Issue:9027

    Topics: Adolescent; Child; Child, Preschool; Cohort Studies; Female; Glomerular Filtration Rate; Humans; Ifo

1996
The influence of ifosfamide scheduling on acute nephrotoxicity in children.
    British journal of cancer, 1997, Volume: 75, Issue:9

    Topics: Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Creatinine; Drug Administrat

1997
The influence of ifosfamide scheduling on acute nephrotoxicity in children.
    British journal of cancer, 1997, Volume: 75, Issue:9

    Topics: Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Creatinine; Drug Administrat

1997
6-Day continuous infusion of high-dose ifosfamide with bone marrow growth factors in advanced refractory malignancies.
    Journal of cancer research and clinical oncology, 1997, Volume: 123, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Female; Granulocyte Colony-Stimulating Factor;

1997
6-Day continuous infusion of high-dose ifosfamide with bone marrow growth factors in advanced refractory malignancies.
    Journal of cancer research and clinical oncology, 1997, Volume: 123, Issue:4

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Female; Granulocyte Colony-Stimulating Factor;

1997
Nephrotoxicity of high-dose ifosfamide/carboplatin/etoposide in adults undergoing autologous stem cell transplantation.
    The American journal of the medical sciences, 1997, Volume: 314, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bicarbonates; Carboplatin; Creati

1997
Nephrotoxicity of high-dose ifosfamide/carboplatin/etoposide in adults undergoing autologous stem cell transplantation.
    The American journal of the medical sciences, 1997, Volume: 314, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bicarbonates; Carboplatin; Creati

1997
[Biochemical parameters in the diagnosis of nephrotoxicity of antineoplastic chemotherapy in children].
    Voprosy onkologii, 1997, Volume: 43, Issue:4

    Topics: Adolescent; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Cispl

1997
[Biochemical parameters in the diagnosis of nephrotoxicity of antineoplastic chemotherapy in children].
    Voprosy onkologii, 1997, Volume: 43, Issue:4

    Topics: Adolescent; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Cispl

1997
Acute changes in urine protein excretion may predict chronic ifosfamide nephrotoxicity: a preliminary observation.
    Cancer chemotherapy and pharmacology, 1998, Volume: 41, Issue:5

    Topics: Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Chronic Disease; Female; Hum

1998
Acute changes in urine protein excretion may predict chronic ifosfamide nephrotoxicity: a preliminary observation.
    Cancer chemotherapy and pharmacology, 1998, Volume: 41, Issue:5

    Topics: Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Chronic Disease; Female; Hum

1998
Excretion kinetics of ifosfamide side-chain metabolites in children on continuous and short-term infusion.
    International journal of clinical pharmacology and therapeutics, 1998, Volume: 36, Issue:5

    Topics: Acetaldehyde; Acrolein; Adolescent; Adult; Antineoplastic Agents, Alkylating; Child; Female; Humans;

1998
Excretion kinetics of ifosfamide side-chain metabolites in children on continuous and short-term infusion.
    International journal of clinical pharmacology and therapeutics, 1998, Volume: 36, Issue:5

    Topics: Acetaldehyde; Acrolein; Adolescent; Adult; Antineoplastic Agents, Alkylating; Child; Female; Humans;

1998
Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1997, Volume: 3, Issue:11

    Topics: Adolescent; Antineoplastic Agents; Biotransformation; Brain Neoplasms; Child; Child, Preschool; Cycl

1997
Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1997, Volume: 3, Issue:11

    Topics: Adolescent; Antineoplastic Agents; Biotransformation; Brain Neoplasms; Child; Child, Preschool; Cycl

1997
Urinary proton magnetic resonance studies of early ifosfamide-induced nephrotoxicity and encephalopathy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1997, Volume: 3, Issue:9

    Topics: Adult; Amino Acids; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocol

1997
Urinary proton magnetic resonance studies of early ifosfamide-induced nephrotoxicity and encephalopathy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1997, Volume: 3, Issue:9

    Topics: Adult; Amino Acids; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocol

1997
Effect of ifosfamide treatment on glutathione and glutathione conjugation activity in patients with advanced cancers.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1995, Volume: 1, Issue:12

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Blood Cells; Bromisovalum; Drug Administration Sched

1995
Effect of ifosfamide treatment on glutathione and glutathione conjugation activity in patients with advanced cancers.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1995, Volume: 1, Issue:12

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Blood Cells; Bromisovalum; Drug Administration Sched

1995
Development of ifosfamide-induced nephrotoxicity: prospective follow-up in 75 patients.
    Medical and pediatric oncology, 1999, Volume: 32, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Fanconi Syndrome; Fol

1999
Development of ifosfamide-induced nephrotoxicity: prospective follow-up in 75 patients.
    Medical and pediatric oncology, 1999, Volume: 32, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Fanconi Syndrome; Fol

1999
Clonogenic potential and phenotypic analysis of CD34+ cells mobilized by different chemotherapy regimens.
    Haematologica, 1999, Volume: 84, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colony-Forming Units Assay; Cyclophosphamide; Drug S

1999
Clonogenic potential and phenotypic analysis of CD34+ cells mobilized by different chemotherapy regimens.
    Haematologica, 1999, Volume: 84, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colony-Forming Units Assay; Cyclophosphamide; Drug S

1999
Possible metabolic interaction between docetaxel and ifosfamide.
    British journal of cancer, 2000, Volume: 82, Issue:2

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-R

2000
Possible metabolic interaction between docetaxel and ifosfamide.
    British journal of cancer, 2000, Volume: 82, Issue:2

    Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-R

2000
Initial measurements of ifosfamide and cyclophosphamide in patients using (31)P MRS: pulse-and-acquire, decoupling, and polarization transfer.
    Magnetic resonance in medicine, 2000, Volume: 44, Issue:2

    Topics: Antineoplastic Agents, Alkylating; Cyclophosphamide; Humans; Ifosfamide; Liver; Magnetic Resonance S

2000
Initial measurements of ifosfamide and cyclophosphamide in patients using (31)P MRS: pulse-and-acquire, decoupling, and polarization transfer.
    Magnetic resonance in medicine, 2000, Volume: 44, Issue:2

    Topics: Antineoplastic Agents, Alkylating; Cyclophosphamide; Humans; Ifosfamide; Liver; Magnetic Resonance S

2000
New insights into the pharmacokinetics and metabolism of (R,S)-ifosfamide in cancer patients using a population pharmacokinetic-metabolism model.
    Pharmaceutical research, 2000, Volume: 17, Issue:6

    Topics: Antineoplastic Agents, Alkylating; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2B6; Cytochrom

2000
New insights into the pharmacokinetics and metabolism of (R,S)-ifosfamide in cancer patients using a population pharmacokinetic-metabolism model.
    Pharmaceutical research, 2000, Volume: 17, Issue:6

    Topics: Antineoplastic Agents, Alkylating; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2B6; Cytochrom

2000
Treatment comparisons based on two-dimensional safety and efficacy alternatives in oncology trials.
    Biometrics, 1999, Volume: 55, Issue:3

    Topics: Antineoplastic Agents, Alkylating; Biometry; Clinical Trials as Topic; Humans; Ifosfamide; Leukemia,

1999
Treatment comparisons based on two-dimensional safety and efficacy alternatives in oncology trials.
    Biometrics, 1999, Volume: 55, Issue:3

    Topics: Antineoplastic Agents, Alkylating; Biometry; Clinical Trials as Topic; Humans; Ifosfamide; Leukemia,

1999
Population pharmacokinetics of ifosfamide and its dechloroethylated and hydroxylated metabolites in children with malignant disease: a sparse sampling approach.
    Clinical pharmacokinetics, 2001, Volume: 40, Issue:8

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Area Under Curve; Child; Child, Preschool; Fea

2001
Population pharmacokinetics of ifosfamide and its dechloroethylated and hydroxylated metabolites in children with malignant disease: a sparse sampling approach.
    Clinical pharmacokinetics, 2001, Volume: 40, Issue:8

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Area Under Curve; Child; Child, Preschool; Fea

2001
Ifosfamide nephrotoxicity in pediatric cancer patients.
    Pediatric nephrology (Berlin, Germany), 2001, Volume: 16, Issue:10

    Topics: Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Cisplatin; Female; Humans; I

2001
Ifosfamide nephrotoxicity in pediatric cancer patients.
    Pediatric nephrology (Berlin, Germany), 2001, Volume: 16, Issue:10

    Topics: Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Cisplatin; Female; Humans; I

2001
The utility of (99m)Tc-DMSA and Tc(99m)-EC scintigraphy for early diagnosis of ifosfamide induced nephrotoxicity.
    Nuclear medicine communications, 2001, Volume: 22, Issue:12

    Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; beta

2001
The utility of (99m)Tc-DMSA and Tc(99m)-EC scintigraphy for early diagnosis of ifosfamide induced nephrotoxicity.
    Nuclear medicine communications, 2001, Volume: 22, Issue:12

    Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; beta

2001
[Prophylactic alkalization of the urine during cytostatic tumor treatment with the oxazaphosphorine derivatives, cyclophosphamide and ifosfamide].
    Onkologie, 1979, Volume: 2, Issue:3

    Topics: Alkalies; Cyclophosphamide; Cystitis; Female; Hemorrhage; Humans; Hydrogen-Ion Concentration; Ifosfa

1979
[Prophylactic alkalization of the urine during cytostatic tumor treatment with the oxazaphosphorine derivatives, cyclophosphamide and ifosfamide].
    Onkologie, 1979, Volume: 2, Issue:3

    Topics: Alkalies; Cyclophosphamide; Cystitis; Female; Hemorrhage; Humans; Hydrogen-Ion Concentration; Ifosfa

1979
Report on carcinogenesis bioassay of isophosphamide.
    American Industrial Hygiene Association journal, 1978, Volume: 39, Issue:6

    Topics: Animals; Carcinogens; Cyclophosphamide; Cystitis; Dogs; Female; Hair; Ifosfamide; Lymphoma; Male; Ma

1978
Report on carcinogenesis bioassay of isophosphamide.
    American Industrial Hygiene Association journal, 1978, Volume: 39, Issue:6

    Topics: Animals; Carcinogens; Cyclophosphamide; Cystitis; Dogs; Female; Hair; Ifosfamide; Lymphoma; Male; Ma

1978
[Clinical experiences with holoxan within the framework of sequential combination therapy (author's transl)].
    Medizinische Klinik, 1978, Sep-08, Volume: 73, Issue:36

    Topics: Adult; Aged; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Female; Hodgkin Disease;

1978
[Clinical experiences with holoxan within the framework of sequential combination therapy (author's transl)].
    Medizinische Klinik, 1978, Sep-08, Volume: 73, Issue:36

    Topics: Adult; Aged; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Female; Hodgkin Disease;

1978
Mass spectrometric characterization of activated N-(2-chloroethyl)amino oxazaphosphorine derivative.
    Biomedical mass spectrometry, 1977, Volume: 4, Issue:4

    Topics: Chemical Phenomena; Chemistry; Cyclophosphamide; Humans; Ifosfamide; Mass Spectrometry; Neoplasms

1977
Mass spectrometric characterization of activated N-(2-chloroethyl)amino oxazaphosphorine derivative.
    Biomedical mass spectrometry, 1977, Volume: 4, Issue:4

    Topics: Chemical Phenomena; Chemistry; Cyclophosphamide; Humans; Ifosfamide; Mass Spectrometry; Neoplasms

1977
[Clinical evaluation of Iphosphamide in phracological treatment of neoplasms].
    Polski tygodnik lekarski (Warsaw, Poland : 1960), 1975, Jun-02, Volume: 30, Issue:22

    Topics: Adult; Aged; Cyclophosphamide; Drug Evaluation; Female; Humans; Ifosfamide; Male; Middle Aged; Neopl

1975
[Clinical evaluation of Iphosphamide in phracological treatment of neoplasms].
    Polski tygodnik lekarski (Warsaw, Poland : 1960), 1975, Jun-02, Volume: 30, Issue:22

    Topics: Adult; Aged; Cyclophosphamide; Drug Evaluation; Female; Humans; Ifosfamide; Male; Middle Aged; Neopl

1975
[Phase II therapeutic trial (screening) of ifosfamide in hematosarcomas and solid tumors].
    Semaine des hopitaux. Therapeutique, 1975, Volume: 51, Issue:1

    Topics: Cyclophosphamide; Drug Evaluation; Hemangiosarcoma; Humans; Ifosfamide; Neoplasms

1975
[Phase II therapeutic trial (screening) of ifosfamide in hematosarcomas and solid tumors].
    Semaine des hopitaux. Therapeutique, 1975, Volume: 51, Issue:1

    Topics: Cyclophosphamide; Drug Evaluation; Hemangiosarcoma; Humans; Ifosfamide; Neoplasms

1975
Pharmacokinetics of divided-dose ifosfamide.
    Clinical pharmacology and therapeutics, 1976, Volume: 19, Issue:3

    Topics: Alkylating Agents; Computers; Cyclophosphamide; Drug Administration Schedule; Humans; Ifosfamide; Ki

1976
Pharmacokinetics of divided-dose ifosfamide.
    Clinical pharmacology and therapeutics, 1976, Volume: 19, Issue:3

    Topics: Alkylating Agents; Computers; Cyclophosphamide; Drug Administration Schedule; Humans; Ifosfamide; Ki

1976
Reduction of ifosfamide toxicity using dose fractionation.
    Cancer research, 1976, Volume: 36, Issue:8

    Topics: Adolescent; Adult; Aged; Cyclophosphamide; Drug Administration Schedule; Female; Hematuria; Humans;

1976
Reduction of ifosfamide toxicity using dose fractionation.
    Cancer research, 1976, Volume: 36, Issue:8

    Topics: Adolescent; Adult; Aged; Cyclophosphamide; Drug Administration Schedule; Female; Hematuria; Humans;

1976
Current developments and future directions with ifosfamide: an update. Proceedings of a satellite symposium of the XV Congress of the European Society for Medical Oncology. Copenhagen, Denmark, December 2, 1990.
    Seminars in oncology, 1992, Volume: 19, Issue:1 Suppl 1

    Topics: Animals; Humans; Ifosfamide; Neoplasms

1992
Current developments and future directions with ifosfamide: an update. Proceedings of a satellite symposium of the XV Congress of the European Society for Medical Oncology. Copenhagen, Denmark, December 2, 1990.
    Seminars in oncology, 1992, Volume: 19, Issue:1 Suppl 1

    Topics: Animals; Humans; Ifosfamide; Neoplasms

1992
Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide, and cisplatin.
    Blood, 1992, Mar-01, Volume: 79, Issue:5

    Topics: Adult; Aged; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cell Coun

1992
Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide, and cisplatin.
    Blood, 1992, Mar-01, Volume: 79, Issue:5

    Topics: Adult; Aged; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Cell Coun

1992
Uroepithelial and nephrotubular toxicity in patients receiving ifosfamide/mesna: measurement of urinary N-acetyl-beta-D-glucosaminidase and beta-2-microglobulin.
    European journal of cancer (Oxford, England : 1990), 1992, Volume: 28A, Issue:12

    Topics: Acetylglucosaminidase; Adult; Aged; beta 2-Microglobulin; Creatinine; Female; Humans; Ifosfamide; Ki

1992
Uroepithelial and nephrotubular toxicity in patients receiving ifosfamide/mesna: measurement of urinary N-acetyl-beta-D-glucosaminidase and beta-2-microglobulin.
    European journal of cancer (Oxford, England : 1990), 1992, Volume: 28A, Issue:12

    Topics: Acetylglucosaminidase; Adult; Aged; beta 2-Microglobulin; Creatinine; Female; Humans; Ifosfamide; Ki

1992
Encephalopathy in ifosfamide-treated patients.
    Acta neurologica Scandinavica, 1992, Volume: 86, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Diseases; Female; Humans; Ifosfam

1992
Encephalopathy in ifosfamide-treated patients.
    Acta neurologica Scandinavica, 1992, Volume: 86, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Diseases; Female; Humans; Ifosfam

1992
Dose escalation of cisplatin (P), etoposide (E), and ifosfamide (I) with GM-CSF for advanced germ cell tumors.
    Pathologie-biologie, 1992, Volume: 39, Issue:9

    Topics: Cisplatin; Drug Therapy, Combination; Etoposide; Granulocyte-Macrophage Colony-Stimulating Factor; H

1992
Dose escalation of cisplatin (P), etoposide (E), and ifosfamide (I) with GM-CSF for advanced germ cell tumors.
    Pathologie-biologie, 1992, Volume: 39, Issue:9

    Topics: Cisplatin; Drug Therapy, Combination; Etoposide; Granulocyte-Macrophage Colony-Stimulating Factor; H

1992
Iphosphamide-induced nephrotoxicity in children.
    Pediatric nephrology (Berlin, Germany), 1992, Volume: 6, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Humans; Ifosfamide; Infant;

1992
Iphosphamide-induced nephrotoxicity in children.
    Pediatric nephrology (Berlin, Germany), 1992, Volume: 6, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Humans; Ifosfamide; Infant;

1992
Ifosfamide vs cyclophosphamide in cancer therapy.
    Oncology (Williston Park, N.Y.), 1991, Volume: 5, Issue:5

    Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cyclophosphamide; Female; Genital Neoplasms,

1991
Ifosfamide vs cyclophosphamide in cancer therapy.
    Oncology (Williston Park, N.Y.), 1991, Volume: 5, Issue:5

    Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cyclophosphamide; Female; Genital Neoplasms,

1991
Ifosfamide in Tumor Therapy: Questions for the Nineties. Satellite Symposium, 15th International Cancer Congress, Hamburg, 1990.
    Journal of cancer research and clinical oncology, 1991, Volume: 117 Suppl 4

    Topics: Humans; Ifosfamide; Neoplasms

1991
Ifosfamide in Tumor Therapy: Questions for the Nineties. Satellite Symposium, 15th International Cancer Congress, Hamburg, 1990.
    Journal of cancer research and clinical oncology, 1991, Volume: 117 Suppl 4

    Topics: Humans; Ifosfamide; Neoplasms

1991
Ambulatory high-dose 5-day continuous-infusion ifosfamide combination chemotherapy in advanced solid tumors: a feasibility study.
    Journal of cancer research and clinical oncology, 1991, Volume: 117 Suppl 4

    Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Admi

1991
Ambulatory high-dose 5-day continuous-infusion ifosfamide combination chemotherapy in advanced solid tumors: a feasibility study.
    Journal of cancer research and clinical oncology, 1991, Volume: 117 Suppl 4

    Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Admi

1991
Subcutaneous continuous infusion of ifosfamide and cyclophosphamide in ambulatory cancer patients: bioavailability and feasibility.
    Journal of cancer research and clinical oncology, 1991, Volume: 117 Suppl 4

    Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Biological Availabilit

1991
Subcutaneous continuous infusion of ifosfamide and cyclophosphamide in ambulatory cancer patients: bioavailability and feasibility.
    Journal of cancer research and clinical oncology, 1991, Volume: 117 Suppl 4

    Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Biological Availabilit

1991
Determination of urinary 2- and 3-dechloroethylated metabolites of ifosfamide by high-performance liquid chromatography.
    Journal of chromatography, 1991, Oct-04, Volume: 570, Issue:2

    Topics: Chromatography, High Pressure Liquid; Humans; Ifosfamide; Neoplasms; Oxidation-Reduction; Reproducib

1991
Determination of urinary 2- and 3-dechloroethylated metabolites of ifosfamide by high-performance liquid chromatography.
    Journal of chromatography, 1991, Oct-04, Volume: 570, Issue:2

    Topics: Chromatography, High Pressure Liquid; Humans; Ifosfamide; Neoplasms; Oxidation-Reduction; Reproducib

1991
Ifosfamide for children with solid tumours.
    Lancet (London, England), 1990, Jun-09, Volume: 335, Issue:8702

    Topics: Child; Child, Preschool; Glomerular Filtration Rate; Humans; Ifosfamide; Neoplasms; Nephritis, Inter

1990
Ifosfamide for children with solid tumours.
    Lancet (London, England), 1990, Jun-09, Volume: 335, Issue:8702

    Topics: Child; Child, Preschool; Glomerular Filtration Rate; Humans; Ifosfamide; Neoplasms; Nephritis, Inter

1990
The pharmacokinetics of ifosfamide given as short and long intravenous infusions in cancer patients.
    British journal of clinical pharmacology, 1991, Volume: 31, Issue:1

    Topics: Adult; Aged; Alkylation; Female; Humans; Ifosfamide; Infusions, Intravenous; Male; Middle Aged; Neop

1991
The pharmacokinetics of ifosfamide given as short and long intravenous infusions in cancer patients.
    British journal of clinical pharmacology, 1991, Volume: 31, Issue:1

    Topics: Adult; Aged; Alkylation; Female; Humans; Ifosfamide; Infusions, Intravenous; Male; Middle Aged; Neop

1991
High-dose ifosfamide with mesna uroprotection: a phase I study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1990, Volume: 8, Issue:1

    Topics: Blood; Bone Marrow; Central Nervous System; Dose-Response Relationship, Drug; Drug Evaluation; Drug

1990
High-dose ifosfamide with mesna uroprotection: a phase I study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1990, Volume: 8, Issue:1

    Topics: Blood; Bone Marrow; Central Nervous System; Dose-Response Relationship, Drug; Drug Evaluation; Drug

1990
Basic principles in preclinical cancer chemotherapy.
    Journal of cancer research and clinical oncology, 1990, Volume: 116, Issue:5

    Topics: Animals; Antineoplastic Agents; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Evaluation,

1990
Basic principles in preclinical cancer chemotherapy.
    Journal of cancer research and clinical oncology, 1990, Volume: 116, Issue:5

    Topics: Animals; Antineoplastic Agents; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Evaluation,

1990
Fractionated ifosfamide therapy produces a time-dependent increase in ifosfamide metabolism.
    British journal of clinical pharmacology, 1990, Volume: 30, Issue:5

    Topics: Female; Humans; Ifosfamide; Infusions, Intravenous; Male; Metabolic Clearance Rate; Neoplasms; Time

1990
Fractionated ifosfamide therapy produces a time-dependent increase in ifosfamide metabolism.
    British journal of clinical pharmacology, 1990, Volume: 30, Issue:5

    Topics: Female; Humans; Ifosfamide; Infusions, Intravenous; Male; Metabolic Clearance Rate; Neoplasms; Time

1990
Advances in ifosfamide chemotherapy. Proceedings of a symposium. November 4-5, 1989, Key Biscayne, FL.
    Seminars in oncology, 1990, Volume: 17, Issue:2 Suppl 4

    Topics: Humans; Ifosfamide; Neoplasms

1990
Advances in ifosfamide chemotherapy. Proceedings of a symposium. November 4-5, 1989, Key Biscayne, FL.
    Seminars in oncology, 1990, Volume: 17, Issue:2 Suppl 4

    Topics: Humans; Ifosfamide; Neoplasms

1990
Ifosfamide neurotoxicity is related to previous cisplatin treatment for pediatric solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1990, Volume: 8, Issue:8

    Topics: Adolescent; Adult; Child; Cisplatin; Humans; Ifosfamide; Neoplasms; Nervous System Diseases; Risk

1990
Ifosfamide neurotoxicity is related to previous cisplatin treatment for pediatric solid tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1990, Volume: 8, Issue:8

    Topics: Adolescent; Adult; Child; Cisplatin; Humans; Ifosfamide; Neoplasms; Nervous System Diseases; Risk

1990
Clinical studies of ifosfamide/mesna at St Jude Children's Research Hospital, 1983-1988.
    Seminars in oncology, 1989, Volume: 16, Issue:1 Suppl 3

    Topics: Adolescent; Child; Child, Preschool; Drug Evaluation; Humans; Ifosfamide; Infant; Mercaptoethanol; M

1989
Clinical studies of ifosfamide/mesna at St Jude Children's Research Hospital, 1983-1988.
    Seminars in oncology, 1989, Volume: 16, Issue:1 Suppl 3

    Topics: Adolescent; Child; Child, Preschool; Drug Evaluation; Humans; Ifosfamide; Infant; Mercaptoethanol; M

1989
Alkylating activity in serum, urine, and CSF following high-dose ifosfamide in children.
    Cancer chemotherapy and pharmacology, 1989, Volume: 24 Suppl 1

    Topics: Adolescent; Alkylation; Child; Child, Preschool; Colorimetry; Drug Evaluation; Drug Therapy, Combina

1989
Alkylating activity in serum, urine, and CSF following high-dose ifosfamide in children.
    Cancer chemotherapy and pharmacology, 1989, Volume: 24 Suppl 1

    Topics: Adolescent; Alkylation; Child; Child, Preschool; Colorimetry; Drug Evaluation; Drug Therapy, Combina

1989
Ifosfamide in pediatric malignant solid tumors.
    Cancer chemotherapy and pharmacology, 1989, Volume: 24 Suppl 1

    Topics: Adolescent; Child; Child, Preschool; Drug Evaluation; Drug Therapy, Combination; Humans; Ifosfamide;

1989
Ifosfamide in pediatric malignant solid tumors.
    Cancer chemotherapy and pharmacology, 1989, Volume: 24 Suppl 1

    Topics: Adolescent; Child; Child, Preschool; Drug Evaluation; Drug Therapy, Combination; Humans; Ifosfamide;

1989
Toxicity of high-dose ifosfamide in children.
    Cancer chemotherapy and pharmacology, 1989, Volume: 24 Suppl 1

    Topics: Adolescent; Bone Marrow; Child; Child, Preschool; Drug Therapy, Combination; Female; Humans; Ifosfam

1989
Toxicity of high-dose ifosfamide in children.
    Cancer chemotherapy and pharmacology, 1989, Volume: 24 Suppl 1

    Topics: Adolescent; Bone Marrow; Child; Child, Preschool; Drug Therapy, Combination; Female; Humans; Ifosfam

1989
Ifosfamide and mesna in the treatment of malignant disease mesna as urothelial protector.
    Investigational new drugs, 1989, Volume: 7, Issue:2-3

    Topics: Adult; Aged; Drug Therapy, Combination; Female; Humans; Ifosfamide; Male; Mercaptoethanol; Mesna; Mi

1989
Ifosfamide and mesna in the treatment of malignant disease mesna as urothelial protector.
    Investigational new drugs, 1989, Volume: 7, Issue:2-3

    Topics: Adult; Aged; Drug Therapy, Combination; Female; Humans; Ifosfamide; Male; Mercaptoethanol; Mesna; Mi

1989
Mesna excretion and ifosfamide nephrotoxicity in children.
    Cancer research, 1989, Dec-15, Volume: 49, Issue:24 Pt 1

    Topics: Adolescent; Adult; Child; Child, Preschool; Creatinine; Female; Humans; Ifosfamide; Kidney Diseases;

1989
Mesna excretion and ifosfamide nephrotoxicity in children.
    Cancer research, 1989, Dec-15, Volume: 49, Issue:24 Pt 1

    Topics: Adolescent; Adult; Child; Child, Preschool; Creatinine; Female; Humans; Ifosfamide; Kidney Diseases;

1989
Current developments and future direction with ifosfamide. Proceedings of a satellite symposium of the European Society of Medical Oncology. October 31, 1988, Lugano, Switzerland.
    Seminars in oncology, 1989, Volume: 16, Issue:1 Suppl 3

    Topics: Animals; Humans; Ifosfamide; Neoplasms

1989
Current developments and future direction with ifosfamide. Proceedings of a satellite symposium of the European Society of Medical Oncology. October 31, 1988, Lugano, Switzerland.
    Seminars in oncology, 1989, Volume: 16, Issue:1 Suppl 3

    Topics: Animals; Humans; Ifosfamide; Neoplasms

1989
Ifosfamide in the treatment of pediatric malignancies. 4th European Conference on Clinical Oncology and Cancer Nursing. Madrid, November 1987. Proceedings.
    Cancer chemotherapy and pharmacology, 1989, Volume: 24 Suppl 1

    Topics: Child; Humans; Ifosfamide; Neoplasms

1989
Ifosfamide in the treatment of pediatric malignancies. 4th European Conference on Clinical Oncology and Cancer Nursing. Madrid, November 1987. Proceedings.
    Cancer chemotherapy and pharmacology, 1989, Volume: 24 Suppl 1

    Topics: Child; Humans; Ifosfamide; Neoplasms

1989
A phase II study of ifosfamide in paediatric solid tumours.
    Cancer chemotherapy and pharmacology, 1989, Volume: 24 Suppl 1

    Topics: Adolescent; Child; Child, Preschool; Drug Evaluation; Drug Tolerance; Female; Humans; Ifosfamide; In

1989
A phase II study of ifosfamide in paediatric solid tumours.
    Cancer chemotherapy and pharmacology, 1989, Volume: 24 Suppl 1

    Topics: Adolescent; Child; Child, Preschool; Drug Evaluation; Drug Tolerance; Female; Humans; Ifosfamide; In

1989
Experience with ifosfamide in paediatric tumours.
    Cancer chemotherapy and pharmacology, 1989, Volume: 24 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Drug Evaluation; Humans; Ifosfamide; Neoplasm

1989
Experience with ifosfamide in paediatric tumours.
    Cancer chemotherapy and pharmacology, 1989, Volume: 24 Suppl 1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Drug Evaluation; Humans; Ifosfamide; Neoplasm

1989
Ifosfamide cardiotoxicity in humans.
    Cancer chemotherapy and pharmacology, 1989, Volume: 24, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Female; Humans; I

1989
Ifosfamide cardiotoxicity in humans.
    Cancer chemotherapy and pharmacology, 1989, Volume: 24, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Female; Humans; I

1989
Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1986, Volume: 4, Issue:8

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Diseases;

1986
Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1986, Volume: 4, Issue:8

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Diseases;

1986
Phase II trial of ifosfamide in children with malignant solid tumors.
    Cancer treatment reports, 1987, Volume: 71, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Drug Eva

1987
Phase II trial of ifosfamide in children with malignant solid tumors.
    Cancer treatment reports, 1987, Volume: 71, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Drug Eva

1987
Recent experience with ifosfamide/mesna in solid tumors. International satellite symposium to the 3rd European Conference on Clinical Oncology. Stockholm, June 1985. Proceedings.
    Cancer chemotherapy and pharmacology, 1986, Volume: 18 Suppl 2

    Topics: Humans; Ifosfamide; Mercaptoethanol; Mesna; Neoplasms

1986
Recent experience with ifosfamide/mesna in solid tumors. International satellite symposium to the 3rd European Conference on Clinical Oncology. Stockholm, June 1985. Proceedings.
    Cancer chemotherapy and pharmacology, 1986, Volume: 18 Suppl 2

    Topics: Humans; Ifosfamide; Mercaptoethanol; Mesna; Neoplasms

1986
The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1987, Volume: 5, Issue:5

    Topics: Adolescent; Adult; Child; Child, Preschool; Cyclophosphamide; Cystitis; Female; Hematuria; Hemorrhag

1987
The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1987, Volume: 5, Issue:5

    Topics: Adolescent; Adult; Child; Child, Preschool; Cyclophosphamide; Cystitis; Female; Hematuria; Hemorrhag

1987
Treatment of advanced malignancies with ifosfamide under protection with mesna.
    International journal of clinical pharmacology research, 1988, Volume: 8, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ifosfamide; Male; Mesna

1988
Treatment of advanced malignancies with ifosfamide under protection with mesna.
    International journal of clinical pharmacology research, 1988, Volume: 8, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ifosfamide; Male; Mesna

1988
Ifosfamide and Mesna in advanced malignancies.
    Chinese medical journal, 1988, Volume: 101, Issue:3

    Topics: Adult; Aged; Carcinoma, Bronchogenic; Female; Hematuria; Humans; Ifosfamide; Lung Neoplasms; Lymphom

1988
Ifosfamide and Mesna in advanced malignancies.
    Chinese medical journal, 1988, Volume: 101, Issue:3

    Topics: Adult; Aged; Carcinoma, Bronchogenic; Female; Hematuria; Humans; Ifosfamide; Lung Neoplasms; Lymphom

1988
Ifosfamide plasma clearance in relation to polymorphic debrisoquine oxidation.
    Cancer chemotherapy and pharmacology, 1988, Volume: 22, Issue:4

    Topics: Adult; Aged; Alkylation; Debrisoquin; Female; Humans; Ifosfamide; Isoquinolines; Male; Middle Aged;

1988
Ifosfamide plasma clearance in relation to polymorphic debrisoquine oxidation.
    Cancer chemotherapy and pharmacology, 1988, Volume: 22, Issue:4

    Topics: Adult; Aged; Alkylation; Debrisoquin; Female; Humans; Ifosfamide; Isoquinolines; Male; Middle Aged;

1988
Ifosfamide: an old drug recently rediscovered.
    European journal of cancer & clinical oncology, 1988, Volume: 24, Issue:6

    Topics: Cyclophosphamide; Drug Evaluation; Female; Humans; Ifosfamide; Male; Neoplasms; Sarcoma; Soft Tissue

1988
Ifosfamide: an old drug recently rediscovered.
    European journal of cancer & clinical oncology, 1988, Volume: 24, Issue:6

    Topics: Cyclophosphamide; Drug Evaluation; Female; Humans; Ifosfamide; Male; Neoplasms; Sarcoma; Soft Tissue

1988
[Ifosfamide treatment for children with malignant tumor].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1987, Volume: 14, Issue:12

    Topics: Adolescent; Adult; Animals; Child; Child, Preschool; Female; Humans; Ifosfamide; Male; Mice; Mice, N

1987
[Ifosfamide treatment for children with malignant tumor].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1987, Volume: 14, Issue:12

    Topics: Adolescent; Adult; Animals; Child; Child, Preschool; Female; Humans; Ifosfamide; Male; Mice; Mice, N

1987
Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapy.
    Cancer research, 1987, Mar-01, Volume: 47, Issue:5

    Topics: Acetylglucosaminidase; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood; Chi

1987
Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapy.
    Cancer research, 1987, Mar-01, Volume: 47, Issue:5

    Topics: Acetylglucosaminidase; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood; Chi

1987
A phase II study of ifosfamide in children with recurrent solid tumours.
    Cancer chemotherapy and pharmacology, 1985, Volume: 15, Issue:3

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Drug Evaluation

1985
A phase II study of ifosfamide in children with recurrent solid tumours.
    Cancer chemotherapy and pharmacology, 1985, Volume: 15, Issue:3

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Drug Evaluation

1985